Aphria läuft und läuft und.....der stärkste Wert unter den Cannabis Herstellern mit Quartals Gewinne - 500 Beiträge pro Seite (Seite 2)

[sunny3999]

Antwort auf Beitrag Nr.: 54.684.470 von wouserxx am 05.04.17 20:24:23

Sieht so aus als ob das weiter geht....

Zitat von wouserxx: Die Jungs scheinen ja richtig was auf der hohen Kante liegen zu haben.

Aus Financial Post:
Aphria takes medical marijuana model to U.S. with $25 million investment in Florida

http://business.financialpost.com/investing/aphria-takes-med…

Die gehen wohl in weitere US-Staaten mit ihrem Business-Modell....

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[wouserxx]

Antwort auf Beitrag Nr.: 54.684.647 von sunny3999 am 05.04.17 20:45:24

Ob der Kurs noch mal unter 7$CA fällt? Bei den News und dem, was noch kommt in den nächsten Wochen, sieht es ja eher nicht danach aus.

[sunny3999]

Antwort auf Beitrag Nr.: 54.685.064 von wouserxx am 05.04.17 21:34:19

Zitat von wouserxx: Ob der Kurs noch mal unter 7$CA fällt? Bei den News und dem, was noch kommt in den nächsten Wochen, sieht es ja eher nicht danach aus.

Wenn du diesen Artikelausschnitt liest aus.... http://business.financialpost.com/investing/aphria-takes-med…:

The company, which will operate in the U.S. as Aphria USA, plans to expand into the 28 states that have legalized medical marijuana, it announced after markets closed Tuesday. It will also raise $35 million through a private placement.


.....und dann dazu weißt das die Kanadier höchsten Wert auf Gaps legen, es jedoch trotz der sehr positiven News kein GAP gab, sollte es nicht mehr unter Can $7 gehen.

Ich hoffe es zumindest schwer!

[sunny3999]

Arcview und Cannacordgenuity Report für den Nordamerikanischen Markt!

Sehr interessante Studien:

https://canaccordgenuity.bluematrix.com/docs/pdf/7b228cfc-4770-4ecf-b2b5-3ce12f085278.pdf

http://arcviewgroup.com/documents/report/5thedition/es/executive-summary_the-state-of-legal-marijuana-markets_5th-edition_22qxqmRQPyp7R.pdf

[sunny3999]

Canada MJ company purchasing Florida grower Chestnut Hill Tree Farm

Beitrag im Miami Herald:
http://www.miamiherald.com/news/politics-government/state-po…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://www.miamiherald.com/news/politics-government/state-politics/6mwkp4/picture142897649/ALTERNATES/FREE_960/Florida%20Election%20Marijuana

[/url]

BY DAVID SMILEY
[e-mail]

One of the largest players in Canada’s cannabis industry is buying into Florida’s expanding medical marijuana market as part of a $60 million bid to purchase and operate one of the state’s seven license-holders.

Aphria, a publicly traded firm based out of Ontario, plans to use an affiliate to purchase most or all the assets of Chestnut Hill Tree Farm, the Alachua nursery that operates CHT Medical. Aphria intends to invest $25 million in the deal, combined with $35 million raised through a private placement, and says the purchase is part of a larger expansion into the U.S. market.

FACEBOOK TWITTER EMAIL SHARE
Inside South Florida's only legal medical marijuana grow operation
Modern Health Concepts owns South Florida's only legal medical marijuana grow operation. The company recently allowed a Miami Herald photographer and reporter to the tour the facility.
C.M. Guerrero Miami Herald
The company that will ultimately take over operations of Chestnut’s CHT Medical marijuana will be called Liberty Health Sciences and is commonly known as Aphria USA. Aphria will own shares and have executives on Liberty’s board, and says it will license its brand and growing technologies to Liberty.

“Aphria’s success story is no longer limited to Canada,” CEO Vic Neufeld said in a press release that according to a disclaimer was not to be distributed to the United States.

With the deal, Aphria becomes the latest out-of-state operator to jump into Florida’s market, joining The Green Solution and Palliatech. Florida’s other six marijuana cultivators have or are currently raising capital for expansions. But so far, only Costa Farms of Modern Health Concepts has officially sold any stake in its company, and that purchase was for a minority stake.

This agreement appears to contemplate the wholesale acquisition of CHT Medical’s operation.

Under state law, the purchase must be approved by the Florida Department of Health, which had not responded as of mid-Wednesday afternoon to questions about the sale. If the transaction goes through, it’s unclear if Chestnut Hill Tree Farm owners Deborah Gaw or Robert Wallace will retain any ownership or stake in the company, as Aphria’s press release did not explicitly say.

Wallace did not return phone calls and an email Wednesday. An attempt to reach Aphria on the phone and through email was similarly unsuccessful.

[Popeye82]

https://equity.guru/2017/03/27/roundup-of-asx-listed-weed-st…

[sunny3999]

PI Financial Analyst schätzt $4.6 Mrd. Cannabis Umsatz in Kanada in 2019

PI Financial Analyst Projects $4.6 Billion Canadian Cannabis Sales in 2019


Exclusive Interview with Jason Zandberg of PI Financial

Jason Zandberg PI FInanancial

With Canada’s Liberal Party prepared to table legislation to legalize cannabis for adult use next week, we checked in with Jason Zandberg, CFA, an analyst covering the sector for Vancouver-based PI Financial, which has participated in capital raises for the sector in excess of $200mm. Zandberg, who focuses on special situations and has been covering the industry for over a year, believes that the cannabis opportunity is “unlike any other sector he has ever looked at” because the demand is already well known. The complete audio interview is included beneath the summary that follows.

Zandberg characterizes the potential market as C$7-10 billion but expects it initially to not fully convert away from the black market, predicting 2019 sales of $4.6 billion but likely exceeding $10 billion over time. One area of concern is that advertising could be highly restricted, and this may be addressed in the legislation, which he expects to mirror the Task Force report from last year. He envisions distribution to vary greatly across the provinces, with dispensaries perhaps in BC and Ontario likely to adopt a model similar to how alcohol is distributed there.

One major positive he projects is that LPs will be able to directly distribute via mail-order at the onset of legalization. As of now, medical cannabis is sold only as dried flower or diluted extracts, and Zandberg expects a much wider range of products, including concentrates, though he isn’t sure if these details will be available when the legislation is introduced.

When trying to distinguish between the companies operating in the industry, Zandberg looks at capacity as a key factor. He seeks companies that are able to scale and generate high yields as measured by grams per sq. ft. of production, noting that the current range is quite wide, with some as low as 50 and the leader at 300. Zandberg thinks that the large producers, including Aphria (TSX: APH) (OTC: APHQF), Canopy Growth (TSX: WEED) (OTC: TWMJF), OrganiGram (TSXV: OGI) (OTC: OGRMF) and privately-held MedReleaf will continue to dominate the market in terms of share, taking advantage of what has been a first-mover advantage. He expects the number of licences, currently at 41, to increase by 20-30 over the next two years, and he also sees further consolidation.

Zandberg believes that the market will be substantially undersupplied due to lack of capacity on July 1, 2018, suggesting that it could be as much as 200mm grams short. While a lot of capacity has been funded and is in the process of being constructed, he cautions that there could be challenges to scaling. Over the long-term, he expects the limited number of suppliers will prevent significant excess capacity.

International opportunities, especially Germany, will create substantial exports, with over $1 billion volume possibly in 2019. He notes that medical cannabis is being adopted increasingly across the globe. Germany, with insurance coverage and pharmacy distribution, should be a substantial market.

Zandberg discussed his coverage list, which includes Aphria, Canopy Growth and Organigram as well as Cronos Group (TSXV: MJN) (OTC: PRMCF) and Emblem (TSXV: EMC) (OTC: EMMBF). He expects Aphria to continue to be a low-cost producer that will be creating large volumes as the feedstock for concentrates. He also expects other LPs to follow the company’s lead into the U.S. over time. Aphria has invested in both Arizona and Florida to date.

Canopy Growth is the market leader, according to Zandberg, and it has been the only real consolidator in the sector. He believes that the Tweed brand stands out in terms of recognition by consumers, and he thinks that it stands to gain the most if advertising rules are somewhat liberal.

Zandberg characterizes Cronos Group as well managed, with the unique position of having facilities on both sides of the country. He also pointed out their joint venture with a First Nations group and their export capabilities as evidence of strong management.

Emblem’s John Stewart has perhaps the best medical background in the industry, and Zandberg expects the company to excel in the medical market. He also believes the company’s high-end focus on the recreational market will help differentiate it from peers.

As far as Organigram, Zandberg sees the recent challenges related to the recall as creating a potentially attractive entry. He also pointed to the company benefitting from its Maritimes location in terms of gaining market share in Eastern Canada.

Zandberg believes that the recent ETF offering by Horizons, the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ), adds legitimacy to the market and also opened the door to more participation by retail investors. He concluded by suggesting that investors realize that a lot of companies have benefitted from the rising tide and to make sure to evaluate them on their own merit.

PI Financial has been paid advisory or investment banking fees from Aphria, Canopy Growth, Cronos Group, Emblem and Organigram.

[sunny3999]

Der Chart sieht gut aus.....oder ?

[wouserxx]

Sind das die Reaktionen auf die Ausweitung des Kerngeschäfts in die USA oder oder werden die Quartalszahlen und der Abschluss von Phase 2 eingepreist?

[sunny3999]

Antwort auf Beitrag Nr.: 54.698.240 von wouserxx am 07.04.17 16:26:42

Mindestens 3 wichtige Ereignisse stehen an!

Zitat von wouserxx: Sind das die Reaktionen auf die Ausweitung des Kerngeschäfts in die USA oder oder werden die Quartalszahlen und der Abschluss von Phase 2 eingepreist?

1. Phase II Abnahme durch Health Canada diese Woche und die Meldung/News dazu,
2. Gesetzgebung zur freien Nutzung von Cannabis in ganz Kanada in der nächsten Woche,
3. Q-Zahlen am 19/20 April.
4. eventuell noch eine Überraschung.....

Heute ist Vic Neufeld (CEO) bei BNN und die haben heute Morgen die Glocke für den Handelstart geläutet an der TSX.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[Poetfan]

Antwort auf Beitrag Nr.: 54.698.297 von sunny3999 am 07.04.17 16:33:05

ja danke für diese Aktie sunny. hast es damals im Poetforum erwähnt

[sunny3999]

Aphria eröffnet die TSX Börse heute am 07.04.2017

[sunny3999]

Vic Neufeld auf BNN!

http://www.bnn.ca/video/aphria-cracking-into-florida-pot-mar…

[wouserxx]

Antwort auf Beitrag Nr.: 54.698.945 von sunny3999 am 07.04.17 17:52:46

In den letzten Sekunden gab es auch die Antwort auf meine Frage, ob Aphria im Rec-Markt Fuß fassen möchte. "Ja, und zwar mit dem Besten"

[Popeye82]

http://westbrookradio.com/2017/04/07/uruguay-will-first-coun…

[sunny3999]

Aphria Inc. shares hit record high, company opens markets in Toronto

http://windsorstar.com/news/local-news/leamington-based-aphr…

WINDSOR STAR
More from Windsor Star
Published on: April 7, 2017 | Last Updated: April 7, 2017 6:51 PM EDT


Employees from Leamington-based medical marijuana producer Aphria Inc. opened the markets Friday in Toronto.

Aphria, which was added to the Toronto Stock Exchange last month, saw its shares open at $7.60 before hitting a record-high of $7.91 to close the day.

Here is a video of Aphria Inc. opening the markets.

[peikler]

Antwort auf Beitrag Nr.: 54.698.138 von sunny3999 am 07.04.17 16:15:12

Hi sunny3999,

bitte verrate mir wie du beim advfn-Chart die Tagesumsätze siehst? Wenn ich den Chart öffne, erhalte ich kein Umsatzdiagramm.

Danke Peikler

[sunny3999]

Aphria is my top pick in the cannabis sector, says PI’s Zandberg

http://www.cantechletter.com/2017/04/aphria-top-pick-cannabi…
APRIL 6, 2017 BY NICK WADDELL



PI Securities yesterday released its quarterly top picks amongst a number of sectors and analyst Jason Zandberg chose Aphria (TSX:APH) as his top pick in the cannabis sector.
Zandberg notes that Aphria grows marijuana in greenhouses, which reduces the power consumption associated with grow lights significantly. He also points out that Leamington, Ontario, where the company’s greenhouse operations are located, is one of the warmest places in the country and has a high caliber agricultural labour pool. This all adds up to the ability to produce marijuana cheaply, something the analyst thinks will be a long-term advantage.
“We have chosen Aphria Inc. as our Q2 Top Pick as the Company is the lowest cost producer among the public licensed producers in Canada and has a strong management team with extensive relationships with Canadian pharmacy professionals,” says the analyst. “We expect Aphria will continue to maintain its position as the lowest cost producer in both the current medical framework and future recreational framework.”
Zandberg currently has a “Buy” rating and a one-year price target of $8.00 on Aphria, implying a return of 19 per cent at the time of publication.
The analyst thinks Aphria will post EBITDA of $4.16-million on a topline of $20.2-million in fiscal 2017. He expects these numbers will improve to EBITDA of $14.9-million on revenue of $42.2-million the following year.
Zandberg says Aphria is at or near the top of its peers with regards to a key metric.
“We believe Aphria is the MJ market leader in terms of funded capacity,” he says. “Having recently closed a $57.5M bought deal financing, we estimate Aphria’s cash balance currently sits at around $130M – $160M. We estimate that Aphria’s total funded capacity is 61,000kg. This estimate includes current capacity of 2,800kg plus funded expansion plans – we have assumed Part 2 and 3 are funded and Part 4 expansion is partially funded. This funded capacity is the highest among the licensed producers in Canada.”
At press time, shares of Aphria were up 3.5 per cent to $7.47.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=t.aph&p…

[sunny3999]

Antwort auf Beitrag Nr.: 54.701.204 von peikler am 08.04.17 08:27:40

@Peikler auf ADVFN ist Volume=0 gesetzt, wenn du das Bild kopierst und vol=1 setzt siehst du das Volumen

Zitat von peikler: Hi sunny3999,

bitte verrate mir wie du beim advfn-Chart die Tagesumsätze siehst? Wenn ich den Chart öffne, erhalte ich kein Umsatzdiagramm.

Danke Peikler

Siehe vol=1: http://de.advfn.com/p.php?pid=staticchart&s=T%5EAPH&t=37&p=0&dm=0&vol=1&width=870&height=600&min_pre=0&min_after=0

[Sandy98]

Antwort auf Beitrag Nr.: 54.701.492 von sunny3999 am 08.04.17 09:33:27

Kursteigerungen....

Hallo denkt ihr wir werden weitere Kurssteigerungen diese Woche erwarten mögliche Gründe: Legslization, Phase 2,...und und oder denkt ihr es ist nun eingepreist....ich bin etwas überfordert😂

[Sandy98]

Antwort auf Beitrag Nr.: 54.708.636 von Sandy98 am 10.04.17 11:39:40

8.00 CAD

Hat soeben 8.0 CAD erreicht in torronto....

[sunny3999]

Marijuana legalization plan to be released Thursday

http://www.cbc.ca/news/politics/marijuana-legalization-plan-…
Much anticipated pot plans are about to be made public
By Catherine Cullen, CBC News Posted: Apr 10, 2017 12:17 PM ET Last Updated: Apr 10, 2017 12:53 PM ET
Canadians will get their first look at the Liberal vision for legalized marijuana on Thursday, CBC News has confirmed.

A senior government source said the proposed federal legislation to legalize and regulate the drug will be tabled in the House of Commons then.

The Globe and Mail reported the date earlier Monday.

As CBC News has reported, the Trudeau government's goal is make legalization a reality in Canada on or before July 1, 2018.

Legalizing was a Liberal campaign promise in the 2015 election campaign. Both as Liberal leader and later as prime minister, Justin Trudeau has pitched to Canadians that legalizing marijuana will make it harder for young people to access pot and take profits away from organized crime.

What to expect

It's expected the government will follow a lot of the advice it got from its task force on cannabis legalization and regulation.

According to recent reporting by CBC News, that will include:

A minimum age of 18 to buy marijuana, though provinces and territories will have the option of setting a higher age limit.
Allowing Canadians to grow four marijuana plants per household.
Licensing of producers, as well as ensuring the safety and security of the marijuana supply will be a federal concern.
Provinces and territories will set the price for marijuana and decide how it is distributed and sold.
Much to discuss

Many of those suggestions will be hot topics of debate.

The Canadian Medical Association has suggested the legal age to buy marijuana should be 21, arguing that would limit damage to developing brains.

Home-growing is not a popular subject for the Canadian Association of Chiefs of Police. That group says it will put added demand on police and make it harder to keep the drug away from children.

Tougher penalties

There is an other element to the Liberal election pledge that hasn't gotten nearly as much attention: stiffer penalties for certain pot-related offences.

In its 2015 platform, the party pledged to "create new, stronger laws to punish more severely those who provide it to minors, those who operate a motor vehicle while under its influence, and those who sell it outside of the new regulatory framework."

Drugged driving presents a particular challenge. The cannabis task force noted that roadside tests to determine whether a driver is impaired because of pot use are still in development. Public Safety Canada has been working with police in several cities to run pilot projects on different roadside detection tests.

Pot profits

Medical marijuana companies have seen their stocks surge and sometimes plunge along the path towards legalization in Canada.

However, both the chair of the government's task force and the parliamentary budget officer have warned that legalizing won't necessarily be a major cash cow for governments, particularly in the first few years.

The prime minister has already suggested that any government revenues from marijuana sales won't go towards fattening the federal bank account. Instead, he said the money could go towards addiction treatment, mental health support and education programs.

[sunny3999]

APHRIA INC COM NPV (OTCMKTS:APHQF) Shares Poised to Rise With These Recent Catalysts

By Michael Luke - April 10, 2017575
Share on Facebook Tweet on Twitter

The Canadian cannabis market is heating up with the potential changes with its laws, which could potentially mean legalization of adult recreational and medicinal use of cannabis throughout all of Canadia. Consequently, APHRIA INC COM NPV (OTCMKTS:APHQF) could ride this wave of growth, and it’s poised to rise with its recent developments.


If you haven’t heard of Aphria Inc yet, it’s one of Canada’s lowest cost producers, engaged in producing, supplying and selling medical cannabis. According to the company, it’s truly powered by sunlight, allowing for the most natural growing conditions available. Moreover, Aphria is also focused on providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. That in mind, Aphria is the first publicly- traded licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.





Let’s move onto some company news. APHRIA INC COM NPV (OTCMKTS:APHQF) recently announced that it made an additional investment of $3M in Copperstate Farms Investors. That said, this investment could potentially advance its capital expenditure program related to extractions, lighting and power generation. Consequently, the investment increases Aphria’s membership units in Copperstate Farms from 10% to 18.5% of those issued.

Now, this could increase Aphria’s exposure to the Arizona medicinal marijuana market. If you’ve never heard of Copperstate, the company owns approximately 1.7M square feet of greenhouses in Snowflake, Arizona and plans to bring approximately 348,000 square feet, into medical cannabis production in the fall of this year.

Moving on, Copperstate recently received a special-use permit for cannabis production in its greenhouse, by the Town of Snowflake. Copperstate projects that its expanded operations are capable of annualized production of approximately 18K kilograms. The current spot price for wholesale bud in the Arizona cannabis market is approximately $3,300 per kilogram. Copperstate has secured 90 different marijuana varieties for eventual offer to its customers. Several of the varieties are currently being tested to determine consumer demand and optimal growing metrics.

According to Aphria Chief Executive Officer Vic Neufeld, “Our expanded investment in Copperstate Farms Investors increases Aphria’s exposure to the particularly attractive Arizona medical cannabis market.”

Aphria CEO continued, “Our partnership with Investors combines Aphria’s extensive agriculture and pharmaceutical experience with Copperstate Farms’ strong operational expertise, all while strengthening Copperstate’s ability to serve Arizona’s approximately 115,000 medical marijuana patients. In all, we believe this important partnership has significant long-term growth potential for Aphria.”

Not only that, but Aphria’s common shares will continue to trade under the symbol “APH”, on the Toronto Stock Exchange now. That said, this could increase brand recognition and attract new investors.

Aphria Chief Executive Officer stated, “Aphria’s listing on the TSX represents a major milestone in our strategic growth plan, helping to increase trading liquidity, access a growing investor base interested in the cannabis industry, and raise capital for further investments…As one of Canada’s leading cannabis companies, we are excited about the opportunities in this rapidly growing market to drive shareholder value and continue Aphria’s success story. The TSX is the premier listings destination and this achievement highlights the strength of our experienced management and team, our commitment to providing safe, quality products and our positive growth trajectory.”
That said, you might not want to miss any developments on APHQF, if you haven’t been keeping up with the stock. However, if you’re busy all day and don’t have time to keep up with news, you might want to sign up to our free newsletter. All you have to do is provide us with your email, and we’ll send you updates, if any, on APHQF.

[MVAL]

Wo liegt Charttechnisch nun die nächste Hürde? Bei den magischen 10 CAD?

Schon lange nicht mehr so einen Anstieg erlebt. Und der Boom steht m.M.n. erst am Anfang...

[Sandy98]

Antwort auf Beitrag Nr.: 54.716.832 von MVAL am 11.04.17 12:57:15

Die Konkurenz

https://www.stockhouse.com/news/press-releases/2017/04/11/au…

[wouserxx]

Mhmm....ich warte eigentlich nur darauf, wann es denn wieder absackt auf 7-7,5$. Dieser Kursanstieg scheint mir nicht nachhaltig zu sein.

[MVAL]

Antwort auf Beitrag Nr.: 54.717.261 von wouserxx am 11.04.17 14:06:13

7 - 7,50 CAD

In dieser Range spekuliere ich auch auf einen weiteren Zukauf zu meiner Position.

In den steigenden Trend, bei Rücksetzern, kaufen. Das ist meine Strategie bei APH.

[sunny3999]

Antwort auf Beitrag Nr.: 54.716.832 von MVAL am 11.04.17 12:57:15

Nach oben keine Grenzen mehr, da Aphria aktuell am ALL TIME HIGH ist....

Zitat von MVAL: Wo liegt Charttechnisch nun die nächste Hürde? Bei den magischen 10 CAD?

Schon lange nicht mehr so einen Anstieg erlebt. Und der Boom steht m.M.n. erst am Anfang...

... da heißt es gibt offiziell nichts an was man sich orientieren könnte.

Oft sind es die 50 cent/ 1$ Hürden die der Wert als Orientierung hat, aber keine Orientierung wann das Ziel erreicht ist, solange immer mehr Käufer als Verkäufer am Markt sind.

Das ist schon der Hammer, die Entwicklung, ich sag nur:

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Oder eben eine kalte Dusche wie eben....

...nach so einem heftigen Anstieg....

[Aktiengeier_1]

Antwort auf Beitrag Nr.: 54.718.113 von sunny3999 am 11.04.17 15:50:07

War bei allen Cannabiswerten der kurze Peak nach unten steigt schon wieder.....Abfischen vom Feinsten!

[sunny3999]

Antwort auf Beitrag Nr.: 54.718.170 von Aktiengeier_1 am 11.04.17 15:57:21

Trading Halt bei APH und OGI wegen Circuit Breaker...

....mal sehen wie es weiter geht....

[sunny3999]

Antwort auf Beitrag Nr.: 54.717.402 von MVAL am 11.04.17 14:25:18

Sehr gute Einschätzung von Euch beiden bei $ 7-7,50 dazu zu Kaufen,

nur so schnell wie das ging konnte ich gar nicht in die Tasten klimpern.

Hoffe es bietet sich nochmal eine Gelegenheit.

[wouserxx]

JA wirklich schade. Da hätte es sich gelohnt, wenn man einfach eine Kauforder mit Limit 5 Euro nebenbei herlaufen lässt. Die Verkäufer werden sich richtig ärgern und haben Lehrgeld gezahlt. Niemals ohne Limit verkaufen.

[wouserxx]

Könnte man eigentlich noch mal versuchen. Das wird nicht das letzte mal gewesen sein.

[wouserxx]

Was denkt ihr? gehts morgen wieder hoch?

[sunny3999]

Antwort auf Beitrag Nr.: 54.720.189 von wouserxx am 11.04.17 19:54:05

Die haben ihre Abfischtechnik perfektioniert, da kann man kaum mithalten

Innerhalb von wenigen Minuten den Kurs um $1,5-2 runter prügeln und alle Stopploss order einsammeln, da kommt man gar nicht zum Zug.

Auch wenn man eine Kauforder gesetzt hätte, ist es schwierig für uns kleinen irgend etwas abzufischen.

Ich denke der Kurs wird sich stabilisieren zwischen $8-8,50, sicher ist jedoch nichts.

[wouserxx]

Ok, aber das liegt doch dann auch am Broker?

[sunny3999]

Antwort auf Beitrag Nr.: 54.720.270 von wouserxx am 11.04.17 20:07:31

Denke nicht das es alleine am Broker liegt, die haben ihre Software so programmiert,

das es schwer ist eine Order gefüllt zu bekommen, hatte 2-3 Order gesetzt, jedesmal sprang der Kurs davon.

[wouserxx]

Ok, hab davon nicht allzu viel Ahnung.

[sunny3999]

http://www.parl.gc.ca/HousePublications/Publication.aspx?Pub…

Das Gesetz zur Legalisierung wird schon Heute vorgestellt im Houses of Parliament - 1 Tag früher als gedacht!


Publications - April 12, 2017 (Previous)
Order Paper and Notice Paper | Projected Order of Business

Notice Paper

No. 165

Wednesday, April 12, 2017 - 3:00 p.m.

April 11, 2017 — The Minister of Justice and Attorney General of Canada — Bill entitled “An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts”. 11 avril 2017 — Le ministre de la Justice et procureure générale du Canada — Projet de loi intitulé « Loi concernant le cannabis et modifiant la Loi réglementant certaines drogues et autres substances, le Code criminel et d'autres lois ».
Recommendation

His Excellency the Governor General recommends to the House of Commons the appropriation of public revenue under the circumstances, in the manner and for the purposes set out in a measure entitled “An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts”.

April 11, 2017 — The Minister of Justice and Attorney General of Canada — Bill entitled “An Act to amend the Criminal Code (offences relating to conveyances) and to make consequential amendments to other Acts”. 11 avril 2017 — Le ministre de la Justice et procureure générale du Canada — Projet de loi intitulé « Loi modifiant le Code criminel (infractions relatives aux moyens de transport) et apportant des modifications corrélatives à d'autres Lois ».

[sunny3999]

Globe says Aphria, rivals hear legal pot makes sense

http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aAPH-24602…
2017-04-12 07:04 ET - In the News

Also In the News (C-ACB) Aurora Cannabis Inc
Also In the News (C-CMED) CanniMed Therapeutics Inc
Also In the News (C-IMH) Invictus MD Strategies Corp
Also In the News (C-MJN) Cronos Group Inc
Also In the News (C-OGI) Organigram Holdings Inc
Also In the News (C-WEED) Canopy Growth Corp

The Globe and Mail reports in its Wednesday, April 12, edition that Ottawa is preparing to introduce legislation to legalize and regulate marijuana. A Globe editorial notes that like tobacco and alcohol, legalization makes sense as a harm-reduction strategy. The reason for legalizing pot is that the experience of the past few decades suggests that a lot of people want to use it and are using it, regardless of its legal status. As a result, the harm of prohibition, notably the criminality caused by its illegality, outweighs the benefits. Legalization means regulation. Like cigarettes and alcohol, marijuana should be sold only to adults, by supervised sellers. It is about ending the situation of drugs being sold by "a guy," not entrenching it. The point of legalizing pot is not to give the imprimatur of legality to all currently illegal activities. The aim is to end the free-for-all. Harms must be minimized. The main purpose of legalization is to end criminality and illegality -- not to provide a windfall of new government revenue. There should be taxes on pot, but they must not be so high as to achieve the unintended consequence of fostering the continuation of a black market.

© 2017 Canjex Publishing Ltd. All rights reserved.

[sunny3999]

Aphria Price Target increased by PI Jason Zandberg!

These three Canadian marijuana LPs could become important exporters, says PI


APRIL 11, 2017 BY NICK WADDELL 0 COMMENTS



PI analyst Jason Zandberg says a few marijuana LPs are uniquely positioned to take advantage of international demand and become the dominant exporters of Canadian cannabis.
The analyst notes that there are a dozen countries that have introduced new medical cannabis laws within the past two years. He points out that there are currently 29 countries that recognize medical cannabis, although currently only a handful import product. Zandberg says The Netherlands and Canada are the only two countries that sell medical cannabis internationally and that just four Canadian LPs have actually exported product, to date. The analyst thinks the market opportunity is huge.
“The global medical cannabis market is expected to reach $55.8B (USD) or $70B-$75B (CAD) by 2025 (Grandview Research). This market size is approximately 10x the size of the total Canadian cannabis market (we estimate that both recreational and medical cannabis sales will reach $7B by 2024), ” notes Zandberg. “We believe the Canadian LPs could export $0.5B to $1.5B in medical cannabis by 2019. We believe that those Licensed Producers that can take advantage of this global opportunity are able to tap into another leg of growth in addition to the Canadian medical and recreational markets.”
Zandberg says there are three companies in particular he thinks are positioned to benefit from what could be a very strong export market.
“Three of the LPs that we cover have exported MMJ internationally – Cronos Group (V-MJN), Canopy Growth (T-WEED) and Aphria (T-APH),” says the analyst. “While initial volumes of medical cannabis have been modest we expect exports to ramp in the next few years to countries that are establishing medical cannabis programs and are opening their borders to countries with high production standards like Canada. We particularly are bullish on the German market (Cronos and Canopy Growth both have agreements in place) in which trade could become material in the next two years. Australia is also in the early stages of a medical program (Aphria and Canopy Growth have exported to Australia) which could develop into meaningful trade levels. Cronos Group, Canopy Growth and Aphria plan to expand their export footprint and are taking a leadership role for Canada.”
In a research update to clients today, Zandberg maintained his “Buy” rating on all three aforementioned stocks, but raised his one-year price target on Cronos Group from $3.00 to $4.00. The analyst raised his one-year price target on Canopy Growth from $14.00 to $15.00, and he raised his one-year price target on Aphria from $8.00 to $9.00.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[Popeye82]

Justin Trudeau Is Making It Legal For Canadians To Hold 30 Grams Of Pot
http://westbrookradio.com/2017/04/10/justin-trudeau-making-l…

[sunny3999]

Government of Canada to make an important announcement

Notice to the media – Government of Canada to make an important announcement
Media Advisory
From Health Canada

April 12, 2017

The Honourable Jody Wilson-Raybould, Minister of Justice and Attorney General of Canada, the Honourable Jane Philpott, Minister of Health, the Honourable Ralph Goodale, Minister of Public Safety and Emergency Preparedness, and the Honourable Diane Lebouthillier, Minister of National Revenue, along with Parliamentary Secretary Bill Blair, will make an important announcement.

Government of Canada officials will hold a media technical briefing following the announcement and will be available to answer questions. Please note: Technical Briefing is not for attribution and cameras or recording devices will not be permitted.

April 13, 2017

Press Conference: 12:05 PM EDT

Media Technical Briefing: 1:15 PM EDT

National Press Theatre
150 Wellington St, Ottawa

Periscope channel for live stream of announcement: www.pscp.tv/HealthCanada

Facebook channel for live stream of announcement: www.facebook.com/JusticeCanadaEn/

Media dial-in for 12:05PM announcement with Ministers and 1:15PM Media Technical Briefing:
1-877-413-4814 / 613-960-7526, passcode 5042411#

Media Inquiries:
David Taylor
Office of the Minister of Justice and Attorney General of Canada
613-992-4621

Andrew MacKendrick
Office of the Minister of Health
613-957-0200

Scott Bardsley
Office of the Minister of Public Safety and Emergency Preparedness
613-998-5681

Chlo Luciani-Girouard
Office of the Minister of National Revenue
613-952-9184

Media Relations:
Department of Justice Canada
613-957-4207
[e-mail]

Health Canada
613-957-2983

Public Safety Canada
613-991-0657
[e-mail]

Canada Revenue Agency
613-952-9184


Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Could Aphria Inc. or Aurora Cannabis Inc. Dethrone Canopy Growth Corp. as Canada’s Favourite Marijuana Stock?

http://www.fool.ca/2017/04/12/could-aphria-inc-or-aurora-can…
Joey Frenette | April 12, 2017 | More on: WEED ACB APH


Aphria Inc. (TSX:APH) has been soaring since its graduation to the TSX last month. The company now has a $1.1 billion market cap and could pass Canopy Growth Corp. (TSX:WEED) with its $1.74 billion market cap over the next few months.

There’s no question Canopy stock has slowed down when compared to its peers such as Aphria and Aurora Cannabis Inc. (TSXV:ACB). Canopy is up approximately 10% since March 24, the date when Aphria moved to the TSX, while Aphria is up a whopping 35.3%, and Aurora Cannabis is up an astounding 44.3% over the same span.

In many of my previous pieces this year, I recommended Aurora Cannabis and Aphria over Canopy because of fundamental reasons and the scandal which suppressed the current upward rally being enjoyed by all marijuana stocks.

Don’t get me wrong. Obtaining a 10% return in less than a month is still extraordinary! But let’s not forget that Canopy got beaten up pretty badly following the class-action lawsuit that resulted from the tainted marijuana scandal, and the stock still hasn’t fully rebounded from the correction that followed.

Sure, all marijuana stocks pulled back slightly, but it looks like investors have decided what their new favourite pot stock is. Over the short and medium term, I believe Canopy won’t get as high as Aurora or Aphria. Both of these companies are firing on all cylinders and are very likely to give Canopy a run for its money.

Back in the day, Canopy was one of the only go-to pot stock for investors. It was the first to graduate to the TSX, and marijuana investors poured money in. But now we’re likely to see more pot stocks suddenly popping up on the TSX, and there’s even a marijuana ETF for those who want a small piece of all marijuana stocks.

There are more options for investors these days, and it’s likely that original Canopy investors will jump ship to more interesting opportunities. The tainted marijuana scandal most likely accelerated this phenomenon.

I still think Aphria and Aurora are better bets over the medium term, but Canopy is likely to get out of its funk and start soaring with a similar magnitude as these two pot powerhouses.

Although any investment in marijuana is risky, I think an investment in Canopy ups the amount of risk without raising the upside potential thanks to the scandal, which may result in more negative news down the road. Eventually, Canopy will become a “value” play in the marijuana industry, and by then, it’s likely that the magnitude of its returns will be more in line with those of its peers.

It’ll be very interesting to see what happens as we head closer to nationwide legalization. I believe all marijuana stocks could skyrocket further, but there’s also the possibility of all marijuana stocks crashing hard if any form of bad news is released in the press.

Marijuana stocks are still speculative plays, so you should be comfortable with headline risk and the stomach-churning amounts of volatility, because it’s pretty much guaranteed to happen over the next year.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Legalizing pot: What to watch for in today's long-awaited bill

http://www.cbc.ca/beta/news/politics/marijuana-pot-legalizat…

Issues of cannabis-laced candy, drugged driving and where pot can be smoked need to be resolved

Catherine Cullen · CBC News
1 Hour Ago
Marijuana Cultivation
The federal government will unveil legislation in Ottawa today to pave the way toward legalizing recreational marijuana on or before July 1, 2018. (CBC)
45 shares

Canada is about to do something very few countries in the world have tried: make recreational pot legal.

Today, Prime Minister Justin Trudeau's government will reveal precisely what it thinks legalization should look like, and there are a ton of fascinating and important questions that need to be answered.

First, let's start with what we already know.

CBC News has reported that the federal government will set a minimum age of 18 to buy marijuana, but will give provinces and territories the option to set the age higher. Where it will be sold and how much it will cost will also be up to the provinces to decide. The federal government will license producers and ensure the safety of the supply.

CBC News has also reported that the personal possession limit will be 30 grams. Households will be allowed to grow up to four plants. There will be restrictions around how cannabis products are marketed and the government will use roadside saliva tests to determine if drivers are impaired.

According to CBC News sources, the goal is to make legalization a reality across the country before July 1, 2018.

But before that happens there are still lots of questions to answer.

It could soon be legal to carry up to 30 grams of marijuana
Liberals want to move up pot legalization to avoid Canada Day
Hold off on homegrown pot, police chiefs urge government
Legal pot is a big deal for a couple of reasons. On the one hand, a sin or excise tax could mean more revenue for the government, which Trudeau has suggested be funnelled back into addiction services and public education. But charge too much, and you wind up with a problem.

As the parliamentary budget watchdog pointed out in its analysis of the fiscal considerations when legalizing pot, if tax is too high, buyers will stick with the black market. The PBO analysis points out that when Colorado legalized pot in 2014, it charged a combined tax rate of nearly 30 per cent. About half of consumers stayed in the illegal market.

And if there is a sin tax, how might it be applied? That same PBO report notes that one option would be to apply it by weight or even based on potency (i.e. THC levels).

What about chocolate bars and gummy bears?

This isn't just a cute question. There are potentially serious public health implications. The chair of the government's cannabis task force, Anne McLellan, said that her group learned some important lessons about edibles from Colorado's experience.

She said at first the state didn't require chocolate bars containing marijuana to be scored into individual pieces. Some people would eat the whole bar in one sitting and wind up in the emergency room, McLellan said.

The concerns are even more serious when it comes to children, who could mistake some edibles, like gummy bears and lollipops, for candy. Children's Hospital Colorado has a warning on its website that the drug can have a stronger and more prolonged effect on kids. Many require hospitalizations.

The federal task force recommended the government ban any cannabis products that could be "appealing to children," based on the products themselves or their packaging.

Where can you smoke it?

What sort of restrictions will the government put in place around where marijuana can be consumed? Should it be subject to the same restrictions as cigarettes? Or perhaps alcohol?

The task force recommended that the restrictions around tobacco products should be extended to cannabis, and that jurisdictions should have Ottawa's blessing to set up cannabis lounges and tasting rooms.

What counts as stoned?

Police enforcement against drugged driving will be tricky. The federal government has been running pilot projects on different saliva tests that can be administered roadside to determine if a driver is under the influence. But the question is not entirely clear-cut.

"Whereas evidence was gathered over many years to arrive at an established metric for alcohol intoxication — blood alcohol concentration (BAC) — these types of data do not exist for cannabis," the cannabis task force report notes.

For some regular users, THC can remain in the brain and body for prolonged periods of time. But does that mean a driver is impaired?

The Liberals have promised harsher penalties for drug-impaired drivers.

"We are confident we will have an arrangement in place that will meet the public interest," Public Safety Minister Ralph Goodale told reporters in Ottawa earlier this week.

What about pot tourism?

Trudeau has said he is legalizing marijuana in order to keep it away from kids and to cut profits to organized crime, but obviously, legalizing pot will have plenty of other consequences.

What about Americans who want to come up for the weekend to check out Canada's beautiful wildlife and legalized marijuana?

The federal government may be happy to embrace the potential financial windfall that would come with marijuana tourism. Officials could also try to repress it (or cash in further), by charging an added tax to tourists.

The marijuana task force also recommended that tourists be informed of their rights and obligations, including not taking drugs across international borders.

Can it be done in time?

Quebec Premier Philippe Couillard said on Wednesday that proposing legislation is the easy part. The hard part, he said, is the work the provinces will still have to do — including on issues like distribution, marketing and road safety.

Couillard said expecting that work to be done by the summer of 2018 is "very fast" for such a complex subject.

Even medical marijuana companies that are anxious to start selling to recreation buyers aren't sure the system will be ready in time.

"I don't think anyone should be expecting to buy recreational marijuana on Day 1," at least by going into a federally sanctioned store front, said Sébastien St. Louis, co-founder of Hydropothecary, a Quebec-based licensed producer of medical marijuana.

"By the time we get around to knowing exactly how the provinces want to move forward it will probably take a bit longer than July 2018."

(For the sake of full disclosure, it's worth noting that one member of Hydropothecary's board has held leadership roles in the federal Liberal Party.)

Still, St. Louis said that even if the bricks and mortar facilities aren't ready, licensed producers will be ready to sell through a direct mail system right off the bat.

[wouserxx]

https://seekingalpha.com/news/3257009-aphria-reports-fq3-res…

Quartalszahlen.

[sunny3999]

Aphria records fifth consecutive quarter of profitability

http://www.marketwired.com/press-release/aphria-records-fift…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://media3.marketwire.com/logos/20140605-aphria_r.png

[/url]
Aphria Inc.

TSX : APH
OTCQB : APHQF


Aphria Inc.
April 13, 2017 08:00 ET

Aphria records fifth consecutive quarter of profitability
Increases capacity expectations for Part II, III & IV expansion projects to meet growing demand
LEAMINGTON, ONTARIO--(Marketwired - April 13, 2017) - Aphria Inc. ("Aphria" or the "Company") (TSX:APH)(OTCQB:APHQF) today reported its third quarter results, for the three and nine months ended February 28, 2017. All amounts are expressed in Canadian dollars.
Q3-2017 Q3-2016
$ 5,118,516 Revenue $ 2,679,878
$ 3,568,069 Gross profit $ 1,883,225
$ 3,582,312 Adjusted gross profit $ 1,968,048
70.0% Adjusted gross margin 73.4%
$ 4,950,250 Earnings before tax $ 3,720
$ 1,005,073 EBITDA $ 423,350
Q3-2017 Q2-2017
652.7 Kilograms (or kilogram equivalents) sold 639.0
$ 5,118,516 Revenue $ 5,226,589
$ 1,005,073 EBITDA $ 1,198,620
$ 1.73 Cash cost to produce / gram $ 1.31
$ 2.23 "All-in" cost of goods sold / gram $ 1.85
$ 84,351,132 Cash and cash equivalents on hand $ 98,614,981
$ 123,144,983 Working capital $ 102,438,357
$ 23,419,877 Investment in capital and intangible assets $ 5,029,872
Business highlights
Fifth consecutive quarter of profitability
Over $3.2 million of year-to-date EBITDA
Increased our capacity expectations for Part II (to 8,000 kgs), Part III (to 22,000 kgs) & to Part IV (75,000 kgs)
Invested $1,000,000 in Resolve Digital Health Inc.
Invested $1,000,000 in Tetra Bio-Pharma Inc., which was subsequently increased to $2,300,000 after exercising warrants in the subsequent events period
Secured 200 acres of serviced farm land in Leamington, Ontario for $6,240,000 as a secondary site to our existing campus
Invested an additional $1,300,000 USD in Copperstate Farms Investors, LLC, which was subsequently increased by a further $3,000,000 USD investment in the subsequent events period
Invested $8,400,000 in Canabo Medical Inc.
Received Board approval to commence Part IV expansion with a $137,000,000 capital budget
Committed $2,000,000 in investment to Green Acres Capital Fund, advancing $300,000
Invested just over $2,000,000 in Kalytera Therapeutics Ltd.
Raised $53,869,357 in a bought deal financing which closed on February 24, 2017
Received final approval to list on the Toronto Stock Exchange ("TSX"). Shares commenced trading on the TSX and were delisted from the TSX-Venture Exchange on March 22, 2017
"With five consecutive quarters of profitability and further growth in our production capacity, Aphria continued to build strong, positive momentum in the third quarter," said Vic Neufeld, Chief Executive Officer, Aphria. "Despite unusual weather conditions that temporarily added to our growing costs for the quarter, we continue to report costs per gram that are among the lowest in the industry. At the same time, we are making strategic investments that will increase our supply of high-quality cannabis and position Aphria to drive further growth in our medical-grade cannabis business, meet future demand for recreational cannabis, and drive strong, sustainable shareholder value creation."
Financial highlights
For the fifth consecutive quarter, the Company reported profitability. In the last five quarters, the Company reported income before tax of $3,720, $102,164, $895,269, $945,678 and $4,950,250, respectively. The increased pre-tax profitability is primarily a result of the increase in fair value of long-term investment portfolio.
The Company continued to report strong EBITDA levels, reporting $1,005,073 of EBITDA in the quarter. This is the Company's third consecutive quarter with EBITDA greater than $1 million. Reported EBITDA levels reflect the Company's continued focus on low cost producer status and industry leading patient care service.
Revenue for the three months ended February 28, 2017 was $5,118,516, representing a 2% decrease over the prior quarter's revenue of $5,226,589. The decrease in revenue for the quarter was consistent with expectations and was primarily a result of the $8.50 per gram cap placed on the price of medical cannabis for veterans. The impact of the price cap on revenue was offset by increased revenue per gram for non-veterans, primarly a result of selling less wholesale product and the continued growth of our cannabis oils.
Adjusted gross profit for the third quarter was $3,582,312 with an adjusted gross margin of 70.0%, generated from both retail and wholesale shipments of medical cannabis. The decrease in the adjusted gross margin from the prior quarter is consistent with the reduction in revenues in the quarter.
During the quarter, our "all-in" costs of dried cannabis per gram increased from $1.79 in the prior quarter to $2.23 in the current quarter, representing a $0.44 increase. The increase largely related to abnormal winter weather conditions in Leamington but also included costs related to preparing for our Part II expansion.
This winter the Leamington area experienced unusual conditions related to the amount of sunlight it received. The most common measure of light intensity is referred to as lumens. During the quarter, the Leamington area received approximately 80% of the historical three-year average of lumens for this period. More specifically, the month of January was 67% of the three-year lumen average and the month of February was 76% of the three-year lumen average. This reduced lumen measure directly led to (i) lower yields on individual cannabis plants during the quarter which caused a $0.20 increase in our "all-in" costs of dried cannabis per gram; and, (ii) increased heating and electrical costs, which caused a $0.14 increase in our "all-in" costs of dried cannabis per gram.
The remaining $0.10 per gram related to incremental labour costs as we added greenhouse staff during the quarter so they would be fully trained to work in our Part II expansion, the moment the area is approved by Health Canada. As we move from Health Canada's approval to use our Part II expansion toward the first sale from that area, we will continue to incur incremental labour costs in our vault and packaging staff. These incremental costs will be directly tied to revised head counts as we properly train staff in advance of additional product flow that will result from the increase in our annual harvest from 2,600 kgs to 8,000 kgs.
Net income for the three months ended February 28, 2017 was $4,950,250 or $0.04 per share as opposed to a net income of $3,720 or $0.00 per share in the same quarter in the previous year and an income before tax of $945,678 or $0.01 per share in the previous quarter.
EBITDA for the third quarter was $1,005,516, compared to an EBITDA of $423,350 in the same period of the prior year and EBITDA of $1,198,620 in the previous quarter.
We have A Good Thing Growing.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://media3.marketwire.com/logos/20140605-aphria_r.png

[/url]

[wouserxx]

Sind eigentlich gut aus, bis auf die gestiegen Kosten pro Gramm. Allerdings klingt deren Erklärung dazu recht schlüssig.

[sunny3999]

Antwort auf Beitrag Nr.: 54.733.098 von wouserxx am 13.04.17 14:27:09

Alle Produktionszahlen je Phase wurden nach oben korrigiert,

das 5 Quartal in Folge mit Gewinn abgeschlossen.

Alle Investitionen benannt und Phase2 abgenommen und Mitarbeiter geschult.

Der schlechte Winter ist das einzige an dem sie nun nichts ändern können.

Ich schätze die haben es deswegen Heute veröffentlicht um weitere Aufmerksamkeit zu bekommen.

Mal sehen wie der Markt es mit der Legalisierungsgesetzgebung aufnimmt, der Kurs wird es bald zeigen.

[MVAL]

Fundamental alles in Bester Ordnung.

Trotzdem denke ich, dass wir jetzt erst mal Luft aus dem Kurs lassen. Der Anstieg war zu heftig. Wahrscheinlich auch der TMX-Euphorie geschuldet. Körbchen unter 5 Euro stehen parat...

[sunny3999]

Heute um 18:05 sollte die Liveschaltung und Verkündung der Regierung erfolgen

Link: www.pscp.tv/HealthCanada
April 13, 2017

Press Conference: 12:05 PM EDT

Media Technical Briefing: 1:15 PM EDT

National Press Theatre
150 Wellington St, Ottawa

Periscope channel for live stream of announcement: www.pscp.tv/HealthCanada

Facebook channel for live stream of announcement: www.facebook.com/JusticeCanadaEn/

Media dial-in for 12:05PM announcement with Ministers and 1:15PM Media Technical Briefing:
1-877-413-4814 / 613-960-7526, passcode 5042411#


Read more at http://www.stockhouse.com/companies/bullboard?symbol=t.aph&p…

[MVAL]

Bei mir funzt nix? Senden die schon? Bei mir nur "schwarz"

[sunny3999]

Etwas verschoben ca. 13:00 EST oder 19:00 h MEZ

LINK: https://www.facebook.com/GlobalNews/videos/1349601808420914/…

[MVAL]

Antwort auf Beitrag Nr.: 54.734.940 von sunny3999 am 13.04.17 18:16:35

Danke. Bin live "on air" ...

[sunny3999]

Live auf allen Kanälen auch auf CTV:

http://www.ctvnews.ca/politics/live-updates-liberals-table-p…

[sunny3999]

Link auf Youtube:

[wouserxx]

Hallo,

sunny, wie lange geht die Produktion mit den aktuellen Erträgen noch in dieser Form weiter? Und wann ist mit mehr Erträgen und dementsprechenden höheren Einnahmen zu rechnen?

[sunny3999]

Antwort auf Beitrag Nr.: 54.735.474 von wouserxx am 13.04.17 19:37:53

Jede Phase die von Health Canada freigegeben wird erhöht die Ernteproduktion

In Phase II = 8.000kg = ca. $ 64 Mio ab April 2017 möglich
in Phase III = 22.000kg = ca. $ 176 Mio ab Sept./Oct. 2017 nach Freigabe durch Health Canada
Phase iV = 75.000 = ca. $ 535 Mio ab Ende 2018 nach Freigabe.....

Dazu kommt der 22,5% Anteil (18.000 kg ab Sept. 17) von Copperstate - Arizona
und 38% Anteil in Florida Mengen noch unbekannt??

[wouserxx]

OK, wann werfen die neuen Anbauflächen Erträge ab?

[sunny3999]

Antwort auf Beitrag Nr.: 54.735.681 von wouserxx am 13.04.17 20:13:21

Es gibt im Thread ein Schaubild, ich meine es sind 6 Wochen + 2-3 Wochen Trocknung

bin mir aber nicht mehr 100% sicher.

[sunny3999]

VIC auf BNN ab 4:45"

http://www.bnn.ca/video/aphria-ceo-marijuana-stock-analyst-r…

[wouserxx]

Antwort auf Beitrag Nr.: 54.736.275 von sunny3999 am 13.04.17 22:00:54

Danke für die Info. Also ist wohl auch in Q4 nicht unbedingt mit höheren Einnahmen durch den Verkauf von Weed zu rechnen, wenn sie die Pflanzen erst nach der Abnahme von Phase II frisch setzen.

[sunny3999]

Antwort auf Beitrag Nr.: 54.737.265 von wouserxx am 14.04.17 08:29:08

Könnte passieren, das auch das nächste Quartal ohne höhere Ernte bei Umsatz etwa gleich bleibt.

Hoffe dennoch das der Umsatz und Gewinn höher ausgewiesen werden.

Enttäuschend war mal wieder die Politik mit ihrem schwammigen Legalisierungsgesetz.

Keine eindeutige Altersangabe, keine Besteuerungshöhe alles sollen die kanadischen Provinzen erledigen.

Schade, das war dann wohl auch der Grund warum der Einbruch auf breiter für alle MJ-Firmen kam.

Unsicherheit und Dauer der Umsetzung schürt Verkaufsdruck.

Spätestens im 4 Quartal 2017 dürfte Aphria wieder neue ALL-TIME-HIGHS erreichen.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[wouserxx]

Antwort auf Beitrag Nr.: 54.738.048 von sunny3999 am 14.04.17 11:18:42

Ja mal schauen, wie weit es runtergeht.

[Scorpio1921]

Antwort auf Beitrag Nr.: 54.738.048 von sunny3999 am 14.04.17 11:18:42

Quartal 6 wird wieder gut.. Marktcap 1Mrd!

Denke eher, dass es erneut ein grünes Quartal gibt.

Man hat bei Kalytera und Copperstate aufgestockt.

Ausserdem müsste von Canabo demnächst doch Ergebnisse von Studien erscheinen?

AphriaUSA expandiert fleissig, wie Vic sagte im BNN Video in 3 weitere US Staaten..

Quartel Nr6 wird uns wieder überraschen..

[sunny3999]

Aphria Welcomes New Federal Recreational Cannabis Legislation

https://aphria.com/aphria-welcomes-new-federal-recreational-…

Company ready to meet recreational demand but calls for strict regulation and enforcement

LEAMINGTON, ONTARIO – April 13, 2017 – Aphria Inc. (“Aphria” or the “Company”) (TSX:APH)(OTCQB:APHQF), a Health Canada Licensed Producer of medical cannabis products, comments on the proposed Cannabis Act announced today.

Vic Neufeld, Chief Executive Officer of Aphria, said: “Aphria has a proven track record of supplying Canadian patients with high-quality, medical grade cannabis. We welcome the federal government’s introduction of a regulatory framework legalizing cannabis for Canadians to keep profits out of the hands of the black market, restrict access to youth, and ensure clean and safe product.”

“Having served tens of thousands of Canadian patients since 2014, we have witnessed first-hand the benefits of cannabis and support expanding access to all eligible Canadians. That said, we firmly believe that there is a critical need to set clear and enforceable rules to ensure that customers are protected and have access to clean and safe product. This is of utmost importance given the expected demand that will come with the introduction of a recreational market. As such, Aphria is calling for a strict product-testing regime across the sector. These costs should be absorbed by the Licensed Producers, not government, to ensure the regulations are enforced and taxpayers do not bear the burden of these costs. This new regime would include Health Canada visiting industry members regularly to survey their operations and test their products for safety.”

“Aphria is very well positioned to supply a significant amount of cannabis to the recreational market, estimated to be at least 600,000 kg annually. Recently, inspectors from Health Canada completed their onsite field inspection of our Part II expansion, which, upon finalized approval, will add an incremental 57,000 square feet of greenhouse capacity, increasing our annualized harvest to 8,000 kg. Upon completion of our vision to build 1,000,000 square feet of greenhouse footprint (inclusive of our Part III and IV expansion presently underway), we will have the capacity to supply more than 75,000 kg of high-quality cannabis at one of the lowest costs in the industry, making for an attractive value proposition in this new market.”

“Canada is on the global stage for cannabis legalization and today marks a milestone in our history. We look forward to working alongside all levels of government on the drafting and implementation of the regulations to ensure product quality and consumer protection and safety.”

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.

We Have a Good Thing Growing.

[sunny3999]

Chartguys: Aphria muß die $6,80 halten, das Gap up bei $6,20 ist für mich das untere Level....

[wouserxx]

Antwort auf Beitrag Nr.: 54.738.735 von Scorpio1921 am 14.04.17 14:45:01

Zitat von Scorpio1921: Denke eher, dass es erneut ein grünes Quartal gibt.

Man hat bei Kalytera und Copperstate aufgestockt.

Ausserdem müsste von Canabo demnächst doch Ergebnisse von Studien erscheinen?

AphriaUSA expandiert fleissig, wie Vic sagte im BNN Video in 3 weitere US Staaten..

Quartel Nr6 wird uns wieder überraschen..

Im 4. Quartal kann der Kurs auch durchaus stagnieren. Was steht in den nächsten Monaten großartig an, was einen erneuten Anstieg rechtfertigen würde? Der Grundstein für die Legalisierung ist gelegt, aber wie sunny bereits ausführte, sind einige Dinge noch in der Schwebe. Auch der CEO hat im Interview einige Unklarheiten bezüglich der zukünftigen Verteilung des Weeds geäußert. Die Regierung hat vieles offen gelassen und viele Kompetenzen in die Hände der einzelnen Bundesstaaten gelegt.
Möglicherweise herrscht bei viele Anlegern eine gewisse Unsicherheit vor, was weitere Kursrutscher provozieren könnte.

Nichtsdestotrotz sind die langfristigen Aussichten super und ich habe Vertrauen ein gutes Investment getätigt zu haben. Jetzt heißt Augen offen halten und Schnäppchen abgrasen.
Stimmts sunny?

[Scorpio1921]

Antwort auf Beitrag Nr.: 54.739.371 von wouserxx am 14.04.17 17:58:59

Ich denke, es wird durchaus Expansionsfortschritte und Aufstockungen in bereits geführte Investitionen geben.

Vic macht das schon, der will Nummer 1 werden.

Oder rechnete Jemand im Vorfeld damit, dass sie aufstocken, was ja zum nächsten Quartal zählen würde?

30g pro Kanadier ist doch Klarheit genug.. 1g pro Tag ist durchaus zu beachten, ob es mehr wird sehen wir in einem Jahr, aber daa sind doch schon mal Zahlen, mit den man mal hochrechnen könnte.

[Sandy98]

Antwort auf Beitrag Nr.: 54.739.386 von Scorpio1921 am 14.04.17 18:07:37

Aphria Aussicht schaut noch gut aus...

Hallo Zusammen,

Ich versuche gerade ein Fazit aus den Bewegungen im Rahmen der letzten bei Wochen zu ziehen. Ich persönlich bin in MJ Stocks seit 16 Monaten investiert und durfte seither des öfteren gute bis sehr gute und leider auch 2 sehr sehr schlechte Erfahrungen mit den LPs sammeln. Mein Portfolio spiegelt fast 25% an MJ Stocks wieder. Ausserdem bin ich in Edelmetalle erneuerbaren Energien und in der Logistik Branche investiert und Handel gerne Long, bin aber durchaus Risikofreudig aufgrund der guten Ertragscgancen.

Fazit: Das langfristige Risiko der MJ Stocks Stufe ich mit dem Anouncement von Donnerstag nun wirklich um Längen reduziert ein. Einschätzung 1: Aurora wird die verlorenen 75 Mio erst einmal auskosten und wird mittelfristig innerhalb 3 Monaten woeder im Rennen sein.
Einschätzung 2: Aphria erfährt auch aufgrund der Medien jetzt noch kurzfristig einen Schub, befindet sich schon sehr im Niveau der Überbewertung und wird diese auch bis spätestens Anfang Mai ganz nach dem Motto Buy the Hype und Sell the News auskosten müssen und das kann sich mittelfristig ziehen. Aohria wird dann Anfang 2018 spätestens wieder im Rennen sein.

- Auroras und Aphrias nächste Rally startet im letzten Quartal 17 und ended bis spätestens Ende Quartal 1 in 2018


Bei Canopy ist es momentan so das es ziemlich ruhig ist und das wird dem Stock sehr gut tun. Ich schätze das dies der einzige LP ist welcher bis Ende dieses Jahres noch eine Rally erlebt. Zwar wird der sehr kurzfristige Aufschwung des Kurses wie bei Aohria nicht erfahren, jedoch ist dies auch der Grund. Hier gab es in den letzten 4 Wochen lediglich die Korrektur von Buy ans sell the News kann hier nicht gesprochen werden. Im Einklang der Legalisierung und dem guten Einstiegs Kurs startet mindestens eine Rally bis Ende Max 2017 die sich bis Ende quartal 1 2018 ziehen kann. (Mann muss sich auch immer vor Augen halten wer momentan die grösste Verhandlungsmacht bei den extrem großen Chancen hat) Canopy kann und wird schneller und effizienter als andere Markteilnehmer reagieren können. Im mittelfristigen Zeitraum sollte man das auch an der Entwicklung der Marktkspitslisierung feststellen können. Das wird sich folgerichtig auch auf am Kurs widerspiegeln.


Hype News, Chart-Technik, Finanz KPIs, Agenda-Zukunft, Börsen Mechanismen, Historische Euphorie und Psyschologie sind Bestandteile für das Fazit meiner Analyse kurz und knapp ausgedrückt obenstehend.

[sunny3999]

Vic Neufeld auf Facebook:

https://www.facebook.com/AphriaMMJ/videos/1117280661716971/Missed our live stream on the legislation for legalizing recreational marijuana in #Canada? You can watch it here. Our CEO, Vic Neufeld, tells us about what the legislation means for Canadians.

[wouserxx]

Hallo Leute,

hattet ihr schöne Osterfeiertage?
Sunny, stehen in den nächsten Wochen irgendwelche News an?

[sunny3999]

Antwort auf Beitrag Nr.: 54.754.438 von wouserxx am 18.04.17 19:28:45

Health Canada war wohl vor 2 Wochen bei Aphria um Phase II abzunehmen...

...dies könnte die nächsten Tage anstehen.

Ansonsten ist gerade die politische Rahmengebung der Regierung, die nun durch die Provinzen unterschiedlich umgesetzt werden kann eine große Unsicherheit.

Dazu kommt, das die Zahlen von Aphria nicht so toll waren und der Umsatz wegen der späten Phase II Abnahme leidet und weiter leiden kann bis eventuell ins nächste Quartal.

Dennoch denke ich das Aphria nach der Neujustierung Ihres REC-Marketing neue Impulse senden wird oder auch schon zum MMJ.

Jetzt muß sich jeder LP für Rec neu orientieren, für MMJ kann jederzeit was an News kommen, ob es den Kurs bewegt wird sich zeigen....

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Der Kultivierungsprozess von Cannabis

Es dauert also ca. 12-14 Wochen bis der gesamte Prozess durchgelaufen ist.

Das heißt Aphria wird nach Phase II approval ca. 3 Monate nicht mehr an MMJ Produktion ausweisen können, ausser sie kaufen beim Wettbewerb zu.

Somit war aufgrund der verspäteten Phase II Abnahme klar, es wird die nächste Zeit Umsatz-/gewinnmäßig eher stagnieren.

News und Fortschritte in Zukäufen/Partnerschaften können dennoch den Kurs treiben.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/cultivationproxp7zw8cuev.jpg

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/cultivationproxp7zw8cuev.jpg

[/url]

[sunny3999]

Antwort auf Beitrag Nr.: 54.758.146 von sunny3999 am 19.04.17 10:41:48

Das Bild des Kultivierungsprozesses im Schaubild wird abgeschnitten - deshalb der Link

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/cultivationproxp7zw8cuev.jpg

[/url]

mit der Quelle von Tilray: http://www.tilray.com/home

[wouserxx]

Danke für die Info. Mal schauen wie sich der Kurs entwickelt. Der Unternehmenswert selbst, wird aller voraussicht nach keine großen Sprünge machen.

[Scorpio1921]

Antwort auf Beitrag Nr.: 54.758.377 von sunny3999 am 19.04.17 11:10:21

Also mit Muttepflanze u Klonen...

Dann sinds fast 4 Wochen weniger 😀

[Scorpio1921]

Antwort auf Beitrag Nr.: 54.758.377 von sunny3999 am 19.04.17 11:10:21

Danke Sunny

Nimm dir die Kanadier nicht zu Herzen.. Du bist ganz stark 😁

Weil du sagtest, Aphria würde 4-8 Wochen Verzug haben, wenn ichs richtig verstanden habe..

Phase1, Copperstate und co produzieren doch weiter?!

Die Phase2, die abgenommen wurde, produziert doch erst ab jetzt?

Phase3 (Oktober) wird auch den Kurs treiben..

Dann wird bestimmt noch irgendwo eingestiegen, etwas aufgestockt, in bereits vorhandene Investitionen höher investiert.

Man war bereits über der 1Mio Marktcap und will und kommt da wieder hin.

Laut Geschäftsbericht hat man 137mio Cash.. Was denkst du was die damit anstellen?

Danke.. Durch dich bin ich auf die Aktie gestossen im November und es ist phänonenal und macht richtig Spass ib den kanadischen Foren zu lesen.. Danke nochmal..

Hab in Facebook ne Gruppe nur mit den grünen Aktien, also falls du Bock hast? 250Mitglieder bis dato.. Die findest bestimmt..

Hast paar Antworten auf die Fragen?

Grüssle Sco

[sunny3999]

Antwort auf Beitrag Nr.: 54.759.265 von Scorpio1921 am 19.04.17 13:42:24

Zitat von Scorpio1921: Nimm dir die Kanadier nicht zu Herzen.. Du bist ganz stark 😁

Weil du sagtest, Aphria würde 4-8 Wochen Verzug haben, wenn ichs richtig verstanden habe..

Phase1, Copperstate und co produzieren doch weiter?!

Die Phase2, die abgenommen wurde, produziert doch erst ab jetzt?

Phase3 (Oktober) wird auch den Kurs treiben..

Dann wird bestimmt noch irgendwo eingestiegen, etwas aufgestockt, in bereits vorhandene Investitionen höher investiert.

Man war bereits über der 1Mio Marktcap und will und kommt da wieder hin.

Laut Geschäftsbericht hat man 137mio Cash.. Was denkst du was die damit anstellen?

Danke.. Durch dich bin ich auf die Aktie gestossen im November und es ist phänonenal und macht richtig Spass ib den kanadischen Foren zu lesen.. Danke nochmal..

Hab in Facebook ne Gruppe nur mit den grünen Aktien, also falls du Bock hast? 250Mitglieder bis dato.. Die findest bestimmt..

Hast paar Antworten auf die Fragen?

Grüssle Sco

Phase 1 produziert weiter, Copperstate fängt erst anim Aug./Sept. 2017.
Phase 2 Info der Abnahme von Health Canada steht noch aus, kann noch 1-2 Wochen dauern.
Phase 3 im Okt. wenn es nicht schone wieder Verschiebungen durch HC gibt.
Partnerinfo ist heute mit Tetra Biopharm erfolgt.
$ 137 Mio ist für Ausbau Phase 4 gedacht.
Ich schau mal in Facebook rein, danke für den Tipp hast du mir den Namen ?

Grüßle zurück Sunny

[sunny3999]

NEWS:TBP & APH Announce Plans for the Joint Distri. of Dried Medical Can. in the Maritime Provinces & Quebec

http://m.marketwired.com/press-release/tetra-bio-pharma-aphr…

Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec
OTTAWA, ONTARIO--(Marketwired - April 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra") (CSE:TBP) (OTCQB:GRPOF) and Aphria Inc. ("Aphria") (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.

Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer's licence, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra's third quarter of 2017 and Aphria's first quarter of 2018.

"This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical," said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. "Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR."

"The commercial venture between Tetra and Aphria will enhance Aphria's brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001," said Vic Neufeld, CEO of Aphria Inc. "As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra's emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria."

Tetra and Aphria have invested in the development of its PPP001 drug and will continue to invest to bring PPP001 to market in both Canada and USA as the first prescription drug using dried cannabis. The corporations have developed a high quality dried cannabis product and would like to make it available to physicians under the current ACMPR program. The quality and clinical research studies completed to date would be integrated into a joint Continuing Medical Education program for physicians and pharmacists. Tetra and Aphria have concluded that there is demand for an evidence-based approach in medical cannabis and the two companies intend on using their pharmaceutical approach to help patients. The venture will also be commercializing devices for the inhalation of medical cannabis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP) (OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

[Scorpio1921]

Antwort auf Beitrag Nr.: 54.760.315 von sunny3999 am 19.04.17 16:07:25

Gruppenlink

https://www.facebook.com/groups/431770210547767/

[sunny3999]

Hier noch ein kleines Geschenk an die Aphria Leser

Habe ich aus einem anderen Forum in Kanada erhalten.

Gesamtvergleich aller Licensed Producer mit allen Kennwerten!

https://docs.google.com/spreadsheets/d/1pTkI0aPcozWyOLcyiv-t…

[absolutejoy]

Hallo,

könnte mir jemand sagen welche Gebühren für die Eintragung der Namensaktien der hier diskutierten Unternehmen anfällt bzw. wo ich diese finde?

Danke

[sunny3999]

Antwort auf Beitrag Nr.: 54.761.062 von absolutejoy am 19.04.17 17:34:44

Nach Namen suchen oder Abkürzung (TICKER)

Company
Ticker Name
TSE:HMMJ HORIZONS MEDICAL MARIJUANA LIFE SCI ETF
Canadian LP's
TSE:WEED Canopy Growth Corp
TSE:APH Aphria Inc
CVE:ACB Aurora Cannabis Inc
CNSX:SL Supreme Pharmaceuticals Inc
CVE:MJN Cronos Group Inc
CVE:EMC Emblem Corp
TSE:CMED CanniMed Therapeutics Inc
CVE:OGI Organigram Holdings Inc
CVE:THCX Hydropothecary Corp
CVE:EMH Emerald Health Therapeutics Inc
CNSX:THC THC Biomed Intl Ltd
CVE:IMH INVICTUS MD STRATEGIES CORP
Canadian LP Applicants
CVE:MGW Maple Leaf Green World Inc
CNSX:BE Beleave Inc
CNSX:MyM My Marijuana Canada Inc
CNSX:PUF PUF Ventures Inc
CNSX:VP Vodis Pharmaceuticals Inc
CNSX:VGW Valens Groworks Corp
US & International LP's
CVE:ICC ICC International Cannabis Corp
CNSX:GLH Golden Leaf Holdings Ltd
CNSX:CRZ CANNAROYALTY CORP
OTCMKTS:ACNNF AUSCANN GROUP HLDG NPV
Industry Related Companies
CNSX:SUN Wildflower Marijuana Inc
CNSX:N Namaste Technologies Inc
CNSX:BLO Cannabix Technologies Inc
CVE:RTI Radient Technologies Inc
CNSX:TBP Tetra Bio Pharma Inc
CNSX:EAT Nutritional High International Inc
CNSX:TNY Tinley Beverage Company Inc
CNSX:IN InMed Pharmaceuticals Inc.
CVE:NSP Naturally Splendid Enterprises Ltd
Upcoming Canadian LP IPO's
MedReleaf
ABcann
WeedMD
CannTrust
MariCann
HVST United Greeneries
TGOD The Green Organic Dutchmen

[absolutejoy]

Antwort auf Beitrag Nr.: 54.761.194 von sunny3999 am 19.04.17 17:51:34

Danke für die schnelle Antwort
Aber wo genau finde ich den bei den Unternehmen die Kosten dafür? Z.B. bei Canopy Growth?
Hab auf der Website geschaut, aber nichts dazu gefunden.
Bin neu auf dem Gebiet und kenn mich da nicht so gut aus.

[sunny3999]

Antwort auf Beitrag Nr.: 54.761.335 von absolutejoy am 19.04.17 18:12:45

Wenn du Aktien kaufen willst dann geht das über deine Bank oder einen Onlinebroker...

...das heißt du brauchst ein Aktiendepot bei einem der genannten (Bank/Onlinebroker) dann kannst du die Aktien über deinen Berater bei der Bank oder wenn du Online Zugang hast direkt über die Onlineplattform kaufen und handeln.

[absolutejoy]

Antwort auf Beitrag Nr.: 54.761.383 von sunny3999 am 19.04.17 18:19:09

Ja habe einen Onlinebroker und auch ein Depot.
Wollte nur wissen wo ich etwas zu dem Umschreibeentgeld für diese Namensaktien finden kann. Mein Broker konnte mir da keine Auskunft geben, da sie sowas nicht für den Kunden recherchieren und ich sollte bei den Unternehmen recherchieren (Prospekte/Website usw.). Konnte da leider nichts finden.
Sind ja bestimmt eher kleine Gebühren.

Danke für deine Hilfe

[sunny3999]

Antwort auf Beitrag Nr.: 54.761.437 von absolutejoy am 19.04.17 18:24:21

Je nachdem wo du kaufst:

In D ca. 1,5% bei deiner Bank oder zwischen 5-15 € beim Onlinebroker
In USA/Kanada teurer plus Währungsgewinn/-verlust.

Dazu kommen Jahresgebühren für das Depot....

[absolutejoy]

Antwort auf Beitrag Nr.: 54.761.482 von sunny3999 am 19.04.17 18:29:35

Wenn ich Namensaktien in D kaufe wurden mir 1,50€ für die Umschreibung gesagt.
Danke, da hab ich schon mal so eine kleine Richtlinie.

Das Depot ist bei mir kostenlos

[sunny3999]

Die Firma Outco in Kalifornien sollte Aphria einfach kaufen......

https://vimeo.com/198311886

http://outco.com/wp-content/uploads/2017/04/OUTCO-Millennial…

Dann wäre Party in der Bude! Aber Vic sagt ja, das er gerne auf dem medizinischen MJ bleiben möchte, bis REC klar ist, schade eigentlich....

[sunny3999]

The Streetregister: Aphria und Tetra Biopharm könnten weiter steigen........

http://streetregister.com/2017/04/19/aphria-inc-com-npv-otcm…

APHRIA INC COM NPV (OTCMKTS:APHQF) Announces Plans for Joint Distribution with Tera Bio-Pharma, and Shares Could Continue to Rise
By Michael Luke - April 19, 2017131

APHRIA INC COM NPV (OTCMKTS:APHQF) shares have been up over 20% recently, and it could continue to rise after it announced its plans for a joint distribution venture with Tera Bio-Pharma, as well as the ongoing changes in the Canadian cannabis industry. First, let’s take a look at the company profile.

Aphria Inc is one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Aphria is truly powered by sunlight, which allows for the most natural growing conditions out there. The company is committed to providing pharma-grade medical cannabis, superior patient care, all while while balancing patient economics and returns to shareholders. Aphria is the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.


Let’s move onto its recent news. Aphria and Tera Bio-Pharma recently announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec. When speaking on this plans, APHRIA INC COM NPV (OTCMKTS:APHQF) CEO Vic Neufeld stated, “The commercial venture between Tetra and Aphria will enhance Aphria’s brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001.”

Neufeld added, “As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra’s emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria.”

Now, Tetra and Aphria have invested in the development of its PPP001 drug, and they will continue investing in the drug in an attempt to bring PPP001 to market in both Canada and the U.S., as the first prescription drug using dried cannabis. The companies have developed a high quality dried cannabis product. Now, they would like to make it available to physicians under the current ACMPR program. With the ongoing changes in the cannabis industry, and states in the U.S. legalizing the medicinal and adult recreational use of marijuana in 2016, as well as the potential legalization of adult recreational and medicinal use of cannabis in Canada, Aphria is well positioned to grow its earnings.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=aphqf&uf=0&type=2&size=2&sid=18169004&style=320&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=7&rand=888548046&compidx=&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1

[/url]

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://bigcharts.marketwatch.com/kaavio.Webhost/charts/big.chart?nosettings=1&symb=aphqf&uf=0&type=2&size=2&sid=18169004&style=320&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=7&rand=888548046&compidx=&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1

[/url]
According to Andre Rancourt, CEO of Tetra Bio-Pharma Inc., “This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical…Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR.”

As we’ve already stated, Canada could potentially legalize the adult recreational and medicinal use of cannabis throughout the country. When speaking on the potential legalization, Neufeld stated, “Aphria has a proven track record of supplying Canadian patients with high-quality, medical grade cannabis. We welcome the federal government’s introduction of a regulatory framework legalizing cannabis for Canadians to keep profits out of the hands of the black market, restrict access to youth, and ensure clean and safe product.”

Neufeld added, “Aphria is very well positioned to supply a significant amount of cannabis to the recreational market, estimated to be at least 600,000 kg annually. Recently, inspectors from Health Canada completed their onsite field inspection of our Part II expansion, which, upon finalized approval, will add an incremental 57,000 square feet of greenhouse capacity, increasing our annualized harvest to 8,000 kg. Upon completion of our vision to build 1,000,000 square feet of greenhouse footprint (inclusive of our Part III and IV expansion presently underway), we will have the capacity to supply more than 75,000 kg of high-quality cannabis at one of the lowest costs in the industry, making for an attractive value proposition in this new market.”

With this large potential production and the demand for cannabis for medicinal purposes, Aphria could increase its earnings and take some market share in the space due to its cost efficiency. If you missed these updates on APHQF, you might want to consider subscribing to our free newsletter. All you have to do is enter your email address in the box below, and you’re on your way to receive updates, if any, on APHQF.

[sunny3999]

Washington Post: Marijuana has truly gone mainstream, survey finds

http://www.denverpost.com/2017/04/19/marijuana-mainstream-st…
By THE WASHINGTON POST
April 19, 2017 at 9:07 pm
By Christopher Ingraham, (c) 2017, The Washington Post

Many marijuana users hide their stash in their closets. Most people who use marijuana are parents. There are almost as many marijuana users as there are cigarette smokers in the U.S.

Those facts and many more are among the conclusions of new survey from Yahoo News and Marist University, which illustrates how pot has become a part of everyday life for millions of Americans.

1. Nearly 55 million adults currently use marijuana

More than half of American adults have tried marijuana at least once in their lives, according to the survey. Nearly 55 million of them, or 22 percent, currently use it – the survey defines “current use” as having used marijuana at least once or twice in the past year. Close to 35 million are what the survey calls “regular users,” or people who use marijuana at least once or twice a month.

Those numbers are larger than what we see in some other surveys. A Gallup poll released last year found that more than 33 million adults identified as “current” marijuana users, although it didn’t specify a time frame the way this survey did. The latest federal survey on drug use found about 33 million adults used marijuana in the past year, considerably lower than the Marist poll’s 55 million figure.

But those federal numbers are from 2015, while the Marist poll was conducted last month. Considering four more states have legalized marijuana since the federal survey was done, attitudes on use may have changed enough that more are comfortable admitting their use to a survey.

Survey mode is another potential factor: The Marist poll was done via phone, while the federal survey involved interviewers speaking with people in their homes. Considering marijuana remains fully illegal at the federal level, people may simply be more comfortable admitting their use to a voice at the end of a phone line than a representative of the federal government.

Regardless, 55 million people is a staggering number. It would mean that there are nearly as many marijuana users as there are cigarette smokers (59 million).

2. Support for recreational marijuana may not be as robust as it seems

Public opinion surveys consistently show that support for marijuana legalization hovers around 60 percent. But most of those surveys don’t ask respondents what, exactly, legal marijuana means to them – they just ask whether marijuana should be legal or not.

The Marist survey asked about medical and recreational marijuana separately. It found that about 83 percent of Americans say they support medical marijuana, in line with what other national surveys have shown. But respondents were closely divided on the question of “legalizing the use of marijuana for recreational use” – 49 percent support it, 47 percent oppose.

That lines up with a detailed breakdown of the legalization issue in a survey by the Associated Press and the National Opinion Research Center last year, where 61 percent said they supported legalization, but 24 percent of those supporters clarified that they only supported medical use.


3. People who have tried marijuana are much more approving of it than those who haven’t

Prior marijuana use is one of the biggest predictors of support for recreational marijuana legalization. Fully 70 percent of Americans who have tried marijuana at least once support legalizing recreational weed. Only 26 percent of those who haven’t tried it say the same.

In short, people who have experience using marijuana generally think it should be legal. This has potentially significant implications for the national legalization debate: As marijuana becomes legal in more states, more people will try it. This could lead to greater support for legalization, even more states legalizing, more people trying it, and so on.

4. Most Americans think smoking weed is ‘socially acceptable’

Regardless of whether they support legalization or use it themselves, 56 percent of Americans say that using marijuana is “socially acceptable,” compared to 42 percent who say it isn’t. Again, there’s a big split here between people who’ve tried it (74 percent say it’s acceptable) and people who haven’t (37 percent).

Majorities also said it would make no difference to them if they learned that their doctor, clergyman, favorite athlete, favorite celebrity or children’s schoolteacher used marijuana in their personal life. Americans do, however, disapprove of parents smoking pot in front of their kids: 79 percent say they would have less respect for such a person.

5. Americans say weed is less risky than tobacco, alcohol or painkillers

By a margin of 72 percent to 20 percent, Americans say that regular alcohol use is more of a health risk than regular marijuana use. The margins for tobacco (76 to 18) and prescription painkillers (67 to 20) are similar.

But the public is split on whether pot is a risk in and of itself: 51 percent say using marijuana is a health risk, while 44 percent say it is not. Like any drug, there are indeed serious risks associated with marijuana use: addiction, long-term health problems, driving impairment, you name it. While it’s true that the risks associated with marijuana are generally lesser than the risks of using alcohol or other drugs, that doesn’t mean that it’s “safe,” full-stop.

6. Marijuana’s legal status isn’t a huge barrier to use

Asked why they don’t use pot, 27 percent of marijuana abstainers cited its illegality. But the rest pointed to a host of other reasons: 26 percent said they simply don’t like it. 16 percent said they don’t use because it’s not healthy. Others said that it would interfere with work or school or that they simply had no desire to use it.

These numbers are mirrored in another question: Asked whether they would use marijuana if the federal government legalized it nationally, only 28 percent said they’d be likely to do so. The rest said the legal change wouldn’t make much of a difference in their behavior.

This points to a simple reality: Marijuana is already the most ubiquitous illicit drug in the country, rivaling legal drugs like tobacco in popularity. For most people who want to use it, getting hold of some pot is simply a matter of a trip to the darkweb, or Craigslist, or a call to a friend-of-a-friend.

7. Most marijuana users are millennials

Fully 52 percent of the country’s 55 million pot users are millennials. Majorities of marijuana users are male, make under $50,000 a year and lack a college degree. Only 14 percent of current users are Republicans, and over two-thirds supported Hillary Clinton in the latest presidential election.

Interestingly, millennial marijuana users appear to be the most conflicted about their use: 25 percent of them say they’ve felt “guilty” about their marijuana habit, compared to only 17 percent of non-millennials. That brings us to the next point:

8. Few people want to admit they use marijuana just for fun

This is one of the survey’s most interesting findings: asked why they currently use marijuana, only 16 percent of smokers said it was “just to have fun.” The rest cited a variety of utilitarian reasons: 37 percent said they used marijuana to relax; 19 percent said they do it to relieve pain, 10 percent said it helps them be social.

If there’s any group in society who do something “just to have fun,” you’d think it would be marijuana users. The stereotypical image of the “stoner” is the guy blazed out of his mind on his couch, eating Funyuns and giggling at his TV.

But most users don’t see themselves this way. For them, marijuana is less about recreation and more of a product that fulfills a specific need in their life: relaxation, or pain relief, or social lubricant.

9. Where people hide their stash – dressers, fake cans or tins, or locked containers

Roughly four in 10 marijuana users hide their stash from others. Among those who hide their pot, the dresser (20 percent) is the most popular place of concealment, followed by fake cans, containers or books (11 percent), in safes or locked containers (11 percent) and the closet (8 percent).

Astonishingly, 3 percent of marijuana users keep their marijuana in their cars. If you’re familiar with the practices of highway drug interdiction you know this is a terrible idea. Drug task forces routinely use minor traffic infractions like busted taillights, failure to turn or speeding as a pretext for searching for contraband in a person’s car, often with the aid of a drug-sniffing dog.

Marijuana users say they hide their stashes to keep it away from the prying eyes of children, law enforcement and parents/grandparents, respectively.

10. More than half of marijuana users are parents

According to Marist, 54 percent of adults who use marijuana are parents. A majority of those parents – 16 million of them – have children under the age of 18.

Childhood exposure has been a big talking point for opponents of marijuana legalization. States like Colorado have seen an uptick in the incidence of small children inadvertently eating marijuana edibles and having to go to the emergency room. In raw number terms, however, these cases are still very rare. Nationwide, poison control centers get calls for pediatric exposure to marijuana and alcohol at identical rates once you control for the total number of users of both substances.

In the Marist survey, 94 percent of marijuana-using parents of underage kids say they’ve never used it in front of their kids or shared it with them.

11. Most people are open about marijuana use with their family and friends.

Marijuana users are very open about their habit with their significant others (95 percent of users have told them) and close friends (95 percent again). 72 percent have told their parents about their marijuana use, and 60 percent have told their kids.

Some families even toke together – 21 percent of users have either smoked marijuana in front of their parents or shared a joint with them. Among older users with adult children, 35 percent have smoked with or in front of their kids. Over 60 percent of users have done so with their close friends.

Millennials are the most social pot users – only 25 percent of them typically smoke alone. The rest usually share with significant others and friends. Older pot users are more likely to smoke alone: 40 percent of the over-35 crowd usually use marijuana by themselves.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Analyse von Tinley Beverages Cannabis Infused Hemplify Drinks

Ich finde die Tinley Beverages Comp. als ein sehr interessantes, junges und dynamisches Unternehmen und habe dazu mal einiges Zusammengeschrieben und analysiert.

Wenn es interessiert hier auf WO unter:

Wird Tinley Beverages Comp. durch Cannabis Infusion ein RED BULL ?

Link: http://www.wallstreet-online.de/diskussion/1251073-1-10/tinl…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://media3.marketwire.com/logos/20170214-TINLEY200.jpg

[/url]

[sunny3999]

Endlich auch mal wieder News vom Aphria Partner - Kalytera Therapeutics

Kalytera beantragt 5 Mio Forschungs- und Entwicklungsgelder von der israelischen Innovationsbehörde IIA
Link: https://globenewswire.com/news-release/2017/04/17/961274/0/e…


Und ein weiteres covering von Kalytera:
4 Top Stocks in the Growing Medical Marijuana Industry
http://www.huffingtonpost.com/entry/4-top-stocks-in-the-grow…

Aphria hatte mehr als 2 Mio in Kalytera investiert, das wird sich hoffentlich mal auszahlen!
• Invested just over $2,000,000 in Kalytera Therapeutics Ltd.

News dazu: https://aphria.com/aphria-records-fifth-consecutive-quarter-…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Auf Nachfrage: Hier der Kalytera Therapeutics Thread

Auf WO :
http://www.wallstreet-online.de/diskussion/1246909-neustebei…

Auf Stockhouse:
http://www.stockhouse.com/companies/bullboard?symbol=quezf

Auf INVESTORHUB bei ADVFN:
https://investorshub.advfn.com/boards/board.aspx?board_id=19…

Wird bei Finanzen unter Santa Maria Petroleum Aktie angezeigt:
Link: http://www.finanzen.net/boersenplaetze/Santa_Maria_Petroleum…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[Snaxico]

Antwort auf Beitrag Nr.: 54.765.400 von sunny3999 am 20.04.17 11:34:34

Definitiv sehr interessantes Unternehmen. US Cannabis Werte sind jedoch ziemlich gefährlich meiner Meinung nach. Klar auf der Staatenebene geht das alles aber man weiß nicht in wie weit die Regierung vielleicht dazwischen funkt. Fraglich ist auch in wie weit Tinley sich da von möglichen Konkurrenten absetzen können, da ja die Idee mit den Cannabis Drinks anscheinend schon was älter ist.

[sunny3999]

Antwort auf Beitrag Nr.: 54.766.570 von Snaxico am 20.04.17 14:01:27

Tinley Beverages Comp. ist ein in Toronto ansässiges kanadisches Unternehmen

Tinley Beverages Comp. Address:
TD Centre, 77 King St W Suite 2905
TORONTO, ON M5K 2A1
Canada

Tinley hat den Markt in den USA speziell Kalifornien ins Visier genommen.

Für weitere Infos und Beiträge gerne auf dem TINLEY Forum zu diskutieren:
http://www.wallstreet-online.de/diskussion/1251073-1-10/tinl…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://media3.marketwire.com/logos/20170214-TINLEY200.jpg

[/url]

[sunny3999]

APHRIA- Trading Halt

Toronto, Ontario--(Newsfile Corp. - April 20, 2017) - The following issues have been halted by IIROC:

Company:

Aphria Inc.

TSX Symbol:

APH (all issues)

Reason:

Pending News

Halt Time (ET)

08:16


IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are issued based on the principle that all investors should have the same timely access to important company information. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

- 30 -

For further information: IIROC Inquiries 1-877-442-4322 (Option 3) - Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.

image: http://www.newsfilecorp.com/newsinfo.php?i=26255&f=194



copyright (c) newsfile corp. 2017

Read more at http://www.stockhouse.com/companies/bullboard?symbol=t.aph&p…

[sunny3999]

Antwort auf Beitrag Nr.: 54.766.792 von sunny3999 am 20.04.17 14:38:39

APHRIA: Halted

LINK dazu: http://iiroc.mediaroom.com/index.php?s=2429&item=149315

[Popeye82]

www.stockhouse.com/news/newswire/2017/04/19/april-20th-a-bri…

[wouserxx]

Was kann das wohl sein? Bankrott?

[sunny3999]

Aphria Raises $100 Million to Fund Continued Expansion of Production Capacity and Other Strategic Op.

http://www.marketwired.com/press-release/aphria-raises-100-m…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://media3.marketwire.com/logos/20140605-aphria_r.png

[/url]

LEAMINGTON, ONTARIO--(Marketwired - April 20, 2017) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Aphria Inc. ("Aphria" or the "Company") (TSX:APH)(OTCQB:APHQF), a Health Canada Licensed Producer of medical cannabis products, announced today that it has secured a $100 million raise, including a $75 million bought deal equity financing and $25 million in debt financing through a five-year term loan. This is the first time Aphria has raised both debt and equity simultaneously.
The Company expects that 50% of the net proceeds of the Offering will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated between the working capital necessary to support the Company once the Part IV expansion is complete and strategic investments.
"This fund raising is a testament to the confidence of the investment community in Aphria's success to date and our vision for the future," said Vic Neufeld, Chief Executive Officer, Aphria.
"Through this raise, we are not only looking at the needs of today, but what Aphria is going to need to do in the years ahead to dominate the market. When completed in 2018, our four-part expansion plan is expected to supply more than 75,000 kg of high-quality cannabis at one of the lowest costs in the industry. We are well positioned to continue to provide shareholder value and meet the increasing consumer demand for medical and recreational marijuana," said Mr. Neufeld.
As part of the raise, Aphria entered into an agreement with Clarus Securities Inc., on behalf of a syndicate of underwriters (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a "bought deal" basis, 11,538,480 Common Shares (the "Common Shares") of the Company at a price of $6.50 per Common Share (the "Offering Price") for aggregate gross proceeds to the Company of $75,000,120 (the "Offering").
The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 1,730,772 Common Shares at the Offering Price, exercisable in whole or in part at any time for a period ending 30 days from the closing of the Offering. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the Offering will be $86,250,138.
The Common Shares will be offered by way of a short form prospectus to be filed in each of the provinces of Canada, other than the Province of Quebec, and in those jurisdictions outside of Canada and the United States which are agreed to by the Company and the Underwriters, where the Common Shares can be issued on a private placement basis, exempt from any prospectus, registration or other similar requirements. The deal is expected to close on May 9, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX.
The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act and all applicable state securities laws or compliance with the requirements of an applicable exemption therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The remaining portion of the raise is comprised of a 5-year, $25 million term loan with WFCU Credit Union ("WFCU") bearing interest at 3.95% and a 15-year amortization ("Debt Financing"). The facility will be entered into on May 9, 2017. The term loan is secured by a first charge on the Company's real estate holdings, a first position on a general security agreement, certain cash security and an assignment of fire insurance to the lender.

[wouserxx]

Wie lange dauert so eine Handelaussetzung? Hat jemand Erfahrung damit?

[wouserxx]

Oh, und scon ist sie wieder freigegeben.

[sunny3999]

Antwort auf Beitrag Nr.: 54.767.269 von wouserxx am 20.04.17 15:45:31

Schon erledigt, es wird wieder gehandelt...Alles GUT!

Die Finanzierung ist in einem Bought Deal verankert.

[Snaxico]

Ich weiß nicht was man davon halten soll. Einerseits ist neues Geld natürlich notwendig um die Expansion zu finanzieren und die 6,50 bilde jetzt eine solide Unterstützung. Andererseits ist das schon mal ne ordentlich Verwässerung.

[sunny3999]

Antwort auf Beitrag Nr.: 54.767.380 von Snaxico am 20.04.17 15:56:20

Es ist nur eine Zahl, die viele übersehen denke ich....

.....Phase 4 wird um 1 Jahr vorgezogen mit 1 Mio sf in 2018 statt 2019.

Ich denke es wird bald eine Neubewertung geben.

Denn die großen Jungs, die bei 6,50 eingestiegen sind werden es gerne sehen, daß ihr Wert steigt.

Ich schätze sonst würden sie keine 75+ Mio $ in ein Unternehmen reinpumpen.

Dazu kommt das Aphria 25 Mio von Banken finanziert bekommen hat, ich kenne kein Unternehmen im Cannabissektor das eine solide Bankfinanzierung erhalten könnte.

Die gestrige News mit TBP war übrigens sowohl für Kanada als auch USA für den Vertrieb vom MMJ gedacht.

Der Markt in dem sich TBP mit P0001 bewegt ist riesig.

Ich denke Aphria wird bald 2stellig Ende 2017 und mit den Partner werden sie nächstes Jahr den Gesundheitsbereich und Rec. Bereich auf den Kopf stellen.

Da wächst was richtig Gutes - und ich meine an kann das Geld schon riechen.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Aphria takes medical marijuana model to U.S. with $25 million investment in Florida

http://business.financialpost.com/investing/aphria-takes-med…

Sunny Freeman | April 5, 2017 | Last Updated: Apr 6 11:44 AM ET
More from Sunny Freeman
Rows of cannabis grows in Aphria's greenhouse.
Dax Melmer for National Post Rows of cannabis grows in Aphria's greenhouse.

Medical marijuana producer Aphria Inc. is expanding into the lucrative U.S. market with an initial $25 million investment to set up shop in Florida, which recently legalized pot for medical use.

The foray is its first major step in a U.S. expansion strategy through a series of transactions. The result will be a new company called Liberty Health Sciences Inc., a subsidiary of Canadian Securities Exchange-listed SecureCom Mobile Inc. that will acquire Chestnut Hill Tree Farm, which is one of the seven companies licensed in Florida to dispense marijuana to patients.

The company, which will operate in the U.S. as Aphria USA, plans to expand into the 28 states that have legalized medical marijuana, it announced after markets closed Tuesday. It will also raise $35 million through a private placement.

“Now it’s time for the next chapter of the Aphria growth story,” said Vic Neufeld, Aphria’s chief executive officer, who will be appointed to Liberty’s board.

The company is focused on medical marijuana in the U.S. to avoid legal headaches. Still, it looked into states, where recreational marijuana is also legal, but none of them allowed an operation as large as Aphria wants.


“If we can’t go big, we’re not going at all.”

Florida’s demographics and regulations were most attractive from Aphria’s standpoint. The company has also identified three other states it is interested in entering in the near future.

Related
Marijuana ETF ‘the most scrutinized fund that we’ve ever launched,’ Horizons CEO says
Marijuana stocks on fire after report that Canada’s legalization bill is in the works for 2018
Liberty will license the Aphria brand in exchange for a three per cent royalty on sales. It will also licence Aphria’s intellectual property in exchange for shares in Liberty. Aphria will appoint two nominees to Liberty’s five-person board of directors and own 37.6 per cent of Liberty shares.

The investment comes after recent comments by U.S. attorney general Jeff Sessions widely interpreted as reassuring that there will not be a crackdown on the contentious status of marijuana in the U.S. Despite the legality of weed in several states, it remains illegal at the federal level, leading to a confusing regulatory environment for companies and investors.

That disconnect between state and federal laws presents Canadian companies with a unique competitive advantage. Aphria will focus on the medical market because it is least contentious at the federal level, Neufeld said.

The move from Aphria, “a very sophisticated and large player in the sector,” points to the increasing “investability” of the U.S. marijuana sector, said marijuana analyst Vahan Ajamian.

“We view this transaction as a clear signal that the skittishness some investors have regarding investing in the U.S. marijuana sector is diminishing,” he wrote in a note Wednesday.

Aphria, which grows products in greenhouses based in Leamington, Ont., has established itself as a leading low-cost marijuana, growing at less than $2 a gram. Growing costs are an important metric in the burgeoning sector as an influx of expected competition will drive prices down and compress margins.

Aphria also has an ownership stake in Copperstate Farms, an Arizona based medical marijuana producer and holds an eight per cent interest in Canadian-listed CannaRoyalty, which holds a portfolio of U.S.-based marijuana-related companies.

Though Canadian companies can not legally export their products into the U.S., the expertise they have gained are a valuable export many are hoping to sell in an increasing number of countries where marijuana is legal in some form.

“We believe as the opportunity set in the U.S. continues to grow, Canadian licensed producers will be primed to invest in U.S. operators that will likely want to leverage the technical proficiency and know-how accumulated as a result of the robust regulatory framework found in Canada,” said Matt Bottomley an analyst at Canaccord Genuity.

Shares in Aphria rose five per cent Wednesday to trade at $7.21 per share in mid-afternoon trading on the Toronto Stock Exchange.

[e-mail]

[Sandy98]

Antwort auf Beitrag Nr.: 54.768.535 von sunny3999 am 20.04.17 18:03:02

Dann gebe die Super Info auch bitte im Bullboard bekannt

Aphrias Strategie ist Perfekt

[sunny3999]

Antwort auf Beitrag Nr.: 54.770.383 von Sandy98 am 20.04.17 21:20:46

Zitat von Sandy98: Aphrias Strategie ist Perfekt

Was genau meinst du und in welchem Bullboard ?

[Sandy98]

Antwort auf Beitrag Nr.: 54.770.416 von sunny3999 am 20.04.17 21:24:09

Verwechselung?

Ohh ich meinte gelegentlich auch was von dir bei Stockhouse.com in dem Forum von Aphria, welches sich Bullboard nennt, gelesen zu haben, vielleichzt verwechsel ich dich auch. Dort ist die Stimmung ziemlich euphorisch...

[sunny3999]

Antwort auf Beitrag Nr.: 54.770.461 von Sandy98 am 20.04.17 21:29:18

Das bin schon ich im Stockhouse nur es wurde dort bereits gepostet...

....deswegen habe ich es nicht nochmal kommentiert....

[sunny3999]

Comparing Marijuana Companies: 2 New Kids on the Block

Chris MacDonald | April 20, 2017 | More on: WEED ACB APH
http://f.canada.foolcdn.com/wp-content/uploads/2017/04/Marij…

In this article, I will discuss two up-and-coming Canadian cannabis producers looking to revolutionize the marijuana industry. Aphria Inc. (TSX:APH) and Aurora Cannabis Inc. (TSXV:ACB) have taken steps to grow their brands and mop up more market share of late.

As most marijuana enthusiasts and investors know, the top spot in the cannabis industry belongs to the incumbent Canopy Growth Corp. (TSX:WEED). With a market capitalization of over $1.5 billion, Canopy has taken advantage of its branding, early Health Canada approvals for sale and export, and a first-mover position in the market to become the dominant force in the industry of late.

Currently, Canopy leads the pack in terms of the number of square feet of production space among its peers with 650,000 square feet available and another 300,000 square feet planned as additions to its base.

The only two companies with the scope, scale, and differentiation abilities to take on a giant like Canopy are Aphria and Aurora. Each company produces marijuana differently and in different parts of the country, enabling the individual companies to better focus on gaining market share in their respective “home turf,” while making Canopy’s job to remain number one a difficult one.

Aphria Inc.

Aphria’s greenhouse facilities in Leamington, O.N., are one of the differentiating factors behind its growth model. While other cannabis producers use greenhouses, Aphria grows 100% of its product using natural sunlight — a selling point for even the most earth-conscious consumer. Aphria’s facility is set to be expanded to 900,000 square feet; that’s enough square footage to officially take on Canopy and challenge for top spot in the Canadian market.

Aurora Cannabis Inc.

Aurora has been busy with a massive production expansion of its own, but in a different way than its competitors. Aurora’s selling point to investors has been the prototype for its new Aurora Sky facility, which promises to revolutionize the way marijuana is grown.

The production plan Aurora has put forward would result in a slightly smaller facility (approximately 800,000 square feet), boasting production efficiencies of nearly double those of Aphria or Canopy. Such cost-reduction and margin-producing initiatives have positioned Aurora as the potential king of profitability in an industry that is soon to be bombarded with supply.

The bottom line

I am a believer in the power of a differentiation advantage as well as a cost advantage. My take on this industry is this: while it may still be considered “niche” as a whole and not yet fully matured or conventional, when the time comes for these three major players to carve out their territories and begin marketing to the masses, the race is on.

I don’t have a horse I would bet on yet, but I would venture a guess that these two competitors will make Canopy’s life difficult, at least in the early stages of legalization. And who knows? More acquisitions could be on the way. In either scenario, things are about to get interesting really fast.

Stay Foolish, my friends.

[wouserxx]

Dann reagiet man jetzt wohl auf die definitive Legalisierung im kommenden Sommer.

[sunny3999]

Antwort auf Beitrag Nr.: 54.770.560 von wouserxx am 20.04.17 21:42:26

Zitat von wouserxx: Dann reagiet man jetzt wohl auf die definitive Legalisierung im kommenden Sommer.

Für Aphria ist die Legalisierung eher zweitrangig, da sie im medizinischen MJ den Markt suchen.

Rec wird dann wohl das Sahnehäubchen.

[wouserxx]

Antwort auf Beitrag Nr.: 54.770.668 von sunny3999 am 20.04.17 21:57:44

Meinste man hätte es trotzdem vorgezogen, wenn man die Legalisierung nicht im April offziell gemacht hätte?

[sunny3999]

Antwort auf Beitrag Nr.: 54.770.842 von wouserxx am 20.04.17 22:21:34

Zitat von wouserxx: Meinste man hätte es trotzdem vorgezogen, wenn man die Legalisierung nicht im April offziell gemacht hätte?

Aphria kann mit Phase III, den anstehenden Markt mit Shoppers Drug Mart nicht bedienen und man will natürlich rechtzeitig den Rec Markt vorbereiten.

Aphria muß schon Gas geben, wenn sie die Marktanteile auch im Rec. gewinnen will.

[sunny3999]

Auch wenn ich der Meinung, bin Aphria könnte noch die nächsten Wochen....

.....ein auf und ab durchlaufen, aber langfristig gesehen wird es wohl doch eine sehr profitable Anlage werden - siehe Schaubild.

Q4 Zahlen könnten nochmal auf dem Level von Q3 sein, damit werden die großen Jungs wohl spielen und die Kurse auf und ab bewegen. Wer darüber hinaus sieht und nicht an ein paar Trades interessiert ist, wird dieser Umstand nichts anhaben.

In 2029 alleine in den USA ein 100 Mrd. US$ Markt und nahezu eine 50/50 Ausrichtung von medizinischem/ Spaßfaktor Cannabis. Deswegen setzt Aphria auch auf die Qualität im medizinischen Sektor, der Rest (Spaßfaktor) kommt dann von alleine.

[wouserxx]

Bei Betrachtung der Zahlen fängt man natürlich an zu träumen. Und noch mehr träumt man, wenn man sieht, dass hier nur vom US-Markt die Rede ist. Für mich sind aber nur die Zahlen bis 2020 ernst zu nehmen. Alles andere ist mir dann doch zu viel der Spekulation.
Wie viel vom Kuchen Aphria abbekommen wird, ist noch einmal eine andere Frage.
Ich werde versuchen mein Einstieg jetzt noch etwas zu verbilligen. Wie du chon sagtest, die Großen werden sich den Kurs vielleicht nochmal etwas zu Herzen nehmen. Vielleicht geht es nochmal kurz unter die 6 Dollar.

[sunny3999]

Antwort auf Beitrag Nr.: 54.773.911 von wouserxx am 21.04.17 11:54:46

Hier noch ein Schaubild warum Aphria seine Hausaufgaben gemacht hat!

Da bekommt die Phrase von Trump "AMERICA FIRST" gleich eine ganz andere Bedeutung!
https://www.royalqueenseeds.de/blog-die-kunterbunte-truppe-d…

[sunny3999]

VICE Canada Talks Marijuana with Prime Minister Justin Trudeau

TORONTO, April 18, 2017 /CNW/ - Following last week's unveiling of the Canadian Government's marijuana legislation, VICE Canada will be sitting down with Prime Minister Justin Trudeau on April 24th to facilitate a national conversation about how this shift in drug policy could bring about a fundamental shift in Canadian society. The Prime Minister will be joined by Bill Blair, Member of Parliament for Scarborough Southwest and Parliamentary Secretary to the Minister of Justice and Attorney General of Canada.

Hosted by VICE Canada's Manisha Krishnan, this event brings together stakeholders from both the legal and grey market cannabis industry to ask the Prime Minister the most pressing questions they have about what's next once marijuana becomes legal in Canada.

"Canadians have a lot of questions, from those who currently use medical marijuana, to those engaged in the active grey markets in cities like Toronto, Vancouver, and Montreal. This is a story that spans across so many sectors and Canadians are curious about how this change will impact their community, their health, and even their livelihood," said Patrick McGuire, Head of Content for VICE Canada. "This is an important, national conversation and we're proud to have VICE Canada facilitate it."

The event will be live streamed on VICE.com and Facebook on April 24th at 6:30 pm ET. Select clips from the broadcast will be made available to media upon request.

For information on how to join the live studio audience, follow VICE Canada on Facebook and Twitter.

ABOUT VICE CANADA:

VICE Canada is a leader in producing and distributing high-quality youth focused content, in both official languages, reaching millions of Canadians a month. VICE's original and often provocative content is available across multiple platforms including, ten award-winning digital verticals, mobile apps, linear television, print and a suite of record-breaking YouTube channels. Since entering into a joint venture with Rogers Media in 2014, VICE Canada has been aggressively expanding, launching a state of the art production studio in Toronto, Daily VICE, a daily mobile news show, and VICELAND -- VICE Media's first television channel. VICE Canada is the recipient of numerous awards for its content including Canadian Screen Awards, The Webby's and Quebec's Gemeaux awards.

SOURCE VICE Canada


For further information: Chris Ball, Head of Communications, VICE Canada, P: 416-737-9559, E: [e-mail]

RELATED LINKS
www.vice.com

[sunny3999]

Übrigens gibt es NEWS bei TINLEY BEVERAGES Comp.

http://www.wallstreet-online.de/diskussion/1251073-1-10/tinl…

oder direkt hier: http://m.marketwired.com/press-release/tinley-produces-initi…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://media3.marketwire.com/logos/20170214-TINLEY200.jpg

[/url]

[sunny3999]

Antwort auf Beitrag Nr.: 54.773.911 von wouserxx am 21.04.17 11:54:46

Zitat von wouserxx: Bei Betrachtung der Zahlen fängt man natürlich an zu träumen. Und noch mehr träumt man, wenn man sieht, dass hier nur vom US-Markt die Rede ist. Für mich sind aber nur die Zahlen bis 2020 ernst zu nehmen. Alles andere ist mir dann doch zu viel der Spekulation.
Wie viel vom Kuchen Aphria abbekommen wird, ist noch einmal eine andere Frage.
Ich werde versuchen mein Einstieg jetzt noch etwas zu verbilligen. Wie du chon sagtest, die Großen werden sich den Kurs vielleicht nochmal etwas zu Herzen nehmen. Vielleicht geht es nochmal kurz unter die 6 Dollar.

Ich hoffe auch noch auf ein paar günstige....

[sunny3999]

Aphria Partner - Tokio Smoke nach dem Legalisierungsvorhaben der Regierung in Canada ab 1,28"

Alan Gertner CEO von Tokio Smoke die haben wohl schon einen zweiten Laden in Seattle (Washignton State-USA):
http://www.citynews.ca/video/iframe/593482582001/BJhT9zpyg/5…

[sunny3999]

Aphria Podcast: Difference between Dried Cannabis and Cannabis Oil

https://aphria.com/podcast-difference-between-dried-cannabis…

Welcome to our second podcast!

The purpose of our podcast series is to help both current and potential patients navigate the complexities of medical cannabis. Through the series, we intend to help you better understand the benefits of medical cannabis by sharing valuable information in the form of informative tips and recommendations across a series of topics.

Today’s podcast explains the difference between dried cannabis and cannabis oil. From consumption methods to onset effects, our Patient Ambassador, Beth Harris, offers a great overview of what you need to know when consuming both forms of medical cannabis.

[sunny3999]

Weitere gute Nachricht von der Regierung Canadas - Steuern werden niedrig sein

http://www.cbc.ca/news/politics/pot-taxes-morneau-1.4079823

Pot taxes will stay low in order to push out criminals, Morneau suggests

Finance minister says key question is: 'How do we tax in a way that makes sure we get criminals out?

By Alexander Panetta, The Canadian Press Posted: Apr 21, 2017 1:18 PM ET Last Updated: Apr 21, 2017 1:18 PM ET

Finance Minister Bill Morneau says maximizing revenues is not the priority on cannabis legalization.

Canadians approve of pot legalization but not all the details: poll
Ottawa wants young teens to avoid criminal record for pot possession
Enforcing new marijuana laws will be costly, warns justice minister
No plan for pot-conviction amnesty amid legalization move, Liberals say
Weed legalization bill gives answers on future of pot in Canada, but questions remain
How to legalize marijuana, without ever saying 'marijuana'
Here's some good news for Canadian pot smokers: high taxes will not join the munchies, the pasties and short-term memory loss as unwelcome side effects of smoking up.

The Canadian government is hinting it wants to keep pot taxes low.

As the feds design taxation policy for soon-to-be-legalized marijuana, Finance Minister Bill Morneau said Friday that he will be guided by one main goal: squeezing out the black market.

Liberals table bills to legalize pot, clamp down on impaired driving
Pot legalization bill provides many answers, but leaves some key issues in limbo
Enforcing new marijuana laws will be costly, warns justice minister
He is adamant that maximizing federal revenues is not, and will not be, the priority on pot, suggesting Ottawa favours keeping prices competitive against the street value in order to push the local pusher out of business.

"The driver as we look at taxation in this sector will be, 'How do we tax in a way that makes sure we get criminals out?'... That gives you context for the way we're thinking about it," Morneau said in a roundtable interview.

"The key issue is to make sure we eliminate the black market. It's straightforward. The first issue has to be our focus on that. Which means we are thinking about taxation in the context of how we get at that first objective...

"Revenue maximization is absolutely not our goal."

Too much tax would spur black market: Report

A new C.D. Howe report puts a price tag on the goal Morneau describes.

It finds that 90 per cent of the illegal market would disappear if pot cost $9 per gram, and governments applied only existing sales taxes, producing $675 million a year in federal and provincial revenues.

But the report concluded illegal sales would retain half the market if governments tried squeezing $1 billion in revenue from the sale of marijuana — and that's the scenario Morneau says he doesn't want.

But don't expect to hear the feds trumpeting Canadians' ability to get high without high taxes. Ottawa's messaging on the issue has been extremely sober, emphasizing the goal of displacing black-market vendors who sell to kids.

"Our current approach on marijuana is failing Canadians," Trudeau told a news conference Friday on Parliament Hill.

"We need to make it more difficult for underage Canadians to access marijuana; we are not doing that right now, the current prohibition does not work, which is why we're going to legalize and control the sale of marijuana ....

"We're going to end the billions of dollars in profits that flow into organized crime and criminal street gangs every year through the sale of this illicit drug."

Vancouver 4/20
Pot advocates gathered in Vancouver and across Canada Thursday for what has become known as 4/20, an annual held to push for legalization of cannabis. (Rafferty Baker/CBC)

In public, Morneau has avoided any deep discussions about marijuana taxation and its potential revenue impact.

Another thing the government has avoided discussing is the potential consequences of disrupting the criminal market.

A lengthy, detailed piece in Esquire magazine charts how Mexican criminal gangs saw U.S. states starting to legalize marijuana a few years ago, figured that market would soon dry up, and ramped up production of another product: heroin.

[sunny3999]

Chartguys Analyse - Konsolidierung auf 6,60 ?

[sunny3999]

Windsor Star schreibt: Medical cannabis producer plans to grow again

Mary CatonMARY CATON
http://windsorstar.com/news/local-news/medical-cannabis-prod…
Published on: April 21, 2017 | Last Updated: April 21, 2017 7:40 PM EDT
A dump truck unloads dirt near the Aphria company in Leamington on April 21, 2017. The medical cannabis grower is working on a multi-million dollar expansion.
A dump truck unloads dirt near the Aphria company in Leamington on April 21, 2017. The medical cannabis grower is working on a multi-million dollar expansion. DAN JANISSE / WINDSOR STAR

The hierarchy at Aphria Inc. had a busy week positioning the company for a significant expansion of its cannabis production in the wake of the federal government’s plan to legalize pot next year.

The Leamington-based producer of medical cannabis products announced Thursday it had secured $100 million to fund continued expansion and strategic investment.

That came on the heels of Wednesday’s joint announcement with Tetra Bio-Pharma Inc. to distribute dried medical cannabis in the Maritime provinces and Quebec.

Tetra and Aphria are also working towards developing a prescription drug that would be marketed in both the U.S. and Canada.

“It really goes back to our vision of Aphria of having one million square feet of greenhouse grow,” CEO Vic Neufeld said.

A dump truck unloads dirt near the Aphria company in Leamington on April 21, 2017. The medical cannabis grower is working on a multi-million dollar expansion. DAN JANISSE / WINDSOR STAR
Aphria negotiated a $75-million equity financing deal with Clarus Securities Inc. with the sale of just over 11.5 million common shares at $6.50 per share.

The remaining $25 million was secured via a five-year loan from the Windsor Family Credit Union.

The company’s footprint occupies 52 acres, employing 120 people and producing 2,600 kilograms of pot a year.

With an eye towards legal recreational use, expansion plans call for producing 75,000 kilos a year and employing up to 400 people.

Recently tabled Liberal legislation will legalize pot for recreational use, sale and cultivation. It will allow those 18 years and older to possess up to 30 grams of dried or fresh cannabis.

“The government is going to need a supply line and that’s what we’re doing,” Neufeld said. “To be first in line, best in class you need to set your sights and commit to it.”

When the company completes Phase 1 of a four-part expansion plan this fall, they will have 300,000 square feet of greenhouse grow available.

Phase 4 plans are focused on the infrastructure needed to supply the recreational use market. That phase will include the brick-and-mortar elements such as a kitchen and bakery for future edible products.

“We don’t need it now,” Neufeld said. “This is to fund our vision and strategies.”

Aphria is currently the second largest medical cannabis grower in the country but Neufeld believes when the dust settles on all of their expansion plans, they’ll own the top spot.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://wpmedia.windsorstar.com/2017/04/aphria-leamington-on-april-21-2017-a-dump-truck-unloa-e1492810553441.jpeg?quality=55&strip=all

[/url]

[sunny3999]

Bei den Americanbulls lag die Verkaufentschediung am 11 April punktgenau!

https://www.americanbulls.com/SignalPage.aspx?lang=de&Ticker…

Aktuell schreiben sie noch Bar beibehalten, man kann aber an der Historie auch erkennen, das sie schon manches mal bei roten Kreuzen daneben lagen....

Mal sehen was geht und ob der Spruch "Sell in May and go away" sich bewahrheitet.....

[sunny3999]

Aphria Direktor kauft Aphria Aktien am Markt

017-04-18 2017-04-20 $APH
Aphria Inc. (formerly, Black Sparrow Capital Corp.)
Waddington, Philip
4 - Director of Issuer
10 - Acquisition or disposition in the public market +5,000 6.7000 30,007

[wouserxx]

Hallo sunny,

du hast doch schon durchgerechnet, wo der Kurs in zwei bis drei Jahren stehen könnte. Wenn man wirklich nur von den Fundamentalwerten ausgeht und annimmt, der Kurs folgt dem Buchwert, also keine Form der Überbewertung stattfindet. Mit welchen Kursen kann dann beispielsweise Ende 2018 rechnen, wenn die Legalisierung ein halbes Jahr durch ist?

[derdieschnautzelangsamvollhat]

Hi @all,

hab mir den Wert in den letzten Wochen etwas näher angesehen und bin zum Schluß gekommen, dass die Aktie zum gegenwärtigen Preis auch unter Einbeziehung mglicher positiver Deals in der Zukunft; overhyped ist.

Die derzeitige MK von 550 Mio.€ entspricht einem jährlichen Umsatz enstsprechend 100 Millionen Gramm getrockneter Grasblüten. Aphria wird derzeit mit dem 5 - 6 fachen des Umsatzes bewertet ! Das Marktpotential mag zwar; entsprechende aber noch nicht beschlossene Legalisierungsgesetze einbezogen; hundertmal größer sein, aber Aphria ist ja nicht alleine am Markt, und ob sich die derzeitigen Verkaufspreise mittelfristig und a la longue halten lassen steht auf einem anderen Blatt.
Theoretisch ist es seit einigen Wochen auch bei uns möglich, Cannabis ziemlich unkompliziert auf Rezept zu erhalten. Das nützt allerdings keinem, wenn Ärzte nach wie vor die Bedenken der 1960er Jahre im Kopf haben, nicht verschreiben, weil sie für herkömmliche Medikamente vielleicht mehr an Benefits erhalten, oder die Kassen die Kostenübernahme verweigern; die Patienten wieder in den Schwarzmarkt getrieben und damit weiter kriminalisiert und bei Auffallen bestraft werden. Natürlich bleibt bei Verweigerung der Kostenübernahme durch die Kassen (die dazu auch noch falsche und unzureichende Informationen zum neuen Gesetz auf ihren Homepages verbreiten) noch der Weg über die Eigenfinanzierung. Nur, warum sollte ein Patiient 20€/g für z.B. Bedrocan in der Apotheke bezahlen, wenn er/sie am Schwarzmarkt oder Coffieshops mit einem Viertel bis Hälfte des Preises für identidsche Ware bedient wird ?

Fazit: Aphria ist eine interessante Anlage mit viel Phantasie, zum derzeitigen Preis aber auch mit viel Risiko dahinter. Bei 450% 12 Monats-Performance ist viel Luft nach unten, nach oben wird sie ziemlich dünn, wie der kurze Ausflug auf 6 € gezeigt hat.

[wouserxx]

Sehe das ähnlich. Interessant wird es auch, wenn die Qualität der Produkte zum tragen kommt. Ich hatte schon mal etwas recherchiert und mich etwas über die Qualität des Stoffs von Aphria informiert. Die meisten Bewertungen waren positiv, aber es gab auch einige negative. Meistens war denen das Zeug zu trocken, aber ob das für die heilende/schmerzlindernde Wirkung von Bedeutung ist, kann ich nicht beurteilen.
Wie wirkt sich die Anbaumethode von Aphria auf die Qualität der produkte aus? Kann das hier jemand beurteilen?

[Aktiengeier_1]

Antwort auf Beitrag Nr.: 54.808.063 von derdieschnautzelangsamvollhat am 26.04.17 11:12:10

Hier eine schöne neueste Austellung zu Aphira mit einer Prognose zum möglichen Gross Profit................trotz Rücksetzer im Cannabis Segment weiter ein Longinvest für mich.




https://smallcappower.com/top-stories/aphria-inc-canadian-ma…

[Scorpio1921]

mit der Überbewertung sehe ich das Anderst.

zum Thema Schwarzmarkt: ein kranker mensch hat bestimmt lust auch noch nach nem dealer zu suchen, der keinen scheiss mit dem zeug macht, dann möchte ich bitte wissen, wie ihr europapreise und dem damit verbundenen europa mit aphria in verbindung bringt..bedrocan mit canopy beliefern D...... aphrias zeug kostet zwischen 6-8CAD und besondere Sorten bis 12,50CAD ..

der REC-Markt wird den Umsatz so oder so steigen lassen, weils ihn vorher einfach nicht gab

[derdieschnautzelangsamvollhat]

Antwort auf Beitrag Nr.: 54.809.986 von Scorpio1921 am 26.04.17 14:22:02

Niemand braucht nach einem Dealer zu suchen, in Kanada können sich im Zuge der Legalisierung sowohl die Kranken als auch die Relaxer mit vier Pflanzen selbst versorgen und damit den Preis auf ca. 2€ oder 3 Can.$ drücken. Wie in den NL auch. Exclusive einmalige Kosten fürs Equipment.

Aphria verlangt 8.50 pro Gramm exc. shipping von den Dispensaries..In Colorado (USA) und Kanada gibt es die Unze (28g) ab 130 US-Dollar, ca. 170 -180 can.$ = Can.$ 6,50/g !! = € 4.50 !! für den Endverbraucher !

Die von Aktientiger eingestellten Revenues und Gross-Profits sind m.E. nicht nur deshalb Wunschträume, sondern weil in Canada quasi seit Jahren eine Duldung durch die Hinterür läuft. Auf Bundesebene zwar verboten, die Provinzregierungen und Städte entscheiden aber im Gegensatz zu uns was läuft. Ähnlich wie in den NL. Den kanadischen Rec-Markt gibt es längst und er wird längst offiziell beleifert. Ähnlich wie es in in Kaliforniuen war, verschreiben die Ärzte gleich nebenan in fünf Minuten gegen geringe Gebühr.

[derdieschnautzelangsamvollhat]

Hier ein Link zu einer Dispensary in Denver; Co. In Canada ca. auf demselben Preislevel.

https://localproduct.co/

[derdieschnautzelangsamvollhat]

Tipp für deutsche Cannabispatienten ohne Kostenübernahme durch die Kassen

Wer nicht allzuweit von der niederländischen Grenze entfernt wohnt, sollte sein Rezept für Medizinalhanf in einer niederländischen Apotheke einlösen und bis zu 50% sparen. Geht auch bei anderen in Deutschland verschriebenen Medikamenten. (Pille etc.)

[AktiesuchtBauer]

Antwort auf Beitrag Nr.: 54.808.063 von derdieschnautzelangsamvollhat am 26.04.17 11:12:10

und bitte nicht wundern, wenn hier nochmals Kurse unter 3,- € zu sehen sein werden

[wouserxx]

Antwort auf Beitrag Nr.: 54.811.450 von AktiesuchtBauer am 26.04.17 16:51:03

Darauf habe ich mich auch schon eingestellt. Die Frage ist nur, wo der Kurs in zwei bis drei Jahren stehen wird, wenn man wirklich konservativ prognostiziert.

[Aktiengeier_1]

Antwort auf Beitrag Nr.: 54.811.450 von AktiesuchtBauer am 26.04.17 16:51:03

Ich halte dagegen.........keine Kurse mehr unter 3 Euronen........im Moment schwächelt das ganze
Segment nicht nur Aphira......wenn der MARIJUANA INDEX wieder nach oben dreht dann werden wir
mal sehen.......DYOR

Die Seite ein schöner Überblick auch zu Einzelwerten.
https://marijuanaindex.com/


Charttechnisch ein schöner Wiederstand bei 6 Can$.... Stochastik am drehen, MACD auch unten.

[AktiesuchtBauer]

Antwort auf Beitrag Nr.: 54.811.618 von wouserxx am 26.04.17 17:05:47

langfristig sehe ich eine positive Tendenz
bis Ende 2018 ~~~ wohl auch 2 stellig

[derdieschnautzelangsamvollhat]

Antwort auf Beitrag Nr.: 54.811.450 von AktiesuchtBauer am 26.04.17 16:51:03

@Aktiengeier;

Kurs hängt wohl auch von der Marktentwicklung insgesamt ab.

Im Posting von 11.12 hab ich mich beim KUV grob vertan, liegt auf Basis der prognostizierten 2018-Soll-Umsätze bei ca. 24 und das KGV bei 7. Danach wirds meiner M. nach schwerstens spekulativ und es würde mich wirklich interessieren, wie man analysiert hat bzw. welche Rahmenbedingungen und Chancen angenommen wurden, um auf diese Zahlen zu kommen. Riusikoanalyse und -Bewertung war wohl nicht.

Erinnert mich ein wenig an die Jahrtausendwende. Da gabs auch massig Unternehmen mit 10 - 20 Mio. Umsatz und in der Spitze einer MK von ein bis zwei Milliarden. War aber auch kein Problem, ein paar Tausender am Tag zu erzocken oder long zu bleiben, wenn man früh genug eingestiegen ist (bevor die Läden über den Jordan gingen oder letzten Endes dort landeten wo sie fiundamental hingehörten.)
Soll kein Bashing sein, Aphria hat Chancen und Potential; bleibt nur die Frage wieweit das bereits ausgeschöpft ist. Kann-Szenarien gibt es nämlich weit mehr, als die nackten Zahlen im forecast suggerieren. Wer schon mit Businessplänen zu tun hatte oder solche selbst geschrieben und anschließend die Ist-Soll-Abweichungen gesehen oder erlebt hat, wird das besonders gut verstehen.

[MPX1989]

Entweder man glaubt an das Potenzial des Marktes und an Unternehmen wie Aphria oder nicht! Ich glaube dran...

[sunny3999]

Gap bei 6,20 $ geschlossen....

...bought deal am 9 May wird geschlossen, Phase 2 News steht an.

Zeit wieder einzusteigen....

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Two Charts Show Why Aphria Is the Top Weed Stock for 2017

http://www.profitconfidential.com/stock/charts-aphria-top-we…
Aphria StockIs Aphria Stock the Top Marijuana Stock?
You’ve seen unicorns, haven’t you? No, not the mythical horse with a horn on its head. I’m talking about the Silicon Valley tech startups that have scored billion-dollar valuations even before going public.
But have you seen narwhals?, the unicorns of the North? They are the billion-dollar companies of Canada. Of particular note is one odd company, the first-ever billion-dollar marijuana company. Yes, marijuana stocks are an actual thing in the investing world. And everyone seems to be out hunting for the top marijuana stocks these days. I’ve hunted down my top pick: Aphria Inc (TSE:APH, CVE:APH).
But first, in case you’ve missed this investment idea, let me break it down for you.
Canada is set to become the second country in the world to legalize pot, after Uruguay. The groundbreaking decision from the federal government is expected to be realized by Canada Day (July 1) next year.
Here’s what happens next.
Once recreational marijuana is legal, the drug’s illegal underground market will breathe its last breath. This can only mean one thing. The money that goes to drug cartels gets diverted to legal marijuana businesses. Plus, the demand for recreational marijuana also goes up in a free environment. As a consequence, legal marijuana growers and sellers make a killing. It’s very simple. No rocket science here.
So naturally, many bought the rumor before Canada’s government confirmed the news of legalization, and started racking up on marijuana stocks. In the last six months, Canadian marijuana stock prices skyrocketed as they became the Holy Grail for investors looking to make quick fortunes.
This brings us full circle to the first unicorn or, so to say, the narwhal in Canada’s marijuana industry. Canopy Growth Corp (TSE:WEED, CVE:CGC), hit a billion-dollar market cap for being the most high-in-demand marijuana stock—not just for having a catchy ticker symbol, but for being the biggest marijuana grower in Canada.
It doesn’t take a highly qualified financial analyst to see that WEED stock is now grossly overvalued because speculators, right and left, are in on it. So, of course, some eyes are now shifting to the next candidate in line.
Aphria Stock Analysis
Aphria is now the front-runner in the race to hit the billion-dollar valuation mark. Aphria’s claim to fame is being one of Canada’s lowest-cost producers of marijuana, and one of the only four marijuana companies in Canada that has gone international.
While there are a handful of other Canadian marijuana stocks out there, this one deserves a special mention for another reason. APH stock is one of the very few that managed to move to the Toronto Stock Exchange (TSX) over a month ago.
Yes, APH stock graduated from TSX Ventures to TSX in February to join the league of top cannabis producers. Why does it matter? Because only the best of the bunch gets listed on the TSX, after meeting the the exchange’s stringent listing criteria. Most other marijuana stocks continue to be listed on the Canadian Stock Exchange (CSE) because they are are less liquid, less transparent, and—as a result—riskier.
There are more reasons why I’m bullish on Aphria stock over Canopy Growth stock.
For starters, Aphria, which grows its plants outdoors in greenhouses, saves on production costs when it compares itself to indoor growers like Canopy Growth, which have to be more capital-intensive. Here’s a snapshot of what Aphria’s costs look like compared to its peers.
Source: Latest Annual Report (*Competitors here mean indoor growers)
*Competitors mean indoor growers
(Source: “2016 Annual Report,” Aphria Inc, July 27, 2016)
Being a low-cost producer, Aphria can pull high margins and divert the savings to its bottom-line numbers. That’s exactly what you see in its latest quarterly report. Aphria’s gross margins are in excess of a whopping 78%. This is why it has managed to return a profit to its stockholders despite most marijuana stocks losing money today.
Secondly, its ongoing expansion makes APH stock a promising growth play. The company is now expanding to a massive one-million square feet of growing capacity, with an aim to deliver up to 70,000 kilograms in output.
On top of that, Aphria is expanding into the U.S. for the first time. The company has announced this month that it is making a foray into the U.S medical marijuana market, with Florida as its first stop and, later, other states. This further opens the doors for U.S. investors who otherwise may find Canadian companies risky.
Take note that Aphria, like its peer, Canopy Growth, has been consistently growing its sales figures. But, if you look at the revenue growth chart below, you’ll notice how Canopy Growth is seeing a steady decline in revenue growth, and Aphria’s growth has added sporadic spikes.
One can see how Aphria’s expansionary initiatives are lending to bursts of revenue growth every other quarter.
Data Source: Company Filings
(Data Source: Aphria Inc and Canopy Growth Corp company filings.)
I must point out that growth is usually volatile during a company’s early years of expansion. But the healthy sign is that Aphria is the first company of its kind that has managed to deliver consecutive quarters of profitability. So I’m not very skeptical in the long run.
Aphria Stock Prediction 2017
Aphria stock is now shooting for the moon, with a triple-digit jump in under six months. Its price chart is a stunning sight with a clear technical uptrend in play. The bullish MACD crosses (I’ve marked in green) reaffirm the bullish advance.
In case you’re new to technical analysis, you don’t have to know the nitty-gritty of technicals here. Just know the basic rule of thumb. The MACD line is a technical indicator (the black line at the bottom of the chart below). Every time it crosses the zero signal-line (the red line at the bottom of the chart) from below, a bullish signal develops. And, when it crosses the zero line from above, a bearish signal develops.
APH stock chart
Chart courtesy of StockCharts.com
But here’s a word of caution. I’m seeing an impending correction in APH stock in the short term. The uptrend in the stock price is now forming into a wedge. A rising wedge like this one is a classic indicator of bears waiting to strike. The latest MACD signal is also seemingly bearish.
Now, investors must understand that the rumors of pot legalization in Canada are nearly confirmed now, so that rumor is presumably priced into the stock. You need to ask yourself: can the stock go past current levels? The simple answer is, only if the company can deliver real growth in fundamentals.
So I’m thinking long-term, which is why I’m not too worried, because the company is headed in the right direction.
Final Word on Aphria Stock
I understand that quick triple-digit ascents to dizzying heights, like the ones that marijuana stocks have seen, make average value investors giddy. It’s also true that most marijuana stocks are being played by speculators and traders right now, and this has added to their volatility. But we cannot tar all marijuana stocks with the same brush.
Aphria and Canopy Growth are two of the top players in the Canadian marijuana industry but, for now, I’m rooting for Aphria stock to be the next narwhal of the marijuana industry.
In short, the company’s international growth and profitability point to more upside in the years to come, as Canada and, later, additional U.S. states move toward legalizing marijuana.

[Popeye82]

www.equities.com/news/why-cbd-is-the-key-to-unlocking-the-ca…

[Scorpio1921]

MACD kreuzt...

.... Zusätzlich die Abnahme News von HealthCanada?

[sunny3999]

Aphria's neue Präsentation: 6000kg MMJ + 3000kg MMJ Öl Verkauf Lizenz!

https://aphria.com/wp-content/uploads/2017/01/Q3_2017_Aphria…
Link Presentation Slide 7:
Bestehende Lizenz - läuft aus September 26, 2017
6,000 kg of dried cannabis (production)
6,000 kg of dried cannabis (sales)
3,000 kg of cannabis oil

PRODUKTION Kapazität:
2,500 kg of dried cannabis (pre-Part II expansion)
8,000 kg of dried cannabis (post-Part II expansion)
600 bottles @ 60 mL per bottle per day (full capacity – two machines)
• Consumes 6 kg of dried cannabis per daily production (3,000 kg per year)
• Assumes production utilizing dried bud only

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[wouserxx]

Beziehen sie die Gewichtsangaben auf das Jahr?

[sunny3999]

Antwort auf Beitrag Nr.: 54.827.326 von wouserxx am 28.04.17 11:05:55

Zitat von wouserxx: Beziehen sie die Gewichtsangaben auf das Jahr?

Bis Sept. 2017 gilt die Lizenz (lt. Präsentation) und somit auch auf das Jahr, ab Phase 2 (jetzt) + Phase 3 Sept. brauchen sie dann eine Lizenz für mind. 23000 kg + Öl.

[wouserxx]

Ich meine, ob sich die prephase II Zahlen auf die Produktionskapazität für ein Jahr beziehen.

[sunny3999]

Antwort auf Beitrag Nr.: 54.828.073 von wouserxx am 28.04.17 12:06:02

Ja, prephase II 2,500 kg of dried cannabis

(pre-Part II expansion)

[sunny3999]

Aphria Werbung auf EuroFormula in Estoril

https://twitter.com/CarlinRacing/status/857877758889930754/p…

[wouserxx]

Antwort auf Beitrag Nr.: 54.828.838 von sunny3999 am 28.04.17 13:30:22

Zitat von sunny3999: (pre-Part II expansion)

Gut danke. Dann passt das auch mit der Absatzmenge im letzten Quartal ( ca 650kg)

[sunny3999]

Euroformula Wochenend Rennen in Estoril - Spanien mit Aphria Werbung!

Dieses Wochenende in Estoril-Spanien.
https://www.facebook.com/devlindefran17/videos/4931546410356…

[sunny3999]

Insider Käufe am freien Markt von Robert Avery Kozlov,

https://www.canadianinsider.com/company?menu_tickersearch=AP…

Filing Date Transaction Date Insider Name Ownership
Type Securities Nature of transaction Volume or Value Price
Apr 27/17 Apr 27/17 Kozlov, Robert Avery Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $6.10
Apr 27/17 Apr 26/17 Kozlov, Robert Avery Control or Direction Common Shares 10 - Acquisition in the public market 2,000 $6.12
Apr 27/17 Apr 25/17 Kozlov, Robert Avery Control or Direction Common Shares 10 - Acquisition in the public market 2,000 $6.40
Apr 20/17 Apr 18/17 Waddington, Philip Direct Ownership Common Shares 10 - Acquisition in the public market 5,000 $6.70
Mar 16/17 Mar 10/17 Staudt, Dennis Joseph Direct Ownership Common Shares 54 - Exercise of warrants 60,000 $1.50

[sunny3999]

Kanadas medizinische MJ Patienten um 227% gestiegen

Canadian Medical Cannabis Patient Population Soars 227%
April 25, 2017 at 9:16 am

Exclusive article by Alan Brochstein, CFA
While Health Canada, which provided an update on April 24th, continues to get the official data out to the public very slowly, the patient enrollment growth in the ACMPR program at 12/31/16 was very strong. The number of patients enrolled in the program grew 31.9% from the prior quarter, adding over patients to reach 129,876. This represented growth of 227% from a year ago, a slight improvement from the 222% growth year-over-year in the quarter ending September 30th.

ACMPR Patients 123116


Enrollment at the end of April is likely to be in excess of 180K assuming the monthly growth rate remains near 10%. Health Canada had suggested that by 2024 the patient enrollment could reach 425K, but this number, which is 1.2% of the population, is likely too conservative. My own projections remain achieving >500K patients by March 2020, which would still be below 2% of the entire population. I am assuming growth slows to 100% over the next year and then 50% in the year ending March 2019 and 25% in the year ending March 2020. This math suggests approximately 600K patients. Of course, overall consumption will likely rise substantially once sales are legal next year to adults for non-medicinal purposes.

While the patient enrollment growth has been strong, the Health Canada data points to lower per capita consumption, which was 0.79 grams per day shipped on prescriptions, down from 0.89 in the prior quarter and from 1.12 a year ago. The popularity of cannabis oils was again demonstrated in the data, with unit sales reported at 4.109mm grams, which represented growth of 69.8% from the prior quarter. Dried flower unit sales grew 7.6% sequentially.

Following the introduction of ACMPR, which replaced MMPR and allowed for limited home growing, Health Canada reported that there are now 2007 active registrations for personal and designated growing, including 1899 for personal production and 108 for production by a designated person.

Exclusive article by Alan Brochstein, CFA

ab-byline-ncvBased in Houston, Alan leverages his experience as founder of online communities 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV.

[sunny3999]

Better Know a Marijuana Stock: Aphria

https://www.fool.com/investing/2017/04/28/better-know-a-mari…
Aphria's Part IV capacity expansion may have impeccable timing.

Sean Williams (TMFUltraLong) Apr 28, 2017 at 12:07PM
If investors look around, they'll struggle to find an industry growing faster than legal marijuana.

Data from cannabis research firm ArcView shows that legal pot sales, including medical and recreational marijuana, grew by 34% in North America last year to $6.9 billion. That might sound like a lot, but ArcView also points out that $46.4 billion were conducted in black-market cannabis sales. There's still plenty of opportunity to attract these under-the-table consumers in the years to come, and this shouldn't be too tough with more and more U.S. states legalizing marijuana, and Canada possibly on the precipice of legalizing the drug nationally.

Cannabis buds in a jar sitting atop a pile of cash.
IMAGE SOURCE: GETTY IMAGES.

However, there's a veritable sea of marijuana stocks for investors to choose from, and with emotions running high, investors may be jumping into these stocks for all the wrong reasons, or worse yet, without understanding the risks they could face by buying into marijuana stocks.

With this in mind, we're going to take the time to dissect one marijuana stock each week until all of the bigger legal pot players are covered (those with market caps of $200 million or greater). Here are the companies we've discussed so far:

Today, we're going to more closely examine Aphria (NASDAQOTH:APHQF).

What Aphria does
Whereas the first two companies we've examined are prescription-drug developers, Aphria is not a drug developer, although it does make its home entirely on the medical side of the equation at the moment.

Aphria is a Canadian-based small-cap marijuana stock that grows marijuana for medicinal purposes. It sells its products, which include dried flowers and cannabis oils, via telephone orders, as well as through its e-commerce presence. Canada has allowed medical cannabis to be sold throughout the country under a regulated platform since 2001.

An indoor commercial marijuana grow farm.
IMAGE SOURCE: GETTY IMAGES.

Promise and opportunities
Investors need only look at Aphria's third-quarter earnings results, which were released two weeks ago, to see why people are extremely excited about this company.

For the quarter, it reported $3.75 million in revenue, which was nearly a doubling from the $1.97 million in sales from the year-ago quarter. More importantly, Aphria's gross profit of $2.62 million was also nearly double that of the prior-year period, and its earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $730,000, which was a 137% improvement from the previous year. Long story short, Aphria has reported five consecutive profitable quarters, and its $2.35 million in year-to-date EBITDA and nearly $5 million in year-to-date net income are a testament to the stock's appeal.

Yet, the real growth could be right around the corner -- just in case a near-doubling in year-over-year sales isn't quite enough. Aphria has been working on a number of organic capacity expansions. This isn't to say that Aphria hasn't turned to acquisitions in the past, but unlike many of its peers, Aphria is choosing to develop its grow capacity internally. In January, its board approved a fully funded $100 million capital project (137 million Canadian dollars), known as its Part IV expansion, that'll increase its growing capacity from 300,000 square feet to 1 million square feet within about 12 months. The company's Q3 report suggests this equates to a capacity increase of 75,000 kilograms. With more than $61 million in cash on hand, $90 million in working capital, and growing sales and EBITDA, funding these expansions hasn't been an issue for Aphria.

Of course, the real icing on the cake could come from the possibility of Canada legalizing recreational cannabis. After years of promises, Prime Minister Justin Trudeau has introduced legislation that could, if approved, usher in an era of regulated recreational pot in Canada by sometime next year. If Aphria's Part IV expansion stays on track, its timing could be impeccable to take advantage of an expected surge in marijuana demand. The Canadian government has suggested that legalizing recreational cannabis could add $5 billion to $7 billion in annual sales in Canada.

A street sign implying investment risk ahead.
IMAGE SOURCE: GETTY IMAGES.

Risks and concerns
Considering how profitable Aphria has been in 2017, and how unprofitable nearly every other marijuana company is, there's a lot to like. But Aphria's not perfect, and there are risks to be aware of.

Competition is a risk that nearly every company in this world faces, and Aphria is no different. Even though Aphria should have an expanded grow capacity by early 2018, it's not alone. Aurora Cannabis (NASDAQOTH:ACBFF) is currently working on its Aurora Sky project, which it claims will be the most technologically advanced and automated grow field on the planet. More important, Aurora Sky will add 800,000 square feet of capacity to a company that doesn't even have 100,000 square feet of grow capacity at the moment (even inclusive of the recent purchase of a 40,000-square-foot production facility in Quebec).

Additionally, Canopy Growth Corp. (NASDAQOTH:TWMJF) is now sporting 665,000 square feet of grow capacity and six licensed facilities following the completion of its Mettrum Health buyout earlier this year. While Aurora Cannabis and Aphria are busy with their organic expansion, Canopy Growth has used its clout (and acquisitions) to beat the other two to market with its increased grow capacity. Whether being able to produce considerably more than its peers (for the time being) provides a long-term advantage to Canopy Growth, and a disadvantage to Aphria, remains to be seen.

Political concerns are also seemingly always at the forefront for marijuana stocks. Even though things are looking better than ever for Canadian pot companies given Trudeau's push for recreational legalization, this is the same story they've been hearing for years. Similarly, despite U.S. public opinion favoring the legalization of recreational pot, and strongly in favor of legalizing medical cannabis, lawmakers in the U.S. have kept a tight lid on the pot industry. Political concerns can always derail marijuana stocks.

Aphria's valuation is a bit concerning, too. Even with about 0.07 CAD per share in year-to-date profits, Aphria is probably going to be valued at more than 50 times its year-end earnings per share. Investors have allowed their emotions to get in the way and pushed pot-stock valuations through the roof. These valuations could deflate just as easily if Aphria's expansion and sales growth don't go according to plan.

A woman with a financial newspaper
IMAGE SOURCE: GETTY IMAGES.

Should you buy Aphria?
Of course, the big question is whether or not you should consider buying Aphria.

Though I would strongly suggest caution and a wait-and-see approach with essentially all marijuana pure plays, Aphria is probably the most intriguing of all marijuana stocks on a purely fundamental basis. Aphria has generated five straight quarterly profits, is well-funded, is growing organically, and, according to its Q3 press release, has the lowest all-in grow costs in the industry. It may be smaller than Canopy Growth, but it's delivering more bang for the buck at the moment.

The real wild card is going to be whether or not Canada's government follows through with its recreational legalization bill, and if Aphria's capacity expansion can stay on track to meet that initial demand if Canada does approve legal recreational pot. If Canada does legalize recreational marijuana and Aphria can stay on track, we could see potentially see sales, EBITDA, and EPS triple by 2019 from current levels, in my best estimate.

If there's a pure-play marijuana stock you want on your radar, it's Aphria.

[sunny3999]

Forza Devlin & Aphria

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://www.fotos-hochladen.net/uploads/aphriadevlinlt81jwn59k.jpg

[/url]
http://devlindefrancesco.com/defrancesco-expecting-to-fight-…

DEFRANCESCO EXPECTING TO FIGHT FOR WINS AT ESTORIL ON EUROFORMULA DEBUT

April 28, 2017
Canadian driver Devlin DeFrancesco is confident of challenging for wins on his debut Euroformula Open weekend with Carlin, but believes qualifying will be key at the Estoril circuit in Portugal (29-30 April).

[Popeye82]

www.forbes.com/sites/debraborchardt/2017/04/28/one-of-canada…

[sunny3999]

AmericanBulls Empfehlung: BUY Aphria

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker…

[sunny3999]

Insider Buying at Aphria Boosts Confidence

https://www.dailymarijuanaobserver.com/single-post/2017/04/2…


Insider Buying at Aphria Boosts Confidence
April 28, 2017
Rachel Douty


In the last week, two different insiders at Aphria Inc. (TSX:APH)(OTC:APHQF)(FRA:10E) have purchased shares of the company. At the close of trading on Friday April 28th, shares of Aphria were at $6.14 CAD per share. Shares of Aphria are down 30% from their all time intraday high of $8.77 CAD that was set on April 11th.

While some have been shaken out of their investment by this recent volatility, directors and insiders at Aphria have been using this as a buying opportunity. Insider buying is often be a strong indicator of confidence in a company going forward, and we believe this to be the case for Aphria.



Robert Kozlov, Director and Chair of the Compensation, Nominating and Governance Committee

Robert Koxolv filed a Form 10 (Acquisition in the Public Market) with SEDI disclosing his purchases of Aphria common stock this week. The purchases were broken into three separate transactions:
2,000 shares acquired on April 27th at $6.10 CAD per share= CAD$12,200
2,000 shares acquired on April 26th at $6.12 CAD per share= CAD$12,240
2,000 shares acquired on April 25th at $6.40 CAD per share= CAD$12,800
Dr. Philip Waddington, Director

Dr. Philip Waddington filed a Form 10 (Acquisition in the Public Market) with SEDI disclosing his recent purchase of Aphria common shares.
5,000 shares acquired on April 18th at CAD$6.70 per share = CAD$33,500
Conclusion

While the shares acquired make up only a small sliver of the roughly 125 million shares outstanding, this buying is a major vote of confidence from Aphria insiders. Shares of Aphria are up over 2% on news of the filings, and investors seem to be using these price levels as a floor.

For more recent news and custom stock charts for Aphria, be sure to check out Aphria's marijuana stock profile. Also, don't forget to connect with us on social media using the links to the right of the article so you never miss a marijuana stock news update.

[sunny3999]

Eine weitere Cannabis Studie über Gehirnerschütterung von Bodhi ist unterwegs, bald in Phase 3

http://www.bnn.ca/video/using-cannabis-to-treat-concussions-…

[sunny3999]

Antwort auf Beitrag Nr.: 54.834.345 von sunny3999 am 29.04.17 12:14:58

Nur zur Erinnerung: Aphria beliefert Bodhi für die Concussion Studie!

Zitat von sunny3999: http://www.bnn.ca/video/using-cannabis-to-treat-concussions-…

Bodhi Research Inc.
Aphria also announced today that it signed a Supply Agreement with Bodhi Research Inc. ("Bodhi") to supply its Rideau Gold cannabis oil for a medical study being conducted by Bodhi on the impact of medical cannabis (primarily CBD) in the management of concussion and post-concussive syndrome. The Supply Agreement is expected to last two years, during which time, Bodhi's study is slated to include over 1,000 patients. The Bodhi group has been advised by several world class experts including Professor Emeritus Lester Grinspoon from Harvard Medical School.

http://www.marketwired.com/press-release/aphria-to-triple-it…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Aphria auf der Cannabis Life Conference Toronto May 13-14, 2017

An Informative Journey Exploring an Alternative Medicine.
Evergreen Brickworks Toronto May 13-14, 2017

[sunny3999]

Antwort auf Beitrag Nr.: 54.835.101 von sunny3999 am 29.04.17 17:17:30

Anbei noch der Link für: Cannabis Life Conference Toronto May 13-14, 2017

Zitat von sunny3999: An Informative Journey Exploring an Alternative Medicine.
Evergreen Brickworks Toronto May 13-14, 2017

http://cannabislifeconference.com/e/cannabis-life-conference…

[sunny3999]

Cannabis Aktien Forum und News mit 500 Mitgliedern in 2 Monaten!

Das von Thomas WO Name Scorpio1921 gegründete

"Cannabis Aktien Forum und News"

findet große Beachtung und stetig steigendes Interesse.

500 Mitglieder in 2 Monaten ein Riesenerfolg!

Dies zeigt welches Potential in diesem Aktien Umfeld und diesen neu aufstrebenden Anlagen besteht.

Vielen Dank Thomas und allen Beteiligten für die intensive Arbeit und euer Engagement.

Hier der Link zur Facebook Gruppe für Interessierte:
https://www.facebook.com/groups/431770210547767/

[sunny3999]

APHRIA INC COM NPV (OTCMKTS:APHQF) New Venture Could be a Springboard

http://oracledispatch.com/2017/04/29/aphria-inc-com-npv-otcm…



APHRIA INC COM NPV (OTCMKTS:APHQF) shares were swept up in cannabis pricing on the eve of the election rallying through the $3.00 level on big volume. The entire industry (unbeknownst to many) was being bought across the board as the Trump team prepared to take office, this unlikely scenario cloaked the accumulation that was happening in cannabis stocks as the world digested the shocking reality of a Trump administration.

A look at the chart shows Aphria tending higher over the next few quarters and topping into April as a bona fide trend in the sector has taken hold.

APHRIA INC COM NPV (OTCMKTS:APHQF) recently announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec along with Tetra Bio-Pharma Inc. Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001.

The formulation and packaging will be completed by Tetra, under its CDSA dealer’s license, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra’s third quarter of 2017 and Aphria’s first quarter of 2018.

“This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR.”

“The commercial venture between Tetra and Aphria will enhance Aphria’s brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001,” said Vic Neufeld, CEO of Aphria Inc. “As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra’s emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria.”

Subscribe below and we’ll keep you on top of what’s happening before $APHQF stock makes its next move.



Tetra and Aphria have invested in the development of its PPP001 drug and will continue to invest to bring PPP001 to market in both Canada and USA as the first prescription drug using dried cannabis. The corporations have developed a high quality dried cannabis product and would like to make it available to physicians under the current ACMPR program.

The quality and clinical research studies completed to date would be integrated into a joint Continuing Medical Education program for physicians and pharmacists. Tetra and Aphria have concluded that there is demand for an evidence-based approach in medical cannabis and the two companies intend on using their pharmaceutical approach to help patients. The venture will also be commercializing devices for the inhalation of medical cannabis.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria Inc.(OTCMKTS:APHQF) is powered by sunlight, allowing for the most natural growing conditions available, and shares have been on a solid growth ramp.

This is the first real test shares will have to show they can hold support levels for the longer term trend. But with federal legalization looming in the US many know the sector has another explosive upside leg coming to stocks across the board. This is a larger valuation than many stocks in the sector, but they will also be required to perform on the top and bottom line. We will keep you informed of any major updates on APHQF stock. For continuing coverage on shares of $APHQF stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

[sunny3999]

Achtung Wallstreet Online zeigt die aktuellen Kurse von Kanada nicht an!

Hier der live Chart mit Volumen:

[sunny3999]

Nach 82 Jahre Cannabis-Verbannung:

Weltgesundheitsorganisation macht eine offizielle Cannabis Studie über die Wirksamkeit!

https://sensiseeds.com/en/blog/confirmed-will-officially-ass…

by Miranda on 01/05/2017 | Medicinal

It’s been confirmed! WHO Will Officially Assess the Medicinal Value of Cannabis
WHO
Cannabis advocacy continues to progress in 2017 with news that has given the cannabis community grounds for optimism. WHO will conduct its 1st official evaluation of cannabis' medicinal value. If the results are favourable, the stringent international restrictions on cannabis may ease and cannabis may finally be reclassified. Read more.


It’s been confirmed! WHO Will Officially Assess the Medicinal Value of Cannabis - Sensi Seeds Blog

Since the beginning of 2017, the cannabis community has had good reason to be optimistic. World Health Organisation (WHO) has announced that it will carry out its first assessment this year of the medicinal value of cannabis and its derivatives. For the first time in 82 years – since the plant was banned internationally – WHO is re-examining the therapeutic value of cannabis. Depending on the results of this report, which has been formally labelled a “pre-review,” it may result in a relaxation of the strict and restrictive international controls on the therapeutic use and the potential and long-awaited reclassification of cannabis.

It looks like there is ongoing progress with cannabis advocacy in 2017, and there has been plenty of good news that has given rise to optimism within the cannabis community. This includes the subject of this article, i.e. that both WHO and the United Nations have confirmed to international media that this study on the medicinal value of cannabis and its derivatives will be carried out in 2017 by a Committee of Experts set up for this purpose.

1st official assessment of the medicinal value of cannabis in 82 years

WHO is a specialised body of the UN – comprised of representatives from all member countries – whose “objective is the attainment by all peoples of the highest possible level of health.” WHO plays a leading role in matters of global health issues. It oversees and coordinates healthcare and public health programmes internationally.

We cannot, therefore, expect that the advice and recommendations of such a body would be up-to-date and based on evidence and scientific proof. This is especially the case with issues that are so controversial for the international community, such as drug policies, and specifically those aimed at cannabis, the world’s most popular “illegal” drug.

Nevertheless, WHO’s recommendations on the benefits and harm of cannabis has for decades been based on a resolution passed 82 years ago by the League of Nations, the United Nations’ predecessor. As a stance, this is surely far too outdated, considering how much society has changed since then in almost all of the world’s countries that follow WHO’s recommendations (197 in total) and the scientific advances that have been achieved through all those years in terms of healthcare.

It’s been confirmed! WHO Will Officially Assess the Medicinal Value of Cannabis - Sensi Seeds Blog

“The Committee is comprised of WHO experts from various fields, such as pharmacology, toxicology, biochemistry, clinical practice, and the review being conducted is based purely on scientific evidence,” according to Gilles Forte, WHO coordinator for essential medicines policy and use.

Even though this organisation has carried out previous research and reports on the therapeutic value of cannabis, it will be the first such assessment by WHO’s “Expert Committee on Drug Dependence (ECDD)” on cannabis since its foundation in 1948.Andsince then, the world has changed a lot, especially the cannabis community.

Better late than never (as with all things)

The importance of this piece of news lies in the fact that this Committee has the power to issue recommendations to the UN on whether or not to continue with the international prohibition of cannabis. This may lead to either a bolstering or relaxation of international restrictions on cannabis – a plant that has been classified since 1961 under the same category of narcotics as cocaine or heroin.

In the first instance, a preliminary study will be conducted, the results of which will be published this year. According to Forte’s statement, “The pre-review is a preliminary stage towards a more in-depth scientific review and this can be carried out very rapidly.”

In the event the “pre-review” produces positive results, WHO will carry out a new, exhaustive and more detailed assessment, called a “critical review,” on the medicinal benefits of cannabis. Depending on the results, the body will issue a recommendation, either to continue with cannabis restrictions or call for their relaxation for medical purposes. Approval for this recommendation will be decided by a vote amongst the 53 States that comprise the UN’s Commission on Narcotic Drugs.

It is therefore clear that if the assessment is favourable, cannabis’s status will be normalised internationally, especially in terms of pharmacology; but in terms of recreational use progress will be slower. More than eight decades later, during which punitive measures, including life in prison or the death penalty in some countries have been in force based on WHO’s recommendations, things may be about to change.

A possible reclassification of cannabis, but only for medicinal purposes

But where does all this nonsense about cannabis come from? The Single Convention on Narcotic Drugs of 1961 classified cannabis under schedules I and IV – together with heroin and other substances. These categories are reserved for the most dangerous narcotic drugs, and which have little or no recognised medical value.

We must not forget that cannabis was classified under these groups despite the fact that WHO did not have any evidence from any studies that supported the contention that it had no medical value – a requirement set by its own international treaties. Curiously, even though at one point there were claims that such a report existed, it appears that no one has managed to unearth it in the past 80 years.

Despite this, cannabis has been classified under these extremely restrictive schedules of controlled substances for decades. During all this time, a large amount of evidence and scientific proof has accumulated that challenge this classification. This situation may finally change thanks to this review.

It’s been confirmed! WHO Will Officially Assess the Medicinal Value of Cannabis - Sensi Seeds Blog

There is plenty of data on the medicinal benefits of cannabis and its derivatives (oils, extracts, tinctures, and so on) which have already been proven: it is far less harmful than alcohol and has real medicinal and therapeutic benefits for treating a wide variety of illnesses and disorders, for example, pain relief, muscular spasticity, some types of epilepsy, and as a palliative treatment for many diseases.

Due to these therapeutic effects, over the last few years, in around 20 countries around the world – both in Europe and elsewhere – and in over half of the states of the US, people now have access to medicinal cannabis via some type of permit or licence. Therefore, it would seem totally obvious that the notion that cannabis has no medicinal value is far less credible today than when it first emerged through the resolution of 1934.

Pressure from the international community backed by evidence

Over the last few years, various groups of experts in the field have urged WHO to carry out this assessment of cannabis, arguing that the plant’s classification under schedule 1 – together with the most prohibited substances with no medical value – is not supported by scientific evidence or therapeutic experience, which for years have shown cannabis’s medical benefits.

And it is worth pointing out that there are now four approved medicines available on the market, of which three can be purchased in Spain, developed from various cannabinoids: Marinol, Cesamet, Sativex and Epidiolex. The lack of scientific grounds for this continued restriction is glaringly obvious.

Moreover, due to the current legal status of cannabis, medical research on its potential benefits – or harm – cannot easily be carried out, and is hampered by the rigid and irrational regulations which apply to substances classed under Schedule 1. In most countries, researchers have to cope with very onerous processes – and go through very limited channels – to access cannabis for their studies, all because their governments still have to comply with UN conventions.

Nevertheless, there are some countries, such as the Netherlands, that for decades have shown that it is possible to change government policies on cannabis without the world coming to an end. However, everything would be much simpler if WHO led this change.

Towards the end of last year, in order to provide the Committee of Experts with the most recent and up-to-date data to carry out their all-important review, the independent body DrugScience, together with the International Drug Policy Consortium (IDPC), drafted and presented a report to WHO.

It’s been confirmed! WHO Will Officially Assess the Medicinal Value of Cannabis - Sensi Seeds Blog

Among the four independent experts who drafted the report was David Nutt, a professor of neuropsychopharmacology at Imperial College, who is also the author of many widely cited studies and books, and who once presided over a public commission which advised the British government over its drug policy. The view of these experts was that WHO could use this document as a basis for carrying out a transparent, fair and evidence-based preliminary review, with a view to the 2018 session of the Commission on Narcotic Drugs.

It looks like the perseverance, and pressure from DrugScience and other associations and groups of international experts, who advocate legal access to medicinal cannabis for patients, has had an effect on WHO.

Cautious optimism

Although this news has given rise to a sense of optimism in the cannabis community, it would be better to be cautiously optimistic. We are more than a year away from finding out the results of WHO’s pre-review and the consequences of the resulting recommendations for the current status of medicinal cannabis worldwide.

Germany’s Werner Sipp, president of the International Narcotics Control Board (INCB) pointed out in his statements that this assessment will only focus on cannabis and its derivatives for medicinal purposes, and insisted that, just over a year ago, WHO carried out a study that showed the harmful health effects of recreational cannabis consumption. There has thus been some progress, albeit not nearly enough.

It’s been confirmed! WHO Will Officially Assess the Medicinal Value of Cannabis - Sensi Seeds Blog

Even in the event that WHO recommends a reclassification, or even a possible total declassification of cannabis and its derivatives, the available room to introduce the desired legislation looks a bit narrow. Amendments to United Nations treaties will have to be made and they could be vetoed by the most prohibitive countries, such as Russia and China, but that is a different story altogether.

It is vitally important to accept scientific and medical evidence in establishing good public health policies of any sort. Let us hope that WHO and the UN take this opportunity to have a major impact on the health of millions of people all over the world. A recommendation to reclassify cannabis would show that they have considered the plight of the millions of people who already use it, and would lessen the social and healthcare prejudice that are the direct result of the current international policy on cannabis.

[sunny3999]

Welcher der MJ Aktien wird 1 Mrd. Marktkapitalisierung erreichen

https://www.fool.com/investing/2017/05/01/which-marijuana-st…

Which Marijuana Stock Will Be Next to Reach a $1 Billion Valuation?
With two marijuana stocks already sporting market caps over $1 billion, one of these four pot stocks is likely next.

Sean Williams (TMFUltraLong) May 1, 2017 at 8:32AM
Both the marijuana industry and marijuana stocks are seemingly unstoppable at the moment.

When it comes to the marijuana industry, sales in the North American market grew by 34% to $6.9 billion last year, according to research firm ArcView. This exceptional year-over-year revenue increase is the result of organic growth within legal U.S. states (as well as medical cannabis use growth in Canada, where medical pot has been legal for 16 years), and the expansion of legal weed to new U.S. states. Last year alone, residents in four states voted to legalize recreational marijuana, while five new states legalized access to medical cannabis.

A marijuana joint and leaf on a table.
IMAGE SOURCE: GETTY IMAGES.

As for marijuana stocks, they've been soaring. Over the past year, many are up well over 100% as investors begin to digest just how large an opportunity cannabis could be. For added context, $46.4 billion in marijuana sales were conducted under-the-table last year in the black market per ArcView, meaning there's still a massive opportunity to draw this business into the legal realm, assuming states and/or the federal government, along with the Canadian government, change their current stances on pot.

Welcome marijuana's billion-dollar stocks
Yet in spite of the legal challenges facing the marijuana industry, some marijuana stocks have truly excelled.

Cannabinoid-based drug developer GW Pharmaceuticals (NASDAQ:GWPH) is currently worth $2.9 billion, and is far and away the largest marijuana stock by market valuation. Its juicy market cap is a reflection of the phase 3 success of cannibidiol-based drug Epidiolex as a treatment for two types of rare childhood-onset epilepsy known as Lennox-Gastaut syndrome and Dravet syndrome. With Epidiolex passing its pivotal trials with flying colors, there's a decent chance it'll be approved by the U.S. Food and Drug Administration (FDA). And if Epidiolex can garner label expansions in the future (assuming approval), it could see north of $1 billion in peak annual sales. Wall Street is projecting healthy recurring profits for GW Pharmaceuticals by 2020.

A commercial cannabis grow operations.
IMAGE SOURCE: PIXABAY.

Canadian-based Canopy Growth Corp. (NASDAQOTH:TWMJF) is also a member of the billion-dollar pot club with its $1.2 billion market cap. Canopy Growth produces and sells medical cannabis in Canada, and in recent years it's been rapidly expanding its production capacity via acquisitions. Earlier this year it closed on a $430 million deal to buy Mettrum Health. Aside from the deal giving Canopy Growth access to almost half of Canada's medical marijuana patients, it also boosted total growing capacity to 665,000 square feet and six licensed facilities. With Canada closer than ever to passing legislation that could legalize recreational pot, Canopy Growth's recent capacity upgrades could prove exceptionally profitable for the company.

And its former billion-dollar stock...
Insys Therapeutics (NASDAQ:INSY) isn't there anymore, but it was once a billion-dollar pot stock. Insys isn't entirely a marijuana stock in the traditional sense, because essentially all of its current revenue comes from sublingual cancer pain medicine Subsys, which has nothing to do with marijuana. However, the FDA approved Syndros, a dronabinol solution that is the pharmaceutical version of tetrahydrocannabinol (THC), the psychoactive component of cannabis, as a treatment for chemotherapy-induced nausea and vomiting and anorexia associated with AIDS this past summer. Following its categorization as a schedule II drug by the Drug Enforcement Agency earlier this year, Syndros is set to hit pharmacy shelves in the second-half of 2017, perhaps pushing Insys well above its current $735 million valuation.

An indoor commercial cannabis grow farm.
IMAGE SOURCE: GETTY IMAGES.

Which marijuana stock will hit $1 billion next?
This big question is which marijuana stock will be next to hit the psychologically important $1 billion market cap mark? Not including Insys, which already spent plenty of time above $1 billion, here are four possibilities.

1. Aphria
With a market cap that's already nearing $630 million, Canadian-based Aphria (NASDAQOTH:APHQF), which sells medical cannabis products online and over the phone, isn't too far from becoming the next billion-dollar pot stock. Working in Aphria's favor is the fact that the company has been profitable in five straight quarters (very few pot stocks are profitable at the moment), and that it's undertaking a pretty substantial organic business expansion known as Phase IV. This fully funded $137 million project is expected to increase its growing capacity from 300,000 square feet to about 1 million square feet.

Aphria also stands to benefit in a big way if the Canadian government chooses to legalize recreational marijuana. Prime Minister Justin Trudeau recently submitted a bill to do just that, with the expectation that recreational weed would be legal in our neighbor to the North by sometime in 2018. With Aphria's Phase IV expansion expected to take about a year, by the time it's completed Aphria may have a brand new market of customers on the recreational side to satisfy.

Medical cannabis on a table and in a bottle.
IMAGE SOURCE: GETTY IMAGES.

2. Aurora Cannabis
Another Canadian producer and retailer of medical cannabis is Aurora Cannabis (NASDAQOTH:ACBFF), which is sporting a market cap that's nearing $660 million. Aphria and Aurora Cannabis are competitors that are rapidly expanding their production capacity, so it's not really a shock that both have very similar valuations.

Aurora Cannabis' major project is Aurora Sky, which could be the most technologically advanced and automated growing facility in the world when completed. The company, even after acquiring a 40,000 square foot facility in Quebec, doesn't have 100,000 square feet of growing capacity at the moment, and it's currently losing money on a quarterly basis. But when Aurora Sky is complete, the company will have added 800,000 square feet of grow capacity. Just as with Aphria, if the Canadian government legalizes recreational pot and opens the door for $5 billion to $7 billion in annual sales, Aurora is likely to benefit.

A researcher in a lab coat taking notes in the middle of a marijuana grow field.
IMAGE SOURCE: GETTY IMAGES.

3. Cara Therapeutics
Among biotech stocks, Cara Therapeutics (NASDAQ:CARA) has a shot at becoming the next billion-dollar pot stock. However, it's important for investors to understand that Cara's situation is a lot like Insys', in that just a portion of its pipeline is dependent on cannabinoid-based drugs.

Cara is currently a developmental-stage drug developer, and kappa opioid receptor agonist (KORA) CR845 is its lead drug. KORAs typically don't cross the blood-brain barrier like opioid medicines, meaning they may offer pain relief without the central nervous system side effects associated with opioids. CR845 is being targeted at both pruritis (itching) and pain; but make no mistake, pain is the far bigger fish in Cara's sea.

Cara Therapeutics' marijuana ties relate to its preclinical development of CR701, a CB receptor agonist. Preclinical studies in animals suggest it could be useful in treating pain and replacing opioid therapies, but it's a very long way away from pharmacy shelves at this point.

A cannabis leaf next to laboratory test tubes and equipment.
IMAGE SOURCE: GW PHARMACEUTICALS.

4. Corbus Pharmaceuticals
Finally, clinical-stage drug developer Corbus Pharmaceuticals (NASDAQ:CRBP), which has a current market cap of just $326 million, could be the next billion-dollar pot stock.

Corbus' entire pipeline is dependent on just one drug, anabasum, which is being tested in four indications: systemic sclerosis, cystic fibrosis (CF), dermatomyositis, and systemic lupus erythematosus. Nearly all of the company's current valuation lies with the aforementioned cystic fibrosis clinical development. There are multiple types of genetic CF variations and there aren't too many treatment options available, so any successful CF treatment could rake in a lot of profit for a drug developer.

Recently, Corbus announced what it deemed to be positive phase 2 results in its CF study; however, forced expiratory volume in one second (FEV1) remained stable in the reported results. Generally, CF drugs would be expected to improve FEV1 in CF patients, but that didn't happen here, leaving anabasum's future somewhat cloudy in the eyes of Wall Street.

And the winner is?
Cannabis buds falling out of a jar onto a pile of cash.
IMAGE SOURCE: GETTY IMAGES.

So which marijuana stock has the best shot at becoming the next billion-dollar pot stock? In theory, Corbus has the most potential if anabasum is successful in pivotal-stage trials in cystic fibrosis, with Cara also having a decent shot should CR845 succeed in pain studies. On the flipside, these stocks also carry a ton of risk being so intricately tied to a single drug or indication.

My guess is Aphria is the next marijuana stock that'll boast a billion-dollar price tag. Aphria is already profitable and has $123 million in working capital, and the completion of Phase IV should come right as Canada readies to legalizes recreational weed.

Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

[sunny3999]

Why These 3 Stocks Are Still My Top 3 Short Plays

http://www.fool.ca/2017/05/01/why-these-3-stocks-are-still-m…
Chris MacDonald | May 1, 2017 | More on: HCG WEED ACB APH


Making bold bearish calls on stocks can be something of a dangerous thing to do.

In an article I wrote just over two weeks ago, I highlighted three of my top short ideas for investors who may want to consider hedging existing positions or going against the grain and providing market efficiencies by shorting Home Capital Group Inc. (TSX:HCG), Equitable Group Inc. (TSX:EQB), and Canopy Growth Corp. (TSX:WEED). At the time of writing, these companies were down 73.8%, 12.4%, and 10.3%, respectively, over the past two weeks alone.

The reality is that financial markets are built on a foundation of bullish, forward-looking investors; most are looking to capitalize on the average 7-8% annual yield the major stock indices provide. Investors would not invest if the market did not predictably increase every year (on average) over a long period of time.

That said, stock corrections and re-valuations of existing stocks are necessary for the stock market to operate efficiently. Many studies have proven that stock markets tend to overreact — on the upside as well on the downside.

Here’s why I believe more downside exists in Home Capital and Equitable Group after their massive declines on Wednesday, and why I would hold on to any hedge or short positions on these companies (though I don’t own any shares or options on these names).

I believe the marijuana industry is still evolving and that the growth prospects of other companies such as Aurora Cannabis Inc. (TSX:ACB) and Aphria Inc. (TSXV:APH) are superior to those of Canopy, and would recommend a long-short strategy for these cannabis companies (long ACB or APH and short WEED) to mitigate any large industry moves one way or the other.

The bull case

Other analysts and pundits have continued to propose that Home Capital and Equitable Group are simply too cheap to ignore. I can’t disagree with the numbers: Home Capital now has a whopping 15.25% dividend yield (at the time of writing), and Equitable Group’s yield has also increased substantially to 2.5% from a relatively insignificant yield just a few days ago.

ROE numbers remain high due to the higher levels of risk taken on by these firms, and these companies are now what many bullish investors consider to be “cigarette butts” with the market capitalizations for Home Capital and Equitable Group dropping from approximately $2 billion and $1.5 billion, respectively, to $420 million and $650 million, respectively, since the beginning of the year (at the time of writing).

The bear case

Having written over a dozen pieces analyzing the downside on Home Capital and a few on Equitable Group, I have seen the bull case firsthand from investors who have attacked my position and repeatedly called out my analysis on these stocks, which I have remained bearish on since the beginning of the year.

Some have claimed these stocks are cheap and therefore have value, while others have challenged my analysis of these companies’ business fundamentals and scandals of late.

Bottom line

The market has spoken and seems to have taken a completely bearish sentiment with respect to these alternative Canadian mortgage lenders. I would recommend extreme caution with these three names and suggest anyone interested in taking a long or short position do their homework on the associated risks with each play.

Stay Foolish, my friends.

Looking for a few great dividend-paying stocks to buy today?

If so, you're in luck! Because we just tapped one of our top analysts -- and experts in this field -- and asked him to put together a special report highlighting three of his favorite dividend-payers to buy right now.

These three "Cash Kings" have an average yield of 4.0%... are poised to profit from three diverse (and highly crucial) sectors of the economy... and look like they have the ability to grow their dividend well into the future.

For a limited time you can get a copy of this brand new special report by simply clicking here.

Fool contributor Chris MacDonald has no position in any stocks mentioned.

[sunny3999]

Das Aphria Home Team grüßt!

The Aphria home team shows support to our executives in Toronto today! Together, we celebrate our recent graduation from TSX-V to TSX #mmj pic.twitter.com/baHc3fsAFL

[sunny3999]

Cole Cacciavillani (Mitgründer und VP Aphria) diskutiert über Qualtätsstandards von Cannabis

Aphria Inc.‏ @AphriaInc 15 Std.Vor 15 Stunden
Our VP, Cole Cacciavillani, discusses the need for consistent quality standards in a seminar on #cannabis distribution @Cannabis_Canada #mmj



Aphria Inc.‏ @AphriaInc 28. Apr.
We are in Ottawa! Come visit us at @Cannabis_Canada 's first National Educational Conference at the @Shaw_Centre #MedicalCannabis #MMJ


Aphria Twitter Link: https://twitter.com/AphriaInc

[sunny3999]

Weitere Insiderkäufe bei Aphria am 1 Mai!

Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction Volume or Value Price
Apr 28/17 Apr 28/17 Merton, Carl Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $5.99
May 1/17 Apr 27/17 Kozlov, Robert Avery Control or Direction Common Shares 10 - Acquisition in the public market 3,000 $6.03
Apr 27/17 Apr 27/17 Kozlov, Robert Avery Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $6.10
Apr 27/17 Apr 26/17 Kozlov, Robert Avery Control or Direction Common Shares 10 - Acquisition in the public market 2,000 $6.12
Apr 27/17 Apr 25/17 Kozlov, Robert Avery Control or Direction Common Shares 10 - Acquisition in the public market 2,000 $6.40
Apr 20/17 Apr 18/17 Waddington, Philip Direct Ownership Common Shares 10 - Acquisition in the public market 5,000 $6.70
Mar 16/17 Mar 10/17 Staudt, Dennis Joseph Direct Ownership Common Shares 54 - Exercise of warrants 60,000 $1.50
Mar 16/17 Mar 10/17 Staudt, Dennis Joseph Direct Ownership Warrants 54 - Exercise of warrants -60,000
Mar 10/17 Mar 10/17 Neufeld, Victor Direct Ownership Common Shares 10 - Disposition in the public market -4,000 $6.80
Mar 10/17 Mar 9/17 Neufeld, Victor Direct Ownership Common Shares 10 - Disposition in the public market -66,000 $6.67

https://www.canadianinsider.com/company?menu_tickersearch=AP…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Streetregister: Aphria erhält massive Finanzierung (100 Mio. $) für weitere Expansion!

http://streetregister.com/2017/05/01/aphria-inc-com-npv-otcm…
APHRIA INC COM NPV (OTCMKTS:APHQF) to Obtain Massive Funding for Expansion
By Michael Luke - May 1, 2017496



APHRIA INC COM NPV (OTCMKTS:APHQF) took a huge step toward furthering its plans for expansion in April, announcing major combined debt and equity fundraising measures.

At the end of last week, the stock itself had tapered back to bounce off of a low of 4.30, and appears to be gearing up for an upswing. We’ll want to keep a close eye on this play, which is one that we’ve already seen big moves from in the past. Between December and early April it ran from the $3-range to the $6-range.

The financing deals that were unveiled by APHRIA INC COM NPV (OTCMKTS:APHQF) which is a Health Canada Licensed Producer of medical cannabis products, totaled a $100 million raise, including a $75 million bought deal equity financing and $25 million in debt financing through a five-year term loan. This is the first time Aphria has raised both debt and equity simultaneously.

The Company expects that 50% of the net proceeds of the Offering will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated between the working capital necessary to support the Company once the Part IV expansion is complete and strategic investments.

“Through this raise, we are not only looking at the needs of today, but what Aphria is going to need to do in the years ahead to dominate the market. When completed in 2018, our four-part expansion plan is expected to supply more than 75,000 kg of high-quality cannabis at one of the lowest costs in the industry. We are well positioned to continue to provide shareholder value and meet the increasing consumer demand for medical and recreational marijuana,” ,” said Vic Neufeld, Chief Executive Officer.





As part of the raise, Aphria entered into an agreement with Clarus Securities Inc., on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis, 11,538,480 Common Shares (the “Common Shares”) of the Company at a price of $6.50 per Common Share (the “Offering Price”) for aggregate gross proceeds to the Company of $75,000,120 (the “Offering”).

The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 1,730,772 Common Shares at the Offering Price, exercisable in whole or in part at any time for a period ending 30 days from the closing of the Offering. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the Offering will be $86,250,138.

The Common Shares will be offered by way of a short form prospectus to be filed in each of the provinces of Canada, other than the Province of Quebec, and in those jurisdictions outside of Canada and the United States which are agreed to by the Company and the Underwriters, where the Common Shares can be issued on a private placement basis, exempt from any prospectus, registration or other similar requirements. The deal is expected to close on May 9, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX.

The remaining portion of the raise is comprised of a 5-year, $25 million term loan with WFCU Credit Union (“WFCU”) bearing interest at 3.95% and a 15-year amortization (“Debt Financing”). The facility will be entered into on May 9, 2017. (Source: Marketwired)



The major moves that APHQF have been making on financing their plans to grow along with the blossoming Canadian cannabis market are too huge to ignore! We’re going to want to continue tracking this stock as closely as we have in recent months. We’ll stay up on any further developments with APHQF and pass them along to you! Stay locked on StreetRegister.com and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in APHQF stock, short or long.

[sunny3999]

Cannabis Canada Forum in 8 weiteren Städten in Kanada!

https://www.cannabiscanadaforums.com/attendees/

The National Education Conference is being held in the following 8 cities. More information coming soon!
Ottawa
April 28 - 29, 2017


Winnipeg
May 5-6, 2017


Vancouver
Fall 2017


Calgary/Edmonton
Fall 2017


Regina/Saskatoon
Fall 2017


Toronto
Fall 2017


Montreal
Fall 2017


Halifax
Fall 2017

[sunny3999]

Aphria Investoren und Fonds bis 31 März 2017

Langsam fangen die Institutionen/Fonds an zu sammeln, bis 31 März war noch nicht viel zu sehen, da die TSX Höherstufung erst am 23 März erfolgte!

LINK: http://quote.morningstar.ca/Quicktakes/owners/MajorSharehold…

[sunny3999]

Phase 2 News wird jetzt dringend benötigt....

....dann kann es weiter auf $6,60-6,70 stabilisieren.

[sunny3999]

Aphria Partner: J. Gilbert CEO Scythian Bioscience Florida-USA

https://www.longislandpress.com/2017/05/02/can-a-cannabis-ba…

Can a Cannabis-Based Pill Help Treat Concussions?
BY RASHED MIAN - MAY 2, 2017

A former investment adviser from Roslyn Heights is taking his talents to South Beach.

Jonathan Gilbert, CEO of Scythian Biosciences Inc., a biotech firm, has secured $16 million in funding for a promising trial at the University of Miami considering the potential impact of a cannabis-based compound to treat concussions and Traumatic Brain Injury (TBI).

The cannabinoid compound at the center of the trials, cannabidiol (CBD), is believed to contain neuroprotective properties that could, in theory, reduce inflammation in the brain caused by head trauma. Adding to the intrigue, the drug would not contain Tetrahydrocannabinol (THC), which creates the psychoactive effect in the brain when using marijuana.

Researchers at the University of Miami hope the trial could produce a first-of-its-kind pharmaceutical answer to concussions, which has recently been the focus of millions of dollars in research, largely in response to the impact concussions have had on current and former NFL players.

For Gilbert, a career investment adviser who worked for a Connecticut-based hedge fund, it’s incredibly exciting transitioning to biotech, focusing his efforts on a potentially game-changing drug, something that has thus far remained elusive to concussion patients.

“I can’t sleep at night thinking about what I can be accomplishing here,” he told the Press. “What an amazing accomplishment to create something that could be effective for everyone on Earth.”

Gilbert founded Scythian Biosciences Inc. three years ago, following a Tourette Syndrome support group session in which teenagers indicated they had used marijuana to “self medicate.” Gilbert and his wife have three kids, the youngest of whom suffers from the neurological disorder.

The conversation with the teens got Gilbert thinking: how could marijuana benefit not only his son, but people inflicted with various ailments, including concussion?

Gilbert knew his extensive list of contacts and ability to raise money and attract talent would make up for whatever experience he lacked in the pharmaceutical industry. In the latter years of his investment career, he noticed an uptick in medical marijuana businesses seeking funding, though most pitches were underwhelming. Still keen on the idea of marijuana-based treatment, he made a decision to go his own route.

Initially Gilbert’s goal was to enter the industry in Canada, whose prime minister, Justin Trudeau, recently introduced legislation to legalize recreational marijuana nationwide. The prospect of similar legislation being proposed by the Trump administration appears far-fetched.

Gilbert went ahead and purchased a facility in Canada with the idea of growing and selling medical marijuana. But instead of joining the growing medical marijuana industry, Gilbert, with his own son in mind, gambled on an entry into the pharmaceutical industry.

Mindful of the surprisingly minimal treatment options for concussions, Gilbert got the sense that it was a “wide open space” with the potential of becoming a billion-dollar industry.

“I’m learning as I go,” he said.

Even so, Gilbert already sounds experienced.

“Our therapy, which involves the use of two drugs, targets two different brain receptors which are involved in suppressing this immune response and the associated inflammation,” he explained.

Scythian Biosciences Inc now has offices in Canada and the United States—including one at the University of Miami. The company has applied for a patent for its treatment and the University of Miami is in the pre-trial phase of the five-year study.

Heading the university’s research is Dr. Gillian Hotz, research professor of neurological surgery and director of the concussion program at University of Miami Health SystemSports Medicine.

When the university announced the study, Hotz acknowledged the previous work her team had done to develop concussion protocols and better educate high school, collegiate and professional athletes.

“One thing has eluded us—a clinically proven medication to treat concussion,’ she said. “Whether or not this study leads to a pill that could treat concussion, this type of research will pave the way for UM and other researchers to better manage concussion. It’s a privilege to help lead this journey.”

Researchers are currently examining TBI in rodents before testing the compound in the form of a pill on humans. Clues to as to whether the treatment could be the game-changer Gilbert is hoping it is won’t come until the third phase, which is expected to take three years.

The University of Miami trial comes as medical professionals have earnestly been scrutinizing new ways to treat concussed patients. The US government has funded studies into hyperbaric oxygen therapy, which uses oxygen to reduce swelling and increase blood flow. At the University of Buffalo, researchers are testing how recently concussed athletes react to light aerobics, which would undermine years of conventional thinking that long periods of rest is best for a concussed brain.

Gilbert welcomes the deluge of research. Given how pervasive concussions have become, he recognizes the need for changes in how concussions are treated—even if it means increased competition. According to the Centers for Disease Control and Prevention, upwards of 3.6 million people suffer a TBI each year. Additionally, an analysis by Blue Cross Blue Shield found that concussions increased by more than 40 percent in the past five years.

Gilbert is hardly alone in advocating for cannabis treatment to tackle America’s concussion problem. Harvard psychiatrist Lester Grinspoon in 2014 penned a letter to NFL Commissioner Roger Goodell urging the league to pursue marijuana treatment.

“Already, many doctors and researchers believe that marijuana has incredibly powerful neuroprotective properties, an understanding based on both laboratory and clinical data,” Grinspoon wrote. “But unfortunately, the extensive research required to definitively determine cannabis’s ability to prevent CTE will require millions of dollars in upfront investment, and despite the great promise many now see in cannabinopathic medicine, it’s hard to imagine who else has both the motive and the means to provide such funding.”

It appears Gilbert is both motivated and has found the financial backing for such an effort. And while he waits for the study to take shape, he said he’ll continue to raise money for his company, and perhaps even find a way to help more people like his son.


Read more at http://www.stockhouse.com/companies/bullboard/t.aph/aphria-i…

[derdieschnautzelangsamvollhat]

Antwort auf Beitrag Nr.: 54.841.105 von sunny3999 am 01.05.17 19:11:17

Der Bericht stimmt eher pessimistisch; denn einmal mehr wird dabei verschwiegen werden, dass die Cannabis-Prohibition zur Aufrechterhaltung der Verfolgungsstrukturen nach Ende der US-Alkohol-Prohibtion einerseits; und blankem Rassismus anderseits eingeführt und aufrechterhalten wurde.
Schon damals bediente man sich gefälschter Gutachten bzw, nur den Gutachten, die im Sinne der Prohibitionsbefürworter eine angebliche Gefährlichkeit implzierten, (bis hin zur blutrünstigen Vermonsterung von Konsumenten, die von konservativen Kreisen bis heute gepflegt wird )

http://www.peachtreenorml.org/end-prohibition/roots-marijuan…

[sunny3999]

Antwort auf Beitrag Nr.: 54.854.923 von derdieschnautzelangsamvollhat am 03.05.17 14:30:41

US consultant says early cannabis sales 'unbelievably high' after legalization

https://theherbnews.com/us-consultant-says-early-cannabis-sa…

OTTAWA—A U.S. consultant appointed by Ottawa to evaluate Canada’s final fun container industry says areas that control cannabis must anticipate “unbelievably high” sales development within the first couple of years as thieves are pushed from company.....

[sunny3999]

Mit Aphria auf das richtige Pferd gesetzt! Im US-Haushalt versteckt, gesetzlicher Schutz für med. MJ.

https://www.forbes.com/sites/richardkestenbaum/2017/05/02/th…

The New Federal Budget Protects Medical Marijuana
Richard Kestenbaum , CONTRIBUTOR
Opinions expressed by Forbes Contributors are their own.


Photographer: James MacDonald/Bloomberg

In the appropriations law expected to be passed by congress this week, there are a number of hidden features that didn't get a lot of attention. The bill passed this week commits to spending over more than $1 trillion. When such a massive bill passes, it's inevitable that there are features and commitments that most people aren't aware of at the time.

Why Is Marijuana Addressed In The Bill?

Attorney General Jeff Sessions previously indicated that he will enforce federal marijuana laws. He told radio host Hugh Hewitt on March 2, 2017, that 'marijuana is against federal law, and that applies in states where they may have repeated their own anti-marijuana laws.. [a]nd I'm not in favor of legalization of marijuana. I think it's a more dangerous drug than a lot of people realize.'

What Does The New Law Say?

One feature in the current bill is aimed right at the cannabis industry. The language blocks the Department of Justice from spending money to prevent states from "implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana." That means that neither President Trump nor Attorney General Jeff Sessions can use the Federal government's resources to enforce federal law to prevent the expansion of medical marijuana. It doesn't apply to recreational marijuana where the Department of Justice can prosecute whoever it wants. But it addresses the expansion of legalized cannabis by protecting one important facet of it from prosecution of any kind in states where it's legal. The bill makes it easy to see how changing attitudes are allowing the expansion of the cannabis industry. It's also easy to foresee how in the future, if enough people want it, a provision will be made to prevent the federal government from prosecuting anyone in the cannabis industry, including recreational users, in states where it's legal.

Where Is This Going?

You don't have to be very old to remember a time where it would have been impossible for a law like that to have passed. It's clear that there will be improving conditions for the cannabis industry as time goes on. It's hard to recall any industry since prohibition that had the opportunity through the loosening of laws for such rapid growth. Now is the time for brands in the cannabis industry to develop and establish relationships with consumers. This time may never come around again.

[sunny3999]

Medizinisches Marijuana auch von Präsident Trump befürwortet

Donald Trump takes a not-half-bad stance on medical marijuana


BY KELLEN BECK
31 MINUTES AGO
President Donald Trump took on the topic of medical marijuana for the first time since he took office in November, and it appears he's kind of in favor of it.

Along with signing the most recent federal funding bill (the one that always brings the threat of a government shut down if it isn't passed), Trump signed an amendment to the bill Friday that stops the Department of Justice and the Drug Enforcement Agency from using federal funds to arrest people simply for working at a medical marijuana dispensary in a state where it's legal.

SEE ALSO: The U.S. government grows some seriously garbage weed for research

Here's Trump's full statement on the amendment:

Division B, section 537 provides that the Department of Justice may not use any funds to prevent implementation of medical marijuana laws by various States and territories. I will treat this provision consistently with my constitutional responsibility to take care that the laws be faithfully executed.

In the United States, marijuana is illegal in all forms at a federal level, but 29 states have legalized the production, sale, and usage of medical marijuana in some form.

Trump's laissez-faire approach isn't exactly an endorsement of medical marijuana, but it's not an active stance against it.

The amendment doesn't include anything about states that have legalized recreational marijuana in any form.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=t.aph&p…

[sunny3999]

Insider kaufen weiter ein: Arlene Dickinson hat noch mal zugekauft!

https://www.canadianinsider.com/company?menu_tickersearch=AP…

[MVAL]

Antwort auf Beitrag Nr.: 54.891.359 von sunny3999 am 08.05.17 15:21:54

Bestimmt nicht der schlechteste Zeitpunkt um nachzukaufen.

[Popeye82]

------> www.forbes.com/sites/janetwburns/2017/05/08/daily-dose-of-ca…

[wouserxx]

Antwort auf Beitrag Nr.: 54.898.916 von Popeye82 am 09.05.17 11:53:56

Die 6 Dollar sind gefallen. Ich vermute der Abwärtstrend wird sich weiter fortsetzen, ähnlich wie es bei Canopy seit einige Zeit der Fall ist.

[AktiesuchtBauer]

Antwort auf Beitrag Nr.: 54.811.450 von AktiesuchtBauer am 26.04.17 16:51:03

Zitat von AktiesuchtBauer: und bitte nicht wundern, wenn hier nochmals Kurse unter 3,- € zu sehen sein werden

[wouserxx]

Antwort auf Beitrag Nr.: 54.911.231 von AktiesuchtBauer am 10.05.17 16:34:46

Was willst du uns jetzt damit sagen?

[sunny3999]

Insider Cole hat 100.000 Aktien und auch andere Insider kaufen zu.....

https://www.canadianinsider.com/company?menu_tickersearch=AP…

Klar kann man darüber nachdenken noch billiger einzukaufen, nur hat Aphria gerade über 100 Mio zu 6,5 $ am Markt platziert und das innerhalb von 2 Wochen ohne Warrants inklusive einer Bankfinanzierung.

Die dürften auf knapp 200 Mio $ Cash sitzen....die 300.000 sf sind bereits finanziert gewesen.

Die 1 Mio sf brauchen knapp 150 Mio $. Also 50 Mio für weitere strategische Beteiligungen.

Bei 1 Mio sf sind knapp 500 Mio Umsatz zu generieren, bei 25-30% Reingewinn sind das 150 Mio $.

Ohne Arizona, Florida sind 2stellige Aktienkurse in € durchaus realistisch.....

Die Großen Jungs spielen den Kurs rauf und runter, wer langfristig investiert ist sollte sich kaum Sorgen machen.

Wer Daytraded und die Swings mitnehmen will -- viel Erfolg.

[wouserxx]

Antwort auf Beitrag Nr.: 54.912.710 von sunny3999 am 10.05.17 19:10:44

Es wäre doch mal interessant zu wissen, wie das KGV bei ähnlich gearteten Genussmittelunternehmen aussieht. Vielleicht können wir daraus auch zukünftiger Kurse ableiten.

[MVAL]

Scheint so, als ob die 200 Tage angefahren werden. Wann habt Ihr vor, nachzulegen?

[wouserxx]

Antwort auf Beitrag Nr.: 54.913.523 von MVAL am 10.05.17 20:14:36

Tendenziell ja, aber ich warte noch. Momentan sehe ich keinen Grund, warum es sich stabilisieren sollte. Aber ich bin blutiger Anfänger, vielleicht verzettel ich mich auch.

[sunny3999]

Aphria Announces 'Seed to Sale Certified' Quality Promise

http://www.marketwired.com/press-release/aphria-announces-se…

[sunny3999]

Chris Damas diskutiert Aphria!

http://www.bnn.ca/market-call/chris-damas-discusses-aphria~1…

[Popeye82]

www.stockhouse.com/news/newswire/2017/05/12/cannabinoids-hum…

[sunny3999]

Aphria ist laut Chartguy Sektorleader ...

...und sollte nächste Woche den geformten Hammer im Chart mit grün bestätigen!

[sunny3999]

Wir werden gewinnen!

DEFRANCESCO SCORES ROOKIE PODIUM ON EUROFORMULA DEBUT
May 3, 2017
Canadian driver Devlin DeFrancesco made a strong start to his debut Euroformula Open campaign with Carlin, as he charged to a rookie podium in the second race at the Estoril circuit in Portugal.

The 17-year-old was fifth overall in Sunday’s race and sits just 10 points off the top three in the drivers’ standings, with 54 points available at each weekend.

Devlin enjoyed a positive start to his first weekend in the two-litre Toyota-powered Formula 3 car, as the F4 British Championship front-runner posted the sixth fastest time during Saturday’s qualifying session.

The Toronto driver was confident of extracting more pace over a race distance, but unfortunately had contact with another competitor whilst in a top-five battle during the first race and was forced to retire four laps from the end.

Under darkening skies in race two, Devlin showed his earlier optimism was not misplaced as he fought through the pack. From ninth on the grid, he enjoyed a good start and quickly caught the top-five, before pulling off a fine move on the last lap to cross the line in fifth and third of the rookies.

The result means that Devlin sits eighth in the Drivers’ Championship and second in the Spanish F3 Championship, as he now looks ahead to round two at the legendary Spa-Francorchamps circuit in Belgium (27-28 May).

[sunny3999]

Das Gesamtpotential der Cannabisindustrie in Kanada

[sunny3999]

Vergleich von Cannabis Herstellern aus Cannabis Wheaton Präsentation (Seite 16)!

Was sagt uns das für Aphria ? Alles grün!

Ich denke jedoch nicht das Cannabis Wheaton wirklich für COGS $ 2,5 + Opex $1 am Markt einkaufen!


http://cannabiswheaton.co/images/CW_Deck_May_WS-2.pdf

[sunny3999]

Cannabis kann eventuell dafür genutzt werden um von andere Substanzabhängigkeiten loszukommen.

Somit ist es keine Einstiegsdroge mehr sondern eher eine Ausstiegsdroge (lt. Bericht):
http://www.alternet.org/drugs/evidence-overwhelming-cannabis…

[sunny3999]

Aphria Triples Production Capacity

Aphria Triples Production Capacity With Approval From Health Canada for Part II Expansion
Combined facility capable of producing 8,000 kgs annually
http://www.marketwired.com/press-release/aphria-triples-prod…
LEAMINGTON, ONTARIO--(Marketwired - May 15, 2017) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Aphria Inc. ("Aphria" or the "Company") (TSX:APH)(OTCQB:APHQF) is pleased to announce that the Company has received a license amendment from Health Canada that provides Aphria with additional production space of 57,000 square feet, as part of its Part II expansion at its facility in Leamington, Ontario. This will more than triple Aphria's production capacity of medical cannabis from 2,600 kgs annually to 8,000 kgs annually.
The Health Canada license amendment falls under the Access to Cannabis for Medical Purposes Regulations (Canada) ("ACMPR"). The first crop cultivated and produced at the Part II expansion will be available for sale in the middle of August.
"The license amendment marks the completion of the second part of Aphria's four-part expansion plan, set to be completed by July 2018," said Vic Neufeld, Chief Executive Officer, Aphria. "This will allow us to continue to produce high-quality cannabis at one of the lowest costs in the industry. The expansion will propel Aphria's greenhouse footprint to become the largest in the industry and deliver on our long-term strategic plan."
We Have a Good Thing Growing.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

APHRIA INC COM NPV (OTCMKTS:APHQF) is Still In The Lead

By Gene Daniel - May 15, 2017
http://oracledispatch.com/2017/05/15/aphria-inc-com-npv-otcm…

[sunny3999]

Phase II von Health Canada abgenommen und schon erste Ernte im Mai lt. Stockhouse

http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[wouserxx]

Antwort auf Beitrag Nr.: 54.948.065 von sunny3999 am 15.05.17 18:39:15

Also in der News steht Mitte August.

[sunny3999]

Aphria News von Bewehere Software könnte die Vorbereitung für Shoppers Drugmart sein

https://www.benzinga.com/content/9465221/aphria-inc-selects-…

[sunny3999]

Why Canadian weed producers will dominate the global marijuana market

https://news.vice.com/story/canadian-weed-producers-will-dom…
“First-mover advantage”
Why Canadian weed producers will dominate the global marijuana market
Canadian weed producers will dominate the global marijuana market
By Vanmala Subramaniam on May 15, 2017
In marketing strategy, there’s a term called “first-mover advantage”. It’s when a few key players in a particular industry gain an advantage because they entered into the marketplace first. These companies are able to establish strong brand recognition, shore up the best sources of funding, and build a loyal customer base simply because there aren’t any competitors in the way during their first few years of operation.

When it comes to the market for exporting weed, big Canadian LPs have clearly established a first-mover advantage. There are currently 29 countries that recognize some form of medical cannabis, but only two of those countries — Canada and The Netherlands — export weed for medical use. In fact, the medical marijuana export market is dominated by just four Canadian weed producers: Cronos Group, Canopy Growth Corporation, Aphria, and Tilray.

To some extent, it’s going to be a decades-long upward battle to really capitalize on the global demand for weed, given that the drug is still illegal in most countries. But Canadian marijuana companies are ahead of the curve in terms of making their mark overseas, as they scramble to collaborate with foreign medical marijuana producers and pharmaceutical companies keen on discovering and potentially patenting marijuana-based cures.

The European Experiment

“There’s huge opportunity for us in Germany,” PI Financial Corp. analyst Jason Zandberg told VICE Money. “They provide national health coverage for medical marijuana. That means, the German market could be more than double that of Canada.”

Medical marijuana officially became legal in Germany in March 2017, opening up a whole new market to Canadian LPs. Very little weed is actually farmed in Germany, although the government’s legalization framework includes a big push to cultivate the crop on its own for medicinal use to ensure its quality. Until then, however, the German cannabis industry will still rely entirely on imports.

In order to export weed to Germany, Canadian weed producers need to get approval from their own government and the German government. Late last year, Canopy Growth Corporation, a Unicorn in the weed industry, acquired the German-based pharmaceutical distributor, MedCann GmbH, which had successfully placed Tweed-branded cannabis strains in German pharmacies.

In fact, a month before that, another big Canadian LP, Cronos Group began the global expansion of their brand by shipping its first batch of “premium” medical marijuana to Germany. They currently own a subsidiary, Peace Natural Projects Inc., which signed an agreement with the German-based Pedanios GmbH, a distributor of medical cannabis.

Germany is just the first domino, believes Zandberg. “More European Union countries will create new medical cannabis laws and expand the export market for Canadian LPs. Currently 12 of the 28 EU members have a medical cannabis program.”

Restricting recreational weed exports

It is estimated that the global cannabis market may be worth $200 billion, with medical marijuana accounting for up to 50 percent of that. But Prime Minister Justin Trudeau’s pot bill continues to make the export of weed for recreational use illegal, a factor that vastly limits the ability of Canadian weed producers to grow their business.

Canopy Growth CEO Bruce Linton however, sees this as a temporary hurdle. “Canada is emerging as a leader in public policy around marijuana and other countries will need its know-how as they shift toward making cannabis and cannabinoids part of standard medical treatment,” he told Bloomberg in an interview last month.

“That gives Canopy the chance to export product while the domestic industry makes that transition, and to set up production on the ground once it has,” Linton said. In other words, get in there first, mark your territory, establish your brand, and your consumers, regardless of nationality, will only want to consume Canadian weed.

Saul Kaye, the chief executive of iCan, a private Israeli firm that focuses on identifying innovators in the medical marijuana space, has dealings with a bunch of Canadian LPs.

“There’s a synergy that’s happening between Israel and Canada when it comes to marijuana. They are focused on the growing, on the agricultural side. We are focused on the R&D side, and we need that supply of different weed strains.”

But former Toronto police chief Bill Blair, a key player in the government’s campaign to legalize weed has made it clear that one of Canada’s biggest priorities is to ensure that there is adequate supply of legal weed in the market, to “weed out” illegal suppliers.

That could potentially mean the crackdown of export permits in order to prioritize the domestic market. Of course, that depends on how weed will be priced in different countries. If obtaining a marijuana pill is more expensive in say, Germany, there will be a greater incentive for big Canadian LPs to focus their sales there.

Big LPs charge ahead

Currently, four Canadian LPs export weed to a combined six countries. According to Jason Zandberg, it is Tilray, a private LP based in Nanaimo, B.C. that has been the “most aggressive LP in the export market,” selling weed to New Zealand, Australia, Chile, Brazil and Croatia.

Australia legalized marijuana for medical consumption back in November, which prompted another Canadian company, Aurora Cannabis, to lock in a 20 percent stake in Cann Group, the first Australian firm to be awarded a license from the Australian government to grow weed for medical purposes. Leamington-based Aphria also took notice of the Australian market by signing an agreement with Medlab, a weed research firm in Australia, to grow and prepare weed for the completion of a clinical trial.

The big prize, of course, is anyone who manages to crack the American market, in the unlikely event that they legalize medical marijuana. Aphria is attempting to do just that — it recently invested $25 million in a dispensing operation in Florida, besides also having a stake in an Arizona-based weed company. Aphria claims that its strategy in the U.S. is to “target key states that have approved medical marijuana.”

“There’s global opportunity out there,” Zandberg said. “The EU countries are a huge export market for us, but I believe that overall we’re positioned really well to tap into an additional leg of growth beyond the Canadian medical and recreational market.”

Follow Vanmala on Twitter

[sunny3999]

Aphria gets approval for next phase of expansion

http://windsor.ctvnews.ca/aphria-gets-approval-for-next-phas…

[sunny3999]

Aphria ist wohl zur richtigen Zeit am richtigen Ort - Florida!

https://greencarpetevents.lpages.co/cannaday-tampa-bay/
CannaBiz Day has organized 2017 to focus on the medicinal applications of Cannabis as well as the legalities of cannabis in Florida. Attendees can expect to hear from Isaac Dietrich (CEO and co-founder, MassRoots) as well as some data and analytics companies to help crunch the data. If you are looking to take your first steps into the cannabis industry, there will be experts in attendance who can advise you on how to proceed.

[sunny3999]

Antwort auf Beitrag Nr.: 54.948.974 von wouserxx am 15.05.17 20:50:48

Zitat von wouserxx: Also in der News steht Mitte August.

Ja, hat GoBlue nacher berichtigt Mai sollte für Phase III in 2018 stehen, da haben sich der CFO und GoBlue mißverstanden.

[sunny3999]

Aphria's Partner Copperstate Farms hat auch eine Seed to Sale Software gekauft!

https://www.einpresswire.com/article/377777049/copperstate-f…

Copperstate Farms select ‘seed to sale’ software from The NAV People for new medical marijuana agribusiness

[wouserxx]

Antwort auf Beitrag Nr.: 54.964.940 von sunny3999 am 17.05.17 17:21:08

Ist der Deal in Florida nun eigentlich unter Dach und Fach? Letztens hieß doch noch, es gebe Probleme?

[sunny3999]

Antwort auf Beitrag Nr.: 54.981.434 von wouserxx am 19.05.17 17:27:29

Termin als Abschluß ist der 1 Juni.

Zitat von wouserxx: Ist der Deal in Florida nun eigentlich unter Dach und Fach? Letztens hieß doch noch, es gebe Probleme?

[sunny3999]

BTV: Aphria als kostengünstigster MJ Produzent

http://www.b-tv.com/aphria-btv-316-feature/

Über alle MJ Produzenten:
http://www.b-tv.com/btv-episode-316/

[sunny3999]

Aphria John Cervini who grows medical marijuana in greenhouse let us know.

http://www.cbc.ca/listen/shows/morning-north/segment/1271063…

[sunny3999]

Aphria ist in Florida durch! Ein 14% US Marktanteil für MMJ

http://www.marketwired.com/press-release/aphria-advances-gro…

[wouserxx]

Antwort auf Beitrag Nr.: 55.009.104 von sunny3999 am 24.05.17 14:37:18

Lässt den Markt kalt.

[sunny3999]

Mehr zum Florida Deal von Aphria

http://www.ocala.com/news/20170524/canadian-backed-group-to-…

[sunny3999]

Der Kurs ist wohl in Wartestellung wegen der noch offenen Gesetzgebung:

http://www.miamiherald.com/news/politics-government/state-po…

Video dazu:
http://www.miamiherald.com/news/local/article127790049.html

[wouserxx]

Antwort auf Beitrag Nr.: 55.011.999 von wouserxx am 24.05.17 21:07:41

Nichtsdestotrotz bin ich gespannt, wo die Reise für Aphria hingehen wird. Für Herrn Neufeld markiert Florida nur den Beginn des internationalen Engagements und das Unternehemn scheint bestrebt zu sein, weiter außerhalb von Kanada Fuß zu fassen. Offensichtlich möchte man eine ganz großes Stückchen vom Kuchen in die eigene Vitrine stellen.

[sunny3999]

Antwort auf Beitrag Nr.: 55.013.775 von wouserxx am 25.05.17 08:58:51

In Florida geht es wohl weiter auch ohne Gesetzgebung

http://www.orlandoweekly.com/Blogs/archives/2017/05/25/after…

After failure from Florida lawmakers, health officials move ahead with marijuana process

[sunny3999]

Aphria wird hier als Top Player im Cannabis Sektor bezeichnet

mit Canada, Florida und Arizona auf dem Sprung zum Big Player im neuen und wachsenden MJ Markt.
https://www.insiderfinancial.com/aphria-inc-com-npv-otcmktsa…

[wouserxx]

Hallo,

Aphria besitzt ca. 20% der Anteile an Copperstate. Noch dieses Jahr sollen 350000 sft voll bewirtschaftet werden, was ca. 18000 kg Weed entspricht. Geht die gesamte Ernte an Aphria oder wie geht das von statten?

[sunny3999]

Antwort auf Beitrag Nr.: 55.027.197 von wouserxx am 27.05.17 10:26:58

Ich schätze mal 22,5% die haben 18,5 %+ 5% =

4050 kg = 13,6 Mio US$ da das kg für 3300$ verkauft werden kann!

[sunny3999]

Antwort auf Beitrag Nr.: 55.027.680 von sunny3999 am 27.05.17 12:30:33

Sorry natürlich 23,5% - Denkfehler wegen den 5% ,

Da die im Gesamtinvest noch Anteile haben....
http://www.marketwired.com/press-release/aphria-strengthens-…

[wouserxx]

Antwort auf Beitrag Nr.: 55.029.087 von sunny3999 am 27.05.17 20:47:28

Andererseits könnte auch die gesamte Menge von 18t an Aphria gehen, da von 1,7 Mio sft 22.5% ca. 374000 sft sind, was fast der Anbaufläche entspricht, die für das Weed bereit gehalten wird.

[sunny3999]

Cannacord trommelt in New York bei über 100 Instis/Fonds/Privaten Anleger!

Start spreading the news: The global cannabis industry assembles in New York City

Canaccord Genuity - Start Spreading the News: Cannabis Industry Assembles in New York

May 24, 2017
|
Canaccord|Genuity



image: https://static.wixstatic.com/media/51c183_26f71f68d321421db2…



On Wednesday, May 10, Canaccord Genuity held its 2017 Cannabis Conference in New York City. The event was attended by over a hundred institutional, retail, and private investors who were able to connect with emerging industry leaders and discussed the key opportunities, risks, and the social/political hurdles ahead of marijuana legalization in a variety of different markets.

In total, there were 28 corporate presentations, including 14 Canadian operators, 13 US operators, and one of Australia’s largest cannabis companies. The conference also included a keynote address by Kris Krane, the co-Founder and President of 4Front Ventures, who gave an illuminating overview of the current state and growth potential of the US cannabis industry. .

READ FULL REPORT >>
Tags:

Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

http://docs.wixstatic.com/ugd/51c183_cdeadcb76ce241a28f68f34…

[sunny3999]

Warum die kanadischen Cannabis Hersteller den globalen Markt beherrschen werden!

“First-mover advantage”
Why Canadian weed producers will dominate the global marijuana market

Auszug in Bezug zu Aphria:The big prize, of course, is anyone who manages to crack the American market, in the unlikely event that they legalize medical marijuana. Aphria is attempting to do just that — it recently invested $25 million in a dispensing operation in Florida, besides also having a stake in an Arizona-based weed company. Aphria claims that its strategy in the U.S. is to “target key states that have approved medical marijuana.”
https://news.vice.com/story/canadian-weed-producers-will-dom…

Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[Popeye82]

www.the-scientist.com/?articles.view/articleNo/49522/title/C…

[sunny3999]

Want to Invest in Marijuana Stocks? Aphria Inc. Is the Best Stock You Can Buy Today

https://ca.finance.yahoo.com/news/want-invest-marijuana-stoc…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[sunny3999]

Sommertief und Unvermögen der Politik zu einem schnellen Ergebnis zu kommen!

https://www.linkedin.com/pulse/off-will-stewart

Die Unsicherheit der Gesetzgebung läßt viele Anleger straucheln, dazu kommt noch der Spruch - Sell in May and Go away.

Hoffe der Juni gibt wieder ein positiveres Bild für die MJ Industrie.

[sunny3999]

APHRIA - The Makings of a Cannabis Titan

http://www.cannabisbusinesstimes.com/article/the-makings-of-…

[sunny3999]

Antwort auf Beitrag Nr.: 55.061.962 von sunny3999 am 01.06.17 21:01:54

Hatte ich vergessen!

Zitat von sunny3999: http://www.cannabisbusinesstimes.com/article/the-makings-of-…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://magazine.cannabisbusinesstimes.com/FileUploads/Publications/38/issues/103118/CBT-June-2017-Cover-hi-res.jpg?w=650&h=867&mode=crop&scale=both&anchor=topcenter

[/url]

[sunny3999]

Das beste Team in der Cannabis-Industrie

Sehr informativer Artikel über das ganze Cannabis Business von Aphria!
http://www.cannabisbusinesstimes.com/article/the-makings-of-…
Best read and best team in the cannabis space!

[sunny3999]

Kanadischer Schwarzmarkt soll bei 77,83 Mrd $ liegen l

May 31: Parliament of Canada
Marco Mendicino Parliamentary Secretary to the Minister of Justice and Attorney General of Canada

"In 2013, Criminal Intelligence Service Canada stated that there were 672 criminal organizations reported in Canada, most of which were located in metropolitan areas, especially in cities where there are ports or a larger economy. CISC also reported that the majority of organized crime groups in Canada are involved in drug trafficking due to the high revenue of Canada's import and export drug market. In this regard, I would just take a moment to note that our government's approach in Bill C-45 aims to deprive criminal organizations and gangs of the very source of revenue they use to continue to profit from the trafficking of illegal drugs.

"Canada's black market is currently valued at approximately $77.83 billion, with drug trafficking accounting for approximately 57%, or $44.5 billion…

"Historically, organized crime consisted of complex and cohesive groups, such as outlaw biker gangs and the mafia, and each group tended to be involved in specific criminal activities for long periods of time….

"Today, organized crime is more fluid; gangs come together for different purposes and work together to achieve their goals, relying on particular skills to carry out a specific criminal act….

"One effective way of combatting organized crime is to prevent these groups from profiting through the black market. In that respect, our government's introduction of Bill C-45, concerning the legalization and strict regulation of cannabis, will have a positive impact on reducing the role of organized crime in the sale of cannabis and will take the illicit profits out of their hands…"

Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Oracle dispatch: Ist Aphria bereit für einen Aufwärtstrend?

http://oracledispatch.com/2017/06/01/aphria-inc-com-npv-otcm…

Is APHRIA INC COM NPV (OTCMKTS:APHQF) Stock Ready To Pop?
By Gene Daniel - June 1, 2017

[sunny3999]

Clarus erhöht Gewinnerwartung von Aphria in 2017

FY2017 EPS Estimates for Aphria Inc (APH) Increased by Clarus Securities

https://baseballnewssource.com/markets/fy2017-eps-estimates-…

[sunny3999]

Bericht zum Florida-Geschäftsabschluß:

https://www.financialstrend.com/aphria-inc-tseaph-records-gr…

[sunny3999]

Die Liberalen treiben das Gesetz voran!

https://news.lift.co/liberals-seeking-limit-debate-cannabis-…

Laut Beitrag soll das Gesetz nächste Woche zur Kommision eingereicht werden, das bedeutet es geht schneller voran als gedacht!

Kommision hatte ja bereits ihre Arbeit letztes Jahr mit einer Empfehlung befürwortet, somit steht ausser einem Feinschliff wohl nicht mehr im Wege um das Gesetz zum Abschluß zu bringen!

Liberals seeking to limit debate of Cannabis Act
Leader of the Government in the House gave notice Friday that the government will propose a motion to limit further debate of second reading

The Liberals will be seeking to limit debate of the Cannabis Act when the House of Commons sits again on Monday.

After several days of debate last week in the House of Commons during the second reading of the Cannabis Act, the Liberals introduced a time allocation motion at the end of debate on Friday afternoon.

Bardish Chagger, Leader of the Government in the House of Commons, gave notice Friday afternoon that a minister of the crown will propose at the next sitting of the House “a motion to allot a specific number of days or hours for the consideration and disposal of proceedings at the said stage of the aforementioned bill.”

“Under the provisions of Standing Order 78(3), I give notice that a minister of the crown will propose at the next sitting a motion to allot a specific number of days or hours for the consideration and disposal of proceedings at the said stage of the aforementioned bill," said Chagger.

Standing Order 78 is a way for the government to restrict the length of debate on bills, whereas Section (1) of Standing Order 78 provides for when all parties are in agreement on time allocation, Section (2) deals with instances where a majority are in agreement and Section (3) deals with instances where an agreement could not be reached under the previous provisions of sections one and two.

Without time allocation, the debate during the second reading could continue until all parties feel they have nothing left to ask or say about the bill in question. It tends to be controversial, and the Liberals have been criticized for it in the past by the opposition.

The next scheduled day for the House to sit is this Monday.

On May 30th, Jody Wilson-Raybould, Minister of Justice and Attorney General of Canada, moved that Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, be read the second time and referred to a committee.

The bill has been debated for 3 days now, with considerable opposition from several Conservative Party members, as well as cautious support from many in the New Democratic Party, who say they support the bill, or aspects of the bill, but want to see other parts of it debated in committee like some of the more strict 14 year penalties proposed under the new regulations for those operating outside the boundaries of the proposed law.

"The NDP is supporting this bill," said Sheri Benson, NDP MP for Saskatoon West (Saskatchewan). "We hope that those things will be worked out in committee and that the committee will be allowed to do its work and make any recommendations based on testimony of witnesses. One thing that could be included is the comments my honourable colleague has shared about some law enforcement agencies and their concerns about the regulation within the act on the number of plants that individuals can have."

After the second reading, a bill moves to a special house committee. Bill C-45 is expected to be reviewed by the Standing Committee on Health (HESA), chaired by Bill Casey (Liberal). Vice Chairs are Len Webber (Conservative) and Don Davies (NDP). The House of Commons Standing Committee on Health studies and reports on all matters relating to the mandate, management, and operation of Health Canada. In 2014, they issued a report entitled Marijuana’s Health Risks and Harms.

[Marcel3394]

Antwort auf Beitrag Nr.: 55.077.859 von sunny3999 am 04.06.17 16:31:22

Aphria läuft immer weiter Richtung Süden.. Was meint ihr? Verkaufen oder nachkaufen?

[wouserxx]

Antwort auf Beitrag Nr.: 55.089.064 von Marcel3394 am 06.06.17 16:29:59

Eine Kauf- oder Verkaufsempfehlung würde ich dir nur ungern geben, aber meine Strategie kann ich dir sagen.

Weiter warten und später nachkaufen.

Vielleicht gibt es in den nächsten Tagen wieder ne Möglichkeit Gewinne mitzunehmen, falls es zu einer ähnlich starken und kurzen Aufwärsbewegung kommt, wie vor ein paar Wochen.

[ChristophRothe]

Antwort auf Beitrag Nr.: 55.089.064 von Marcel3394 am 06.06.17 16:29:59

Chart angeschlagen, nächster Widerstand bei rund 2,60 Euro...
Vorher kauf ich nix

[sunny3999]

Antwort auf Beitrag Nr.: 55.089.064 von Marcel3394 am 06.06.17 16:29:59

Also jetzt hat es mich auch kalt erwischt!

Kann leider keinen Tipp gegeben, sieht so aus als es kein Halten mehr gibt. Ich schätze dennoch bei 4,5 C$ sollte der Boden sein! Hoffe es zumindest.....

[MVAL]

Wenn ich mir den Chart seit Mitte 2016 so anschaue, machen wir gerade eine Korrektur durch. So bei 4 - 4,5 CAD sollte m.E. der Boden sein. Fundamental sieht doch so weit alles gut aus. I.d.R. werden die Retracements abgearbeitet, dann sollte es, spätestens im Herbst wieder hoch laufen. Ich warte auch noch mit dem Nachkaufen...bei 4 bis 4,5 CAD werde ich meine Position weiter ausbauen.

[sunny3999]

Aphria auf der ReThink Breast Cancer am 21 Juni als Sponsor und Teilnehmer!

https://e-activist.com/page/9808/event/1?ea.tracking.id=tw

[sunny3999]

Aphria hat letztes Wochenende an Arthritis Veranstaltung gesponsert und teilgenommen!

https://www.facebook.com/AphriaMMJ/photos/pcb.11704703797313…

[sunny3999]

Warum Aphria für weiteres Wachstum bestimmt ist!

http://stocknewsunion.com/why-aphria-inc-com-npv-otcmktsaphq…

WHY APHRIA INC COM NPV (OTCMKTS:APHQF) IS DESTINED FOR FURTHER GROWTH

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://stocknewsunion.com/wp-content/uploads/2017/06/Aphria-iStock-500428621.jpg

[/url]

[sunny3999]

200 Ja Stimmen 76 Nein - zur Abkürzung des Cannabis Gesetz !

Die Politiker Kanadas haben 200 für Ja zur Abkürzung des Cannabis Verfahren abgestimmt 76 waren dagegen! Es ist also durch und geht nun den schnellen Weg in die Kommission! Danach nur noch die 3 Lesung und ab dafür!

[sunny3999]

Cannabis Act moves on to standing committee The Cannabis Act, Bill-C45, has passed second reading!

https://news.lift.co/cannabis-act-moves-standing-committee/

Cannabis Act moves on to standing committee
The Cannabis Act, Bill-C45, has passed second reading in the House of Commons today, and will now be referred to the Standing Committee on Health (HESA)

[pickuru]

Benj Gallander discusses Aphria

http://www.bnn.ca/video/benj-gallander-discusses-aphria~1142…

[sunny3999]

Copperstate Farms expands facility, work force

http://www.wmicentral.com/news/latest_news/copperstate-farms…
By Barbara Bruce The Independent Jun 6, 2017 Updated Jun 6, 2017 1
Copperstate Farms in the news again, making progress
Buy Now
Barbara Bruce/The Independent
Looking back, it was just a little over a year ago that J. Fife Symington IV announced the intention of Copperstate Farms to purchase the Nutro Sweet Tomato Plant west of Snowflake, and bring 136 average paying jobs with benefits to Snowflake. After much controversy and legal entanglements over the medical marijuana growth facility coming to Snowflake, Copperstate closed on the property in September 2016. Though there have been unanticipated equipment and renovation delays, today Copperstate is pretty-much out-of-sight/out-of-mind, except for those seeking employment — they are finally ramping up hiring at the rate of 10 a week, favoring Navajo County citizens first, as promised.
SNOWFLAKE — About eight months ago, Copperstate Farms closed on the Nature Sweet Tomato Plant facility west of Snowflake, amid great controversy over their proposed medical marijuana growth facility.

Almost totally out-of-sight and out-of-mind today, the only thing making news is they are hiring to the tune of 10 employees per week.

Having received certification May 26 for 8 acres for production from the Arizona Department of Health Services, they are moving forward with their plans.

Plagued with material delays for renovation, Copperstate Farms’ planned schedule for hiring employees was delayed. The magic number given at the initial press conference in May 2016 was 136 jobs.

Though some contested that number, J. Fife Symington IV, managing partner of Copperstate, has continued to stand by 132 to 136 as the number of average paying jobs with benefits that will be on the Copperstate payroll.

For the last eight months, the facility has not been dormant. Sixty-four people have been working. Many of the things Symington promised as he laid out the plans for the facility with the public have been put into operation or are in motion.

Security has been a concern of many. Though you may see the 40-acre greenhouse facility behind Larson Waste at Industrial Park, no one can enter without authorization. A security guard checks for approval and, if approved, people are given a badge. After entering the building, the badge must be visible at all times.

Security cameras are strategically placed all throughout the building. Employees have I.D. cards similar to credit or debit cards with chips. Though all employees have the chip I.D. card, the chips do not open all doors. The cards are sophisticated and can limit entry depending on the clearance of the individual employee. Should an employee be escorting a visitor, the employee must sign in, listing the visitor with the entry time and then on exit, the time of exit.

Lab coats, hairnets and gloves are required, even of visitors, depending upon the area of entry. There is also a panic button in each room should an emergency occur. After ones business is conducted at the greenhouse, the visitor badge must be surrendered and the visitor must sign out with the time.

Another area of concern the public had was with ventilation and odor control. Copperstate invested in a hallway which is a quarter-mile long. Air comes down the hallway and is forced through the filtration system, which then sucks the air back up through the middle and up above. Another way of describing it is that side vents in the hallway pull the air in, then the vents above treat the air before sending it out the roof vents.

Initially, ADHS certified Copperstate for three acres, but has now certified them for five more, for a total of eight. Having gone through various stages from the mother plant to the clone or propagation, to vegetation, the last steps are extraction and processing, which is the next phase.

“Next week we will start the extraction and processing area,” Symington said.

Copperstate’s technology is state-of-the-art. For year-round growth, a computer tricks the cannabis plants into believing it is dark when it is actually light, or vice versa — and it is working. They have flowering plants that are healthy and thriving. They use organic pesticide for the plants and also use biological pest control, placing packets of “good bugs” on or near the plants so they can eat the “bad” bugs.

Temperature and moisture control are also important for the plants and those are also strictly controlled. Cuttings from the mother plant produce the clone. There is a bar code on each plant container that enables the facility to find the plant and its strain all the way to back to when it was cut from the mother plant. When the propagation takes place, the cutting in placed into rock wool and then gets a lot of moisture for positive growth.

“By September the whole North section will be full,” Symington said.

His goal, though he has agri-business interests in other areas of the world, is to focus 100 percent on the Snowflake operation this year. Except for some commitments previously made, he will be totally hands-on locally.

As promised in the press conference in May 2016, and moving beyond the initial 64 employees first hired, Copperstate is pushing for 120 total hires for this first phase.

Being a good corporate citizen by honoring the promises made to the Town of Snowflake, providing jobs — first to those of Navajo County, and taking care of business is the only way Copperstate wants to be in the newspaper these days.

Symington said he is pleased with the people they have hired thus far, and according to a couple of employees, they are pleased with the work environment, job, pay and benefits at Copperstate.

Copperstate is paying regular employees $15 per hour and supervisory or managerial employees $40 per hour, both with benefits. Applications are online at copperstatefarms.com.

Reach the reporter at [e-mail]

[sunny3999]

Singlepoint entwickelt eine Bitcoin Lösung für die Cannabis Industrie!

https://btcmanager.com/singlepoint-develops-bitcoin-solution…

[wouserxx]

Antwort auf Beitrag Nr.: 55.118.392 von sunny3999 am 10.06.17 21:57:03

Der Kurs scheint erst einmal gedreht zu haben. Ob das mit der Gesetzgebungsdebatte zusammenhängt?

[sunny3999]

Berührende Geschichte eines todkranken Jungen mit Krebs - Cannabis hat ihn wohl gerettet!

http://video.genfb.com/2807683719254669

[sunny3999]

5 Canadian Marijuana Companies With Explosive Growth Potential

https://smallcappower.com/top-stories/5-canadian-marijuana-1…

[sunny3999]

Aphria kauft sich in Scythian Biosciences Inc. ein

https://web.tmxmoney.com/article.php?newsid=8925731761788974…

Kitrinor Metals Inc. and Scythian Biosciences Inc. Announce Signing of Business Combination Agreement

Auszug:
The Delavaco Group, a lead and strategic investor in Aphria, Inc. (TSX:APH) (“Aphria”), a Health Canada Licensed Producer of medical cannabis products, secured Aphria’s interest, and financial participation in the Offering as a strategic and lead investor. The Delavaco Group also participated in the Offering as a lead and strategic investor.

[wouserxx]

Antwort auf Beitrag Nr.: 55.135.397 von sunny3999 am 14.06.17 05:47:02

WOzu soll das Investment gut sein?

[sunny3999]

Antwort auf Beitrag Nr.: 55.135.955 von wouserxx am 14.06.17 08:39:19

Scythian Bioscience mit der University of Miami machen eine Cannabis-Studie zu Gehirnerschütterungen und deren positive Wirkung.

[sunny3999]

APHRIA INC COM NPV (OTCMKTS:APHQF) On a Steady Climb

https://oracledispatch.com/2017/06/13/aphria-inc-com-npv-otc…

[sunny3999]

Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors

http://www.marketwired.com/press-release/tetra-bio-pharma-ap…

[wouserxx]

Antwort auf Beitrag Nr.: 55.138.835 von sunny3999 am 14.06.17 15:54:06

Beim Lesen der NAchricht kam mir sofort der Gedanke einer möglichen Übernahme in den Kopf. Mal schauen, ob dem so sein wird.

[sunny3999]

Aphria Launches First Partnership with Major North American Union

http://www.marketwired.com/press-release/aphria-launches-fir…

[sunny3999]

Die Berichte zur Partnerschaft mit LiUNA in der Presse

http://windsor.ctvnews.ca/aphria-launches-partnership-with-l…
http://www.cbc.ca/news/canada/windsor/southwestern-union-med…

[sunny3999]

Freitag vermeldete eine weitere Gewerkschaft (130.000 Mitgliedern) eine $3000 Absicherung für Mitarbeiter an

https://opseu.org/news/opseu-cover-medical-cannabis-employee…

OPSEU to cover medical cannabis for employees
Publication Date

Friday, June 16, 2017 - 1:15pm
Toronto – On June 15, the Ontario Public Service Employees Union (OPSEU) began rolling out a new benefit that provides medical cannabis coverage for insured OPSEU staff.

“Cannabis can be an effective treatment for a variety of medical conditions,” said OPSEU President Warren (Smokey) Thomas. “And as the laws around it continue to modernize, employers should keep up with the times.”

With this new benefit, insured employees and their spouses and dependants can claim up to $3,000 a year for medical cannabis. For these claims to be eligible, they must be prescriptions from licensed physicians, and the cannabis must be obtained from organizations legally authorized to produce and sell medical cannabis.

There will be no limitation on the medical conditions eligible for medical cannabis coverage under the new benefit.

[sunny3999]

Berichtigung der Partnerschaftsmeldung mit LiUNA625

Echt komische Vorgehensweise, erst Meldung einer Zusammenarbeit und nun Revidierung seitens der LiUNA....da gab es wohl Mißverständnisse wie das veröffentlichte werden kann.

TORONTO, June 19, 2017 /CNW/ - Laborers International Union of North America ("LiUNA"), North America's single largest construction union with over 100,000 Canadian members, is issuing a release today to correct inaccurate information released by Aphria Inc. on June 15, 2017, with respect to a partnership announced with LiUNA Local 625. We wish to clarify that LiUNA in fact has no partnership or agreement with Aphria, nor will it be entering into any such partnership.

http://www.newswire.ca/news-releases/liuna-corrects-inaccura…

[sunny3999]

Erste Ernte aus Phase 2 Erweiterung am 10 July

https://www.facebook.com/AphriaMMJ/videos/1183194338458936/

Phase 2 Expansion
We’ve filled up our phase 2 expansion bringing us to 100,000 sq.ft. of greenhouse grow yielding an annual production of 8,000 kgs. First harvest scheduled for July 10th. #medicalcannabis #mmj

[Popeye82]

www.dof.gob.mx/nota_detalle.php?codigo=5487335&fecha=19/06/2…
www.forbes.com/sites/janetwburns/2017/06/21/mexico-casually-…

[Popeye82]

Antwort auf Beitrag Nr.: 55.197.207 von Popeye82 am 24.06.17 12:51:24

" Al margen un sello con el Escudo Nacional, que dice: Estados Unidos Mexicanos.- Presidencia de la República.
ENRIQUE PEÑA NIETO, Presidente de los Estados Unidos Mexicanos, a sus habitantes sabed:
Que el Honorable Congreso de la Unión, se ha servido dirigirme el siguiente
DECRETO
"EL CONGRESO GENERAL DE LOS ESTADOS UNIDOS MEXICANOS, D E C R E T A:
SE REFORMAN Y ADICIONAN DIVERSAS DISPOSICIONES DE LA LEY GENERAL DE SALUD Y DEL CÓDIGO PENAL FEDERAL.
Artículo Primero.- Se reforman los artículos 237, párrafo primero; 245, fracciones I, II y IV; 290, párrafo primero; y se adicionan el artículo 235 Bis y un segundo párrafo a la fracción V del artículo 245 de la Ley General de Salud, para quedar como sigue:
Artículo 235 Bis.- La Secretaría de Salud deberá diseñar y ejecutar políticas públicas que regulen el uso medicinal de los derivados farmacológicos de la cannabis sativa, índica y americana o marihuana, entre los que se encuentra el tetrahidrocannabinol, sus isómeros y variantes estereoquímicas, así como normar la investigación y producción nacional de los mismos.
Artículo 237.- Queda prohibido en el territorio nacional, todo acto de los mencionados en el Artículo 235 de esta Ley, respecto de las siguientes substancias y vegetales: opio preparado, para fumar, diacetilmorfina o heroína, sus sales o preparados, papaver somniferum o adormidera, papaver bactreatum y erythroxilon novogratense o coca, en cualquiera de sus formas, derivados o preparaciones.
...
Artículo 245.- ...
I. Las que tienen valor terapéutico escaso o nulo y que, por ser susceptibles de uso indebido o abuso, constituyen un problema especialmente grave para la salud pública, y son:
Denominación Común
Internacional

Otras Denominaciones
Comunes o Vulgares

Denominación Química





CATINONA
MEFEDRONA

NO TIENE
4- METILMETCATITONA

(-)-a-aminopropiofenona.
2-methylamino-1ptolylpropan-1-one

NO TIENE

DET

n,n-dietiltriptamina

NO TIENE

DMA

dl-2,5-dimetoxi-a-metilfeniletilamina.

NO TIENE

DMHP

3-(1,2-dimetilhetil)-1-hidroxi-7,8,9,10-tetrahidro-6,6,9-
trimetil-6H dibenzo (b,d) pirano.

NO TIENE

DMT

n,n-dimetiltriptamina.

BROLAMFETAMINA

DOB

2,5-dimetoxi-4-bromoanfetamina.

NO TIENE

DOET

d1-2,5-dimetoxi-4-etil-a-metilfeniletilamina.

(+)-LISERGIDA

LSD, LSD-25

(+)-n,n-dietilisergamida-(dietilamida del ácido d-lisérgico).

NO TIENE

MDA

3,4-metilenodioxianfetamina.

TENANFETAMINA

MDMA

dl-3,4-metilendioxi-n,-dimetilfeniletilamina.

NO TIENE

MESCALINA (PEYOTE; LO-
PHOPHORA WILLIAMS II
ANHALONIUM WILLIAMS II;
ANHALONIUM LEWIN II.

3,4,5-trimetoxifenetilamina.

NO TIENE

MMDA.

dl-5-metoxi-3,4-metilendioxi-a-metilfeniletilamina.

NO TIENE

PARAHEXILO

3-hexil-1-hidroxi-7,8,9,10-tetrahidro-6,6,9-trimetil-6h-
dibenzo [b,d] pirano.

ETICICLIDINA

PCE

n-etil-1-fenilciclohexilamina.

ROLICICLIDINA

PHP, PCPY

1-(1-fenilciclohexil) pirrolidina.

NO TIENE

PMA

4-metoxi-a-metilfenile-tilamina.

NO TIENE

PSILOCINA, PSILOTSINA

3-(2-dimetilaminoetil)
-4-hidroxi-indol.

PSILOCIBINA

HONGOS ALUCINANTES DE
CUALQUIER VARIEDAD
BOTANICA, EN ESPECIAL
LAS ESPECIES PSILOCYBE
MEXICANA, STOPHARIA
CUBENSIS Y CONOCYBE, Y
SUS PRINCIPIOS ACTIVOS.


fosfato dihidrogenado de 3-(2-dimetil-aminoetil)-indol-4-ilo.
NO TIENE

STP, DOM

2-amino-1-(2,5 dimetoxi-4-metil) fenilpropano.

TENOCICLIDINA

TCP

1-[1-(2-tienil) ciclohexil]-piperi-dina.





CANABINOIDES
SINTÉTICOS


K2



NO TIENE

TMA

dl-3,4,5-trimetoxi--metilfeniletilamina.

PIPERAZINA TFMPP


NO TIENE

1,3- trifluoromethylphenylpiperazina

PIPERONAL O
HELIOTROPINA





ISOSAFROL





SAFROL





CIANURO DE BENCILO





...
II.- Las que tienen algún valor terapéutico, pero constituyen un problema grave para la salud pública, y que son:
AMOBARBITAL
ANFETAMINA
BUTORFANOL
CICLOBARBITAL
DEXTROANFETAMINA (DEXANFETAMINA)
FENETILINA
FENCICLIDINA
HEPTABARBITAL
MECLOCUALONA
METACUALONA
METANFETAMINA
NALBUFINA
PENTOBARBITAL
SECOBARBITAL.
TETRAHIDROCANNABINOL, las que sean o contengan en concentraciones mayores al 1%, los siguientes isómeros: 6a (10a), 6a (7), 7, 8, 9, 10, 9 (11) y sus variantes estereoquímicas.
Y sus sales, precursores y derivados químicos.
III.- ...

IV.- Las que tienen amplios usos terapéuticos y constituyen un problema menor para la salud pública, y son:
GABOB (ACIDO GAMMA AMINO BETA HIDROXIBUTIRICO)
ALOBARBITAL
AMITRIPTILINA
APROBARBITAL
BARBITAL
BENZOFETAMINA
BENZQUINAMINA
BIPERIDENO
BUSPIRONA
BUTABARBITAL
BUTALBITAL
BUTAPERAZINA
BUTETAL
BUTRIPTILINA
CAFEINA
CARBAMAZEPINA
CARBIDOPA
CARBROMAL
CLORIMIPRAMINA
CLORHIDRATO
CLOROMEZANONA
CLOROPROMAZINA
CLORPROTIXENO
DEANOL
DESIPRAMINA
ECTILUREA
ETINAMATO
FENELCINA
FENFLURAMINA
FENOBARBITAL
FLUFENAZINA
FLUMAZENIL
HALOPERIDOL
HEXOBARBITAL
HIDROXICINA
IMIPRAMINA
ISOCARBOXAZIDA
LEFETAMINA
LEVODOPA
LITIO-CARBONATO
MAPROTILINA
MAZINDOL
MEPAZINA
METILFENOBARBITAL
METILPARAFINOL
METIPRILONA
NALOXONA NOR-PSEUDOEFEDRINA (+) CATINA
NORTRIPTILINA
PARALDEHIDO
PENFLURIDOL
PENTOTAL SODICO
PERFENAZINA
PIPRADROL
PROMAZINA
PROPILHEXEDRINA
SERTRALINA
SULPIRIDE
TETRABENAZINA
TETRAHIDROCANNABINOL, las que sean o contengan en concentraciones iguales o menores al 1%, los
siguientes isómeros: 6a (10a), 6a (7), 7, 8, 9, 10, 9 (11) y sus variantes estereoquímicas.
TIALBARBITAL
TIOPENTAL
TIOPROPERAZINA
TIORIDAZINA
TRAMADOL
TRAZODONE
TRAZOLIDONA
TRIFLUOPERAZINA
VALPROICO (ACIDO)
VINILBITAL.
Y sus sales, precursores y derivados químicos.
V.- ...
Los productos que contengan derivados de la cannabis en concentraciones del 1% o menores de THC y que tengan amplios usos industriales, podrán comercializarse, exportarse e importarse cumpliendo los requisitos establecidos en la regulación sanitaria.
Artículo 290.- La Secretaría de Salud otorgará autorización para importar estupefacientes, substancias psicotrópicas, productos o preparados que los contengan, incluyendo los derivados farmacológicos de la cannabis sativa, índica y americana o marihuana, entre los que se encuentra el tetrahidrocannabinol, sus isómeros y variantes estereoquímicas, exclusivamente a:
I. y II. ...
...
Artículo Segundo.- Se adiciona un último párrafo al artículo 198 del Código Penal Federal, para quedar como sigue:
Artículo 198.- ...
...
...
...
La siembra, cultivo o cosecha de plantas de marihuana no será punible cuando estas actividades se lleven a cabo con fines médicos y científicos en los términos y condiciones de la autorización que para tal efecto emita el Ejecutivo Federal.
Transitorios
Primero.- El presente Decreto entrará en vigor al día siguiente de su publicación en el Diario Oficial de la Federación.
Segundo.- A partir de la entrada en vigor del presente Decreto, la Secretaría de Salud reforzará los programas y acciones a que hace referencia el Capítulo IV, del Título Décimo Primero de la Ley General de Salud, con énfasis en la prevención, tratamiento, rehabilitación, reinserción social y control del consumo de cannabis sativa, índica y americana o marihuana y sus derivados, por parte de niñas, niños y adolescentes, así como el tratamiento de las personas con adicción a dichos narcóticos.
Tercero.- El Consejo de Salubridad General, a partir de los resultados de la investigación nacional, deberá conocer el valor terapéutico o medicinal que lleve a la producción de los fármacos que se deriven de la cannabis sativa, índica y americana o marihuana y sus derivados, para garantizar la salud de los pacientes.
Cuarto.- La Secretaría de Salud tendrá 180 días a partir de la entrada en vigor del presente Decreto, para armonizar los reglamentos y normatividad en el uso terapéutico del TETRAHIDROCANNABINOL de los siguiente isómeros: 6a (10a), 6a (7), 7, 8, 9, 10, 9 (11) y sus variantes estereoquímicas.
Ciudad de México, a 28 de abril de 2017.- Sen. Pablo Escudero Morales, Presidente.- Dip. María Guadalupe Murguía Gutiérrez, Presidenta.- Sen. Lorena Cuéllar Cisneros, Secretaria.- Dip. Raúl Domínguez Rex, Secretario.- Rúbricas."
En cumplimiento de lo dispuesto por la fracción I del Artículo 89 de la Constitución Política de los Estados Unidos Mexicanos, y para su debida publicación y observancia, expido el presente Decreto en la Residencia del Poder Ejecutivo Federal, en la Ciudad de México, a dieciséis de junio de dos mil diecisiete.- Enrique Peña Nieto.- Rúbrica.- El Secretario de Gobernación, Miguel Ángel Osorio Chong.- Rúbrica.



En el documento que usted está visualizando puede haber texto, caracteres u objetos que no se muestren debido a la conversión a formato HTML, por lo que le recomendamos tomar siempre como referencia la imagen digitalizada del DOF o el archivo PDF de la edición. "

[Popeye82]

".........................We have companies like MYM announcing up to 1.5 million square feet of expansion, WEED now with total expansion of approx. 1.4 million square feet, ACB with over 800,000 square feet under construction, etc.
www.stockhouse.com/companies/bullboard/c.thc/thc-biomed-inte… "

[Popeye82]

www.equities.com/news/california-green-tree-gives-investors-…

[Popeye82]

www.forbes.com/sites/daviddisalvo/2017/06/29/marijuana-treat…

[wouserxx]

Ist ganz schön ruhig geworden. Aber heute gibts mal wieder eine Neuigkeit.

https://ceo.ca/@marketwired/aphria-inks-major-wholesale-supp…

[sunny3999]

Aphria partner Tokyo Smoke leads Canadian cannabis space and will expand into the U.S. market in fall 2017.

About Tokyo Smoke:
Tokyo Smoke BrandCo is a category defining cannabis company. Its portfolio of premium brands, including Van der Pop and Tokyo Smoke, is designed to provide immersive experiences and designer retail spaces with coffee, clothing and products. With the recent completion of Series A funding, resulting in $3 million in raised capital, recent acquisition of fellow designer cannabis brand Van der Pop, development of Nesta Brands and partnership with Aphria ("Aphria") (TSX VENTURE: APH) (OTCQB: APHQF) Tokyo Smoke continues to be the leading Canadian brand in the cannabis space. Tokyo Smoke will expand into the U.S. market in fall 2017.

https://www.efe.com/efe/english/news-release/tokyo-smoke-to-…

[sunny3999]

Haywood Securities gibt Aphria ein Zielpreis von $ 8,25 vor.

Ziemlich detaillierte Analyse nun dürfte bald etwas Volumen reinkommen.....
http://mmjphytotech.com.au/wp-content/uploads/2017/06/CSJun2…

[sunny3999]

Aphria CEO präsentiert am Richmond Club Lunch, Toronto

http://www.richmondclub.com/2017/04/aphria-developing-the-me…

[sunny3999]

Aphria beeindruckt mit Rekord -Umsatz, -Gewinn und -Produktivitätssteigerungen

https://aphria.com/ebitda-increases-181-in-the-quarter-excee…

https://technical420.com/cannabis-article/earnings-report-ap…

https://www.newcannabisventures.com/aphria-q4-sales-rise-106…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/wehaveagoodhie4jdkl9c.jpg

[/url]

[wouserxx]

Antwort auf Beitrag Nr.: 55.312.510 von sunny3999 am 12.07.17 19:20:10

Hallo,

klingt erst mal super, aber das aktuelle Quartal wurde mit einem Verlust beendet, der wohl durch die strategischen Investments zustande gekommen sein soll.

Mich würde noch interessieren, wie genau die Steigerung der Prokuktionskapazitäten zu erklären ist. Ich erinnere mich dunkel an eine Änderung der Vorschriften für den Anbau von Cannabis durch HC, der zufolge jetzt ungenutzter, vorher nicht zugenlassener, Freiraum in den Gewächshäusern, ab sofort für den Anbau freigegeben ist. Täuscht mich meine Erinnerung oder ist dem wirklich so?

[sunny3999]

Antwort auf Beitrag Nr.: 55.313.305 von wouserxx am 12.07.17 21:11:07

Kann damit zusammenhängen, das sie eine höhere Ernte wg. Vorbereitung auf Phase 2 hatten.

Phase 1 MJ von der Lagerung optimiert und nach Phase 2 approval verteilt und Flächennutzung mit dem guten Frühlings-/Sommerwetter die größere Ernte eingefahren. Die Vaults (gesicherte Gewölbekammern) werden wohl erst in Phase 3/4 kommen, da HC die erst nach Abnahme Phase 2 genehmigt hatte.

[Complexity]

Antwort auf Beitrag Nr.: 55.313.305 von wouserxx am 12.07.17 21:11:07

Das sollte deine Erinnerung auffrischen:

https://aphria.com/aphria-triples-production-capacity-with-a…

[wouserxx]

Antwort auf Beitrag Nr.: 55.313.644 von Complexity am 12.07.17 21:48:01

Die Vaults meinte ich, thx.

[wouserxx]

Antwort auf Beitrag Nr.: 55.314.169 von wouserxx am 12.07.17 23:04:04

Aus dem stockhouse:

Ein kurze Zusammenfassung von dem, was Vic Neufeld im letzen Interview bei BNN von sich gegeben hat.

I’d be disappointed if we didn’t double all of our metrics across the board in the coming year,” Neufeld said.

“The real opportunity for growth comes when we finish Phases III and IV of our expansion.”

The company added 53,000 square feet of space this spring with the second phase of expansion. The first crop of cannabis from the Phase II expansion began being harvested last week.

Currently Aphria has 100,000 square feet of greenhouse space at its Leamington site. However, after Phase IV is completed by late next summer or early fall, the company will have one million square feet of greenhouse space.

A 350,000 square foot processing and storage centre and a $20-million co-generation power plant will also be built as part of the expansion. The power plant is expected to save the company nine or 10 cents a kilowatt-hour.

The company currently employs 150 people, but that will swell to 400 employees once the expansion is fully operational.

“No one has plans like this on the table,” Neufeld said. “Once Phase IV is completed, we’ll be able to produce over 100,000 kg annually.

“Our production costs will go down even further with that volume. We’ll be able to lower our price $1 or $2 a bottle to handle the price compression when it comes.”

Neufeld said Aphria has also invested $25-million in Florida-based Liberty Health Science, which launches at the beginning of August. The company is also eying expansion into the German and Australian markets. http://windsorstar.com/news/local-news/aphria-doubles-revenu…

[Popeye82]

www.cannabisfn.com/wp-content/uploads/2017/02/CFN-Cannabis-O…

[wouserxx]

Die nächsten Quartalszahl werden dann wirklich interessant, wenn dann 2000 + x kg verkauft werden könnten. Das müssten dann schon deutlich über 10 Mio. an Umsatz sein.

[sunny3999]

Der Chart sieht sehr gut aus laut Charting Man Dan!

Da er auch an ein langfrist Invest von 1, 2, 5 bis 10 Jahren denkt ist für ihn Aphria, das Pferd auf das er setzen würde......er spricht nun von einem sicheren Invest!

[sunny3999]

Aphria USA (Liberty Health Science -Holdco) wird nächste Woche am 20 Juli im AGM verkündet!

Am 20 Juli ist es dann soweit Liberty Health Science (HOLDCO) wird aus einer Fusion von Aphria USA - Securecom Mobil - Chestnut Hill Farm - DFMMJ Invest unbenannt und dürfte bald an der Börse gehandelt werden. Ein Auszug aus dem über 230 seitigen Sedar filling http://www.sedar.com/CheckCode.do :

Outlook Holdco
Upon the completion of the Business Combination, Holdco, as a wholly owned subsidiary of the Resulting Issuer,
intends to continue operating in accordance with its core strategy and primary objectives.
Holdco’s strategy is to further expand their operations in states that have a medical platform in place. The
expansion will be through both acquisitions of current licensed producers as well as through Holdco’s participation
in the application phase in emerging states. The mission is to be the leading aggregator of medical cannabis
businesses in the United States. Management believes that Holdco is uniquely qualified to apply its cultivation
know-how and low cost approach obtained from Aphria. pursuant to the Know-How License to acquire companies
to further improve operations and cultivation. The acquisition of Chestnut in Florida is already starting to benefit
from the know-how and methodologies and improvement initiatives obtained from Aphria pursuant to the KnowHow
License. Additionally, Holdco will be able to leverage its expertise in retail to become leaders in markets that
allow for vertical integration. As with Florida, Holdco will offer a leading platform for its dispensary model in order
to have best-in-class patient interaction.
Holdco will maintain a disciplined approach to investing by focusing on states that have implemented a medical
cannabis system, and a large enough population which allows for numerous conditions to be prescribed the use
of medical cannabis. In addition, Holdco expects to focus on states with a limited number of licensed producers
and no growing or canopy limits, such as Maryland, Massachusetts, Connecticut and Ohio, among others.
Chestnut
Chestnut is the owner of one of seven dispensing organization licenses that were issued by the Florida Department
of Health, Office of Compassionate Use (the “Department”). The License, which was granted November 23, 2015,
only permitted low THC cannabis to be sold to treat a very limited number of medical conditions. Under the License,
Chestnut is allowed to only sell to qualified medical patients that are registered with the State.
Florida is a vertically integrated system which enables Chestnut to cultivate, harvest, process and sell/dispense
their own product. In the State of Florida, only cannabis that is grown in the state can be sold in the state. At the
present time, dry flower cannot be sold, but cannabis oil and oil related products can be sold. Today, Chestnut’s
principal products include oil in pill and vapor form.
In November of 2016, the voters of Florida overwhelmingly approved the expansion of the uses for medical
marijuana to treat more than twenty medical conditions as well as those conditions that a physician believes could
be alleviated with the use of medical cannabis. Since Chestnut had one of the seven low THC dispensing licenses,
it was grandfathered into the new broader medical cannabis framework, including the ability to produce and sell
high THC cannabis. In June 2017, the Florida Legislature enacted revisions to the existing medical cannabis
statute in Florida. Under the new statutory framework, Chestnut can now produce and dispense a full array of
vaping and other cannabis derivative products and edibles. In addition, chronic pain was added as a qualifying
condition which should substantially increase the eligible patient population. While new licenses were included in
the bill, the licensing process will take time and Chestnut is expected to enjoy a substantial operations and
dispensary acquisition/roll out head start against any new licensees that may come onboard.

- 71 -
Since the first harvest and extraction of oil in December 2016, production has been increasing as the operations
stabilize. In light of the modest levels of production, Chestnut has been delivering all product to patients by car and
does not operate a dispensary. With the plan to ramp-up production, a detailed dispensary strategy and plan is
being developed. Targeted sites include: South Florida, Central Florida, the west coast of Florida (Tampa/St.
Petersburg, Sarasota and Naples) and North Florida (St. Augustine and the Jacksonville corridor), where qualifying
dispensary sites have been located and are being assessed and acquired. Under the License, Chestnut can
operate up to twenty-five dispensaries state wide. Currently, the dispensaries can be in any geographic location
within the state subject to a local municipality’s zoning regulations.
The medical cannabis marketplace in Florida is in its infancy, which is evidenced by the fact that less than 20,000
patients have been added to the compassionate use patient registry to date state wide. With over 20 million people,
Florida’s patient population is vast (with the largest population over the age of 70 in the United States and a
substantial veteran population) and with the newly developed expansion and dispensary plans, management
expects that Chestnut is poised to aggressively grow and become a leader in the marketplace. The patient
registration volume has grown significantly in recent months as more supply becomes available and is expected
to continue that expansion in light of the broader medical uses as well as the approval of high THC products. With
expanded production capabilities, a primary goal of the business moving forward is the acquisition of qualified
patients.

[sunny3999]

Aphria USA - Liberty Health Science Homepage ist Online

http://libertyhealthsciences.com/blog/masonry/

[sunny3999]

Liberty Health Science - Aphria USA Homepage

[wouserxx]

Antwort auf Beitrag Nr.: 55.341.509 von sunny3999 am 17.07.17 19:44:24

Wie darft man sich denn LHS vorstellen? Ist das so eine Art REIT?

[sunny3999]

Antwort auf Beitrag Nr.: 55.342.529 von wouserxx am 17.07.17 21:54:43

Zitat von wouserxx: Wie darft man sich denn LHS vorstellen? Ist das so eine Art REIT?

Weißt du was eine REIT ist ?

[wouserxx]

Antwort auf Beitrag Nr.: 55.342.580 von sunny3999 am 17.07.17 22:02:06

Nicht allzu viel. Nur, dass sie viel mit Immobilien zu tun haben und dort vor allem investieren. Auf der LHS Homepage hat sich das so gelesen. "Liberty Health Sciences was launched to acquire and operate U.S. – based companies in the medical cannabis market."

Allerdings steht ja dort "operate U.S. – based companies", also ist wohl eher doch kein REIT.

[sunny3999]

Could Aphria Inc. Be the Turnaround Play of the Year?

https://www.baystreet.ca/articles/stockstowatch.aspx?article…

[sunny3999]

Aphira auf Europatour mit Devlin Defrancesco - Euroformule - Delavaco Group ?

[sunny3999]

Lasst Aphria im Herbst verdreifachen....

Our 200,000 sq.ft., phase 3 columns are up! This fall we will be ready to harvest 30,000 kgs of Seed-to-Sale Certified #medicalcannabis.



Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Vic Neufeld bei Marc Bunting diese Woche auf Sendung bei Capital Ideas

Are you ready for @AphriaInc’s Vic Neufeld?! A special episode of @capitalideasr TV next week! Subscribe: http://www.youtube.com/c/CAPITALIDEASTV … #marijuana

[sunny3999]

Investor Deck update July 2017

https://aphria.com/wp-content/uploads/2017/01/Q4_2017_Aphria…

[sunny3999]

Canadian Medical Cannabis Provider Expanding into US Market Through RTO

https://www.streetwisereports.com/pub/na/canadian-medical-ca…
Liberty Health Sciences Inc. (LHS:CSE), an operator in the medical cannabis market, expects to begin trading on the Canadian Securities Exchange on Wednesday, July 26, under the symbol LHS. The company is being formed through a reverse takeover with privately held DFMMJ Investment Ltd. and SecureCom Mobile Inc., whose shareholders approved the arrangement on July 20, and renamed Liberty Health Sciences.

In April, Aphria Inc. (APH:TSX) announced a $25 million investment in DFMMJ Investment Ltd. Aphria is licensing its Aphria medical brand as well as its greenhouse growing intellectual property system to Liberty.

According to the company, Aphria is one of Canada's lowest cost producers, and "produces, supplies and sells medical cannabis," and is "the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters."

Liberty stated that it was "launched to acquire and operate U.S.-based companies in the medical cannabis market." In its first transaction, it entered into an agreement with Chestnut Hill Tree Farm LLC, which "grants the company all economic risk and rewards associated with the Florida-based operation." Chestnut holds one of seven licenses in Florida and is a "nursery authorized by the Florida Department of Health, Office of Compassionate Use, as a dispensing organization of medical cannabis to patients in need in the State of Florida."

Liberty's investment strategy, according to its website, is to invest in states in the U.S. that have an established medical cannabis market, grant a limited number of cultivation licenses, do not impose canopy restrictions and have a large population of users, at least 2%. The company stated that this strategy "reduces investor risk and aims to maximize shareholder value."

Liberty is helmed by George Scorsis, who has an "extensive background in managing growth within highly regulated environments." He served as president of Mettrum Health Corp., a producer of medical cannabis in Canada that was acquired by Canopy Growth Health Corp. for $430 million. He also was president of Red Bull Canada, and in that capacity "worked closely with Health Canada on guidelines regulating the energy drink category."

The board of directors includes Vic Neufeld and John Cervini, cofounders of Aphria Inc. Cervini is the founding chair of the Ontario Greenhouse Marketing Association and brings extensive experience in greenhouse growing technology. Aaron Serruya, CEO of Yogen Fruz, also serves on the board and has extensive retail expertise as president of International Franchise Inc., which is the home of the Yogen Fruz, Pinkberry and Swensen's Ice Cream brands, with 4,500 franchises globally.

Liberty Health Sciences has 287 million shares outstanding at an issue price of $0.624 per share. After the reverse takeover, Aphria will hold 37.6% of Liberty Health Sciences, management and the board 9% and SecureCom shareholders 14%, leaving approximately 39% for new shareholders.

[sunny3999]

Aphria's Dronen-Video von der 200.000 sf Erweiterung

https://www.facebook.com/AphriaMMJ/videos/1217646618347041/

[sunny3999]

Es geht munter weiter mit Aphria und Ohio News:

http://www.springfieldnewssun.com/news/ohio-based-retailer-…

Officials from a Canadian medical marijuana company say they partnered with a Columbus family known for fashion retailers American Eagle and DSW — as well as an Ohio State University sports arena — to help score some home turf advantage as they hope to grow, process and sell medical marijuana in Ohio.
Schottenstein Aphria LLC is one of 185 companies seeking one of two dozen licenses the state will award for entities looking to become medical marijuana cultivators in Ohio. They are seeking a license to grow initially up to 25,000-square-feet of medical marijuana.

Aphria co-founder Cole Cacciavillani said in an interview this week the company — if granted a license in Ohio — would operate under the newly formed business Liberty Health Science, which went live today on the Canadian Stock Exchange.

“I don’t think you could’ve found a better partner than the Schottenstein family in Ohio,” he said.

He said they hope to put their indoor growing facility outside of Amherst in Lorain County to be close to their Canadian operations.

Cacciavillani said his company — which operates in Canada and Florida, and is setting up operations in Arizona — partnered with the Schottenstein family because of its knowledge of the retail industry and familiarity with the Ohio market.

“Combined, we could be a really strong entity,” he said.

Messages left for a spokesman of the Schottenstein Store Corporation were not returned.

Aphria is one of several major players in the North American medical marijuana market looking to stake a claim in Ohio, where nearly a quarter of the state’s 11.6 million residents could qualify to receive medical cannabis.

[sunny3999]

Aphria's Vic Neufeld bei Capital Ideas TV, Special Episode

[sunny3999]

Habe gestern die Analyse von 8 Capital für Aphria erhalten Zielpreis von $7,50:

https://www.file-upload.net/download-12629865/8CapitalCannab…

[sunny3999]

Antwort auf Beitrag Nr.: 55.411.085 von sunny3999 am 28.07.17 11:23:34

Sorry das war die Gesamtmarktanalyse hier kommt die Aphria Analyse bei ,50

Hier ist die Aphria Analyse bei $7,50: https://www.file-uplo…

Zitat von sunny3999: https://www.file-upload.net/download-12629865/8CapitalCannab…

[sunny3999]

Antwort auf Beitrag Nr.: 55.411.202 von sunny3999 am 28.07.17 11:34:27

Hier ist die Aphria Analyse bei ,50:

https://www.file-upload.net/download-12629872/APH071317Eight…

[sunny3999]

Antwort auf Beitrag Nr.: 55.411.217 von sunny3999 am 28.07.17 11:35:31

$ 7,50 sollte das heißen -

habe wohl bei copy paste die 7 gelöscht, hätte auch kein Problem wenn es auf $50,0

[sunny3999]

Eight Capital’s Daniel Pearlstein joins Bloomberg TV Canada’s Mark Bunting

http://bloombergtv.ca/2017-07-31/news/marijuana-stocks-losin…

[sunny3999]

Aphria Ups Tokyo Smoke Stake

Tokyo Smoke closes on $4 million of Series B funding

Cannabis lifestyle and retail brand’s latest funding to be upsized with lead investment from Aphria and Green Acre Capital

https://www.newcannabisventures.com/aphria-ups-tokyo-smoke-s…

http://www.marketwired.com/press-release/tokyo-smoke-closes-…

[techinvestor69]

Support durchbrochen

[sunny3999]

Antwort auf Beitrag Nr.: 55.453.809 von techinvestor69 am 03.08.17 19:08:38

Ja, leider das Gesetz mit Investitionen IN US-MJ Werte setzt den Werten zu

http://www.bnn.ca/video/cannabis-stocks-may-face-curb-over-u…

Aphria - US connection
Investors sent shares of cannabis companies with U.S. exposure tumbling on Thursday after learning that Canada's only clearinghouse for equities is considering a move that could disrupt trading of those stocks.
The potential ban, which was reported by The Globe and Mail, is being contemplated by Canadian Depository for Securities Ltd. (CDS). As a subsidiary of TMX Group Ltd., CDS operates key back-office functions that ensure when investors trade stocks, the cash and securities wind up in the right hands. If CDS prohibits these cannabis stocks from being cleared and settled, it would become virtually impossible to trade these shares.
Although Canadian exchanges have been more willing to list these stocks, in part due to this country's more liberal marijuana laws, there are lingering concerns at TMX about the legal risks for cannabis companies with U.S. operations. While marijuana is legal in some form in more than two dozen states, it remains illegal under federal law. That's created a dilemma for CDS and TMX.

Aphria Inc., the Leamington, Ont.-based company with cannabis assets in Arizona and Florida, saw its shares fall 6 per cent on the Toronto Stock Exchange.
On the Canadian Securities Exchange, which has become the go-to market for pot listings, many of the 10 cannabis companies with U.S. assets the exchange identified as being at risk if such a ban was adopted also saw their share prices decline.

Nutritional High International Inc. dropped 8 per cent. Vodis Pharmaceuticals Inc. stumbled 7 per cent, while both iAnthus Capital Holdings Inc. and Golden Leaf Holdings Ltd. declined 6 per cent.
Players in the cannabis sector said they were fielding calls from investors and other stakeholders.
"I received no less than 100 messages and calls over the last 12 hours from people asking, 'What's does this mean?'" said Brayden Sutton of Sutton Ventures Ltd., a long-time consultant in the sector. "Lots of waves out there, for sure. And there has been for some time. Lawyers have advised me that the consequences would be far too vast and affect too many shareholders for a change like this to be made."

http://archive.is/o1rWV#selection-6805.0-6883.406

[AktiesuchtBauer]

Antwort auf Beitrag Nr.: 55.455.870 von sunny3999 am 04.08.17 08:01:14

denke jetzt ist ein günstiger Zeitpunkt, einzusteigen, bzw. nach zulegen ...
der Tiefpunkt sollte erreicht sein ....
nun sollte man wieder Aufwärts marschieren ****

[techinvestor69]

Level um 5,20 CAD sieht interessant aus, wobei ich Invictus MD (IMH.V) viel spannender finde.

[sunny3999]

Vic Neufeld kontert auf den Bericht der Globe & Mail mit einem Interview

Das nenne ich mal einen CEO - der steht hin und strahlt 100% Sicherheit aus, in dem was er macht und sagt!

http://www.bnn.ca/video/regulatory-concerns-swirl-around-can…

[sunny3999]

Antwort auf Beitrag Nr.: 55.461.495 von techinvestor69 am 04.08.17 19:09:44

Ich denke die ,20 wird Aphria dieses Jahr nicht mehr sehen!

Zitat von techinvestor69: Level um 5,20 CAD sieht interessant aus, wobei ich Invictus MD (IMH.V) viel spannender finde.

Ich denke die $5,20 wird Aphria dieses Jahr nicht mehr sehen und hoffe sogar nie mehr!

Zu Invictus gibt es eine Menge Insider/Institutionen die gerade verkaufen - da ist Vorsicht geboten:

https://www.canadianinsider.com/company?ticker=IMH

oder um alle Verkäufe zu sehen auf SEDI-IMH klicken:

https://ceo.ca/imh

[sunny3999]

Jetzt kommen schon die ersten MJ-Produkte

[techinvestor69]

@sunny - okay, 5.30 CAD



Zu IMH: da verkauft nur (1) Insider und der Fonds verkauft, weil seine Position in IMH einfach zu groß ist...sehe da kein Alarmsignal, sondern es gibt mir die Möglichkeit meine Position zu günstigen Kursen auszubauen. Die nächsten Ernten werden im August eingefahren. Siehe News.

[sunny3999]

Antwort auf Beitrag Nr.: 55.463.958 von techinvestor69 am 05.08.17 10:40:47

@techinvestor:

Aphria hat im July geerntet, das bedeutet weitere 4-5 Wochen zum Trocknen, behandeln und vorbereiten zum Verkauf, bevor Umsätze generiert werden können.

Ich denke bei Aphria war das der letzte durch Medien gelenkte Absturz um Kleinanleger und schwache Hände raus zu schütteln.

Die neuen Fonds und ETF's haben Geld eingesammelt und werden nun anfangen Positionen aufzubauen.

Die Marketingaktionen für REC mit Tokio Smoke sind erst am anlaufen, das wird sicher in den nächsten Wochen an Fahrt gewinnen, nachdem sie jetzt mit Green Acre Capital/Aphria 4 Mio gesammelt haben.

Aphria beweist durch Gewinn, hohen Ertrag und USA Strategie die Entschlossenheit ein Big Player zu werden, da gibt es eben Neider.

Mit Delavaco, Serruya Capital, Schottenstein sind einige namhafte Geldgeber und Investoren an Aphria beteiligt, ich schätze das wird eine Sogwirkung auslösen.

Ich sage wir sehen Aphria in 2017 noch 2stellig!

[sunny3999]

und die USA also Session wackelt auch: Task force doesn’t back Sessions’ anti-pot views

https://apnews.com/0b738164f8d64c43a7934fdbee6b9083/Sessions…

https://thejointblog.com/department-justice-task-force-recom…

https://apnews.com/ad37624fcb8e485a8d57a013d48a227c

[sunny3999]

Aphria - Jahresreport auf Sedar Top professionell

http://www.sedar.com/CheckCode.do

[sunny3999]

Sedar Jahresreport ist hier:

http://www.sedar.com/GetFile.do?lang=EN&docClass=2&issuerNo=…

[sunny3999]

Antwort auf Beitrag Nr.: 55.464.876 von sunny3999 am 05.08.17 14:03:24

und die USA also Session wackelt auch: Task force doesn’t back Sessions’ anti-pot views

[techinvestor69]

@Sunny - verstehst Du das Investment von Aphria in Canabo Medical?

Erst zahlt Aphria einen Aufschlag von 36 Prozent auf den damaligen Aktienkurs und erwirbt 6 Mio. Canabo-Aktien zu 1,40 CAD und dann verkauft Aphria im Mai einen Teil zu 0,46 CAD.

Verlust: 2,35 Mio. CAD



.

[techinvestor69]

@sunny

EBITDA von Aphria war im letzten Geschäftsjahr (per Ende Mai) negativ - minus 1,39 Mio.

[sunny3999]

Antwort auf Beitrag Nr.: 55.468.557 von techinvestor69 am 06.08.17 17:52:59

Aphria's Canabo Invest im Video erklärt @8,30"

Aphria wollte an die Klinik Auswertungen von Canabo um den Bedarf besser zu steuern.

Jetzt gehen sie direkt an die Kliniken ran.

[sunny3999]

Antwort auf Beitrag Nr.: 55.468.569 von techinvestor69 am 06.08.17 17:57:16

Negativ Ergebnis nur wegen dem Verkauf von negativen Beteiligungen,

vergleiche bitte die Zahlen im operativen Geschäft, nach Bekanntgabe der Zahlen ist Aphria über 10% gestiegen.

[techinvestor69]

@sunny - ich verstehe es immer noch nicht. Die Erklärung vom CEO ist auch falsch.

Fakt ist, dass Aphria 500.000 Stücke von Canabo verkauft hat, obwohl sie noch einer Sperrfrist unterlagen. Der CEO labbert irgendwas von Blackout, was Bullshit ist. Der Fehler wurde zwar schnell bereinigt. Die Stücke wurden über den Markt gecovert, aber irgendjemand hat da Sch... gebaut. Vielleicht sollte Aphria mal seinen Broker wechseln.

https://www.newcannabisventures.com/aphria-books-2-35mm-loss…

Der strategische Grund des Investments, Patientenakquise, ist mir klar.

Aber wieso hat Aphria im Mai das Investment reduziert, anstatt zu warten, bis der Kurs von Canabo sich mal wieder erholt?

Das Geld hat Aphria mit Blick auf den hohen Kassenbestand sicher nicht gebraucht, selbst wenn ich die langfristigen Verbindlichkeiten dagegenrechne. Vielleicht hat Canabo einfach operativ nur underperformed.

[techinvestor69]

Die GUV irritiert mich etwas - warum sind die consulting revenues nicht oben bei revenue?

Nächste Woche Dienstag geht übigens eine Beteiligung von Aphria public: Scythian BioSciences - siehe mein neuer Thread. Da hat Aphria 2 Mio. investiert.

[sunny3999]

Antwort auf Beitrag Nr.: 55.469.151 von techinvestor69 am 06.08.17 20:19:52

Das Canabo unterperformed hat sagt der CEO auch, deswegen gehen sie direkt an die Kliniken ran.
Canabo hat so schnell an Aktienwert verloren, das Aphria den Ausstieg bevorzugt hat, statt zu warten.

Ich habe auch das Gefühl, das Canabo mit Canopy verbandelt ist und gesponsert wird, es gibt ein Video auf Youtube dazu. Das kann Aphria auch bewogen haben zu verkaufen.

[sunny3999]

Antwort auf Beitrag Nr.: 55.469.172 von techinvestor69 am 06.08.17 20:29:21

Scythian wird wohl die Forschung von Gehirnerschütterungen in Florida untersuchen.

Scythian ist in einem frühen Stadium, Aphria sichert sich dadurch auch wieder zukünftige Märkte.

Finanziert sind die zumindest ganz gut mit insgesamt ca. 12 Mio. soweit ich weiß.

[sunny3999]

Aphria in Florida und die Verbindungen - sehr eindrucksvoll beschrieben!

http://www.firstcoastnews.com/news/local/florida/the-canadia…

[sunny3999]

US Senators: Stop Using Racist Term, Demands American Cannabis Report

Wenn USA die Cannabis Gesetze aufweicht und auf Schedule 2 runterstuft ist Aphria der Sieger im Markt!

Sollte dann gar REC ausgerufen werden ist Aphria mit seiner USA Vernetzung die Nummer 1 in Nordamerika mit Aphria 1 Mio sf; Copperstate Arizona, LHS Florida und eventuell Schottenstein-Aphria in Ohio - es bleibt spannend.

http://www.bioportfolio.com/news/article/3263653/US-Senators…

[sunny3999]

Schreiben an alle US Senatoren

[techinvestor69]

Thread zur Aphria-Beteiligung Scythian BioSciences: https://www.wallstreet-online.de/diskussion/1258605-1-10/scy…

[wouserxx]

Antwort auf Beitrag Nr.: 55.470.795 von techinvestor69 am 07.08.17 09:46:25

Liest hier noch jemand auf stockhouse mit?

Was ist das eigentlich für ein Kindergarten dort. ManManMan!!! Ist das durchschnittliches nordamerlikansches Forenniveau?

[sunny3999]

Antwort auf Beitrag Nr.: 55.480.386 von wouserxx am 08.08.17 15:27:58

Ja, ich lese und schreibe dort, nur manch einer wie quantum8pattern...

....ging mir schon lange auf die Nerven, mit seinen sinnlos Beiträgen - deswegen hat er nach viel Geduldsprobe eine sinnlos Antwort auf seinen Beitrag erhalten.

Habe schon eine Weile vor gehabt ihn zu ignorieren - jetzt ist es soweit - der wurde von mir gesperrt!

[sunny3999]

APHRIA INC COM NPV (OTCMKTS:APHQF) Gets Creative with Its Cash

https://oracledispatch.com/2017/08/07/aphria-inc-com-npv-otc…

[wouserxx]

Antwort auf Beitrag Nr.: 55.480.479 von sunny3999 am 08.08.17 15:39:41

Was ist eigentlich mit diesem Typen verkehrt? Ständigt himmelt er sein indoor Cannabis von CGC an und lobt es über den Klee. Sind das bezahlte Marionetten?

[sunny3999]

Antwort auf Beitrag Nr.: 55.481.079 von wouserxx am 08.08.17 16:31:41

Harter Wettbewerb um Platz 1 zwischen Canopy (Platzhirsch) und Aphria (Herausforderer) und

man sagt Indoor aufgrund der künstlichen Beleuchtung, eine marginal bessere Qualität nach - was noch zu beweisen wäre, da Aphria nun auch an Sonnen schwachen Tagen mit künstlichem Licht arbeitet.....bleibt spannend!

Zitat von wouserxx: Was ist eigentlich mit diesem Typen verkehrt? Ständigt himmelt er sein indoor Cannabis von CGC an und lobt es über den Klee. Sind das bezahlte Marionetten?

[sunny3999]

Aphria als Lead Investor in Scythian Bioscience - zur Erforschung von Gehirnerschütterung mit MMJ

https://www.streetwisereports.com/pub/na/company-developing-…

[sunny3999]

Globale Partnerschaft mit Abnahmegarantie und Bau weiterer 1 Mio sf in Leamington für Partner

Aphria Announces Global Strategic Partnership With Emerging International Leader Nuuvera Corp.

http://markets.businessinsider.com/news/stocks/Aphria-Announ…

[techinvestor69]

klingt nach einem sehr guten Deal

[sunny3999]

Antwort auf Beitrag Nr.: 55.489.269 von techinvestor69 am 09.08.17 15:16:06

Da sind mal einige gro0e Namen und Investoren drin, mit einer Initialinvestition von über 43,65 Mio $. !

https://markets.ft.com/data/announce/detail?dockey=1323-1314…

[sunny3999]

Nicht schlecht jetzt kommen sie nach Deutschland-Europa und Israel!

[sunny3999]

Die deutsche Internetseite von Nuuvera GmbH

https://nuuvera.de/

[sunny3999]

Die News nochmal auf New Cannabis Venture!

https://www.newcannabisventures.com/late-stage-acmpr-applica…

[sunny3999]

News im "Windsor Star":

Aphria part of new joint venture to produce more marijuana in Leamington

http://windsorstar.com/news/local-news/aphria-part-of-new-jo…

[sunny3999]

Nachdem auf der Aphria Homepage bereits CHT mit USA-Florida erscheint...

...passt die Präsentation von LHS zum Aphria Gesamtbild!

https://libertyhealthsciences.com/wp-content/uploads/2017/05…

[sunny3999]

Bald gibt es wöchentlich oder gar täglich News von Aphria oder einem seiner Partner!

Tokyo Smoke partners with Aphria to launch medical cannabis
http://m.marketwired.com/press-release/tokyo-smoke-partners-…

[sunny3999]

BNN Interview: Aphria Partner - Green Acre Capital investiert in Tokio Smoke!

http://www.bnn.ca/commodities/video/marijuana-fund-green-acr…

[sunny3999]

Aphria deal with Nuuvera gets thumbs-up at Canaccord Genuity

Viele News, Berichte und Höherstufungen zu Aphria...

http://www.cantechletter.com/2017/08/aphria-deal-nuuvera-get…

https://smallcappower.com/news/market-news/aphria-inc-stock-…

https://weekherald.com/2017/08/10/aphria-inc-aphqf-given-a-7…

https://baseballnewssource.com/markets/aphria-inc-nasdaqaphq…

[sunny3999]

Providing investors with access to the growing U.S. cannabis

Our new CEO @GeorgeScorsis is assembling the best team in the industry. Watch to learn about his immediate goals at Liberty. #mmj

[sunny3999]

Chartman Dan spricht auch über shorter bei Aphria, die diese US-Meldung mit delisting von Aphria meldeten!

[sunny3999]

Ich schätze spätestens ab Sept. 2017 wird es sich kurstechnisch entwickeln......

Publicly-Traded Cannabis Stocks Are Beginning to Look Like Real Revenue Producing Companies
August 13, 2017 at 10:55 am

Exclusive article by Alan Brochstein, CFA

https://www.newcannabisventures.com/publicly-traded-cannabis…

[sunny3999]

Giants & Gentlemen named AOR for Aphria

http://strategyonline.ca/2017/08/04/giants-gentlemen-named-a…
Giants & Gentlemen named AOR for Aphria
The Toronto agency will help the cannabis producer as it prepares for legalization of recreational use.

By Josh Kolm1 week ago
Greenhouse-650x335
Giants & Gentlemen has been named agency of record for medical cannabis producer Aphria as the company sets itself on a growth path ahead of next year’s expected legalization of recreational use.

Aphria is one of the largest cannabis producers in Canada and one of a handful that are publicly listed on the Toronto Stock Exchange. It was founded by multi-generational greenhouse growers in Leamington, Ont., where the greenhouses and sunlight in the region have traditionally been used to grow tomatoes year-round.

It is also one of the 50 licensed producers in Canada preparing itself for July 1 of next year, when cannabis is expected to be legalized for recreational use and become an $8 billion industry. Heading into next year, Aphria plans to expand its production facilities to over one million square feet of greenhouses as part of its goal to become a global leader in producing high-grade cannabis through sustainable growing processes and a lower carbon footprint. Yesterday, it was announced that Aphria led the series B funding for cannabis lifestyle brand Tokyo Smoke.

Giants & Gentlemen won the business after an RFP process that included multiple agencies.

“We were very impressed by how the team at [Giants & Gentlemen] understood the complexities of task at hand and the key challenges that we would face marketing in such a highly regulated environment,” Megan McCrae, Aphria’s director of marketing and communications said in a release. “Most importantly, they shared our enthusiasm and passion for building brands and making a positive impact in the cannabis sector as we transition out of the prohibition era.”

This year, Giants & Gentlemen has also picked up new assignments with Mucho Burrito, Big Smoke Burger and Toronto radio station Indie88.

The agency is also growing internally, having hired Steven Kim as its new senior art director. Kim has spent the last five years at DentsuBos, where he was an ACD and worked on the agency’s Lexus account, and has also had roles at Marshall Fenn and and BBDO. At Giants & Gentlemen, Kim will be partnered with senior copywriter Brandon Tralman-Baker, and the team will lead work for Mucho Burrito, Days Inn and Fisherman’s Friend, among others.

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://www.bilder-upload.eu/show.php?file=179657-1502649314.jpg

[/url]

[sunny3999]

Booooooom und wieder ein strategischer Invest von Aphria in Scientus:

http://markets.businessinsider.com/news/stocks/Aphria-Announ…

[sunny3999]

Homepage von Scientus Pharma

http://hydrx.ca/facilities/

[sunny3999]

Es kommt noch viel besser: Scientus Pharma kommerzialisiert Ende des Jahres 2017

http://www.biotuesdays.com/features/2017/7/27/scientus-enter…

[sunny3999]

Liberty Health Sciences kauft 36ha Land in Florida:

http://www.businesswire.com/news/home/20170816005473/en/Libe…

[sunny3999]

News auch in New Cannabis Venture

https://www.newcannabisventures.com/liberty-health-purchases…

[sunny3999]

Aphria Inc. Keeps Making Marijuana Deals

https://seekingalpha.com/amp/article/4099037-aphria-inc-keep…

[sunny3999]

Midas Letter VIDEO: Aphria Inc. (TSE:APH) Leamington Cannabis Grow Operations

https://www.midasletter.com/2017/08/video-aphria-inc-tseaph-…

[techinvestor69]

Ein wichtiger Schritt in die richtige Richtung

https://www.wallstreet-online.de/nachricht/9829590-cannabis-…

[sunny3999]

Nuuvera hat gestern sein Sedar filling erstellt.....

Nuuvera Corp Sedar filling with Directors & Executives
Directors, executive officers and promoters of Nuuvera
Schmeichel Ronald Dale - Ontario
Abony Lorne - United States
Eaton James - Ontario
Lacavera Anthony - Ontario
Greenberg Jordan - Ontario
Epstein Joshua - United States
Nuuvera Paperwork on Sedar

Fasken Martineau is a leading international business law and litigation firm with more than 700 lawyers across Canada, Europe and South Africa. Our clients include industry giants worldwide.



Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[techinvestor69]

Van Sun says Aphria, others see pot shops aren't paying

Aphria Inc (C:APH)
Shares Issued 138,819,504
Last Close 8/16/2017 $5.97
Wednesday August 16 2017 - In the News

The Vancouver Sun reports in its Wednesday edition that the value of unpaid tickets issued to the city's rogue pot shops is high and keeps getting higher. The Sun's Dan Fumano writes that recently, the value of unpaid dispensary tickets passed the $1-million mark. While Vancouver continues to crack down on scofflaw dispensaries, the latest numbers show they are having limited success. As of this week, 64 dispensaries were operating without a licence, compared with 31 working within the city's licensing system, while the city had issued 2,024 tickets to dispensaries with only 406 tickets (or 20 per cent) paid. Of the $1.2-million worth of tickets issued by the city to unlicensed illegal dispensaries in the last 15 months, officials had collected only $160,000 as of last week, while $1.04-million remained unpaid. City data show that of the 350,385 parking tickets issued each year, an average of 86 per cent of those tickets were paid. Some cities have been far less tolerant of dispensaries, including Toronto, where police have shown chains like Cannabis Culture and Canna Clinic how unwelcome they are with large-scale raids. The federal government is working to legalize non-medicinal, or recreational, pot.

[sunny3999]

Aphria*s Partner Tokio Smoke eröffnet weitere Filialen:

http://www.marketwired.com/press-release/tokyo-smoke-calgary…

[sunny3999]

Why Aphria Inc. Could Be a Canadian Marijuana Market Leader

https://www.fool.ca/2017/08/17/why-aphria-inc-could-be-a-can…

[Popeye82]

http://www.fool.ca/2017/08/17/why-aphria-inc-could-be-a-cana…

[Popeye82]

http://www.midasletter.com/2017/08/video-aphria-inc-tseaph-l…

[sunny3999]

Aphria und LHS erhalten schriftliche Bestätigung von TMX - kein Bann von TSX

Aphria and Liberty Respond to TMX Group Statement Regarding Regulatory Engagement
https://www.newcannabisventures.com/aphria-and-liberty-respo…

[sunny3999]

Aphrias "Seed to Sale" Qualität

https://www.facebook.com/AphriaMMJ/videos/1247191608725875/

[berny1984]

bei 2,60 werd ich kaufen... oberhalb viel zu teuer und überhaupt wird diese Aktie erst in ein paar Monaten steigen, dann aber Bullenstark...

[sunny3999]

Ei kuck mal in Bellinzona Schweiz an der Autobahnraststätte...

...erst habe ich eins gekauft, nach dem Geschmackstest wollten alle...

und wir mußten auf vier weitere erhöhen- erfrischend und entspannend! Es kommt scheller als gedacht und die waren fast ausverkauft.

[berny1984]

Antwort auf Beitrag Nr.: 55.656.974 von sunny3999 am 03.09.17 13:18:50

@sunny3999
Die gibts in Österreich schon seit ca 15 Jahren... Ich mein, ich bin selbst guter Dinge was dies Aktie so bitte 2018 aufwärts betrifft, aber teilweise geben mir deine Argumente schon stark zu denken...

[berny1984]

Antwort auf Beitrag Nr.: 55.657.040 von berny1984 am 03.09.17 13:31:28

*mitte meinte ich natürlich...

[sunny3999]

Antwort auf Beitrag Nr.: 55.657.040 von berny1984 am 03.09.17 13:31:28

Ich kannte es nicht und war überrascht....

und ich wünsch dir noch viel Glück mit Aphria Aktien bei 2,60 €.

[wouserxx]

Antwort auf Beitrag Nr.: 55.655.555 von berny1984 am 03.09.17 08:54:22

Wann willste denn die 2.60 sehen?
Ich kann mir nicht vorstellen, noch einmal so die Tiefe Preise zu sehen. Das Chartbild spricht im Moment völlig dagegen. Selbst die anhaltende Diskussion bzgl. der angeblichen Verstöße gegen Börsenrecht, lässt den Kurs nahezu kalt.

[AktiesuchtBauer]

Antwort auf Beitrag Nr.: 55.658.586 von wouserxx am 03.09.17 20:29:16

denke wir haben aktuell die untere grenze des Kurses erreicht,
Rücksetzer wird es zwischendurch wohl immer mal geben,
doch die eigentliche Tendenz zeigt für mich nach OBEN

[sunny3999]

Aphria befürwortet Apothekenvertrieb von Cannabis....

https://www.ourcommons.ca/Content/Committee/421/HESA/Brief/B…

und Aphria Nuveera

https://www.ourcommons.ca/Content/Committee/421/HESA/Brief/B…

[sunny3999]

Vic Neufeld auf dem Canada Summit als Sprecher und Aussteller mit Aphria

https://events.economist.com/events-conferences/americas/can…

The Canada Summit - Panel "Silicon Valley meets Bob Marley"
Vic our CEO speaks at the #CanadaSummit on why it's important to do things the right way when it comes to legalizing #marijuana..

The Economist Events‏ @EconomistEvents 31 Min.Vor 31 Minuten
@AphriaInc The vision was to go big or go home. At first, people laughed when we spoke about growing cannabis in a greenhouse #canadasummit

[sunny3999]

Aphria Partner Tokio Smoke sucht Filialleiter und Barista:

https://tokyosmoke-retail.workable.com/

[sunny3999]

Aphria in der Cannabis Show

[sunny3999]

Aphria Phase 3 das Glasdach ist drauf!

https://twitter.com/AphriaInc/status/905915859767582721

All of the glass is up! Part 3 is making great progress and expects to yield 21,000 kgs bringing us to an annual production of 30,000 kgs.

[sunny3999]

Vic Neufeld auf BNN zur MJ Regulierung in Ontario

[sunny3999]

Antwort auf Beitrag Nr.: 55.701.429 von sunny3999 am 08.09.17 19:34:05

Vic Neufeld auf BNN zur MJ Regulierung in Ontario

Youtube Link funktioniert nicht...
http://www.bnn.ca/commodities/video/pot-pricing-at-ontario-s…

[sunny3999]

Aphria Welcomes Ontario Government's Commitment to Providing Safe and Sensible Access to Recreational Cannabis

http://markets.businessinsider.com/news/stocks/Aphria-Welcom…

[sunny3999]

Entscheidung der Regierung von Ontario über CCBO zu verkaufen stärkt Aphria als low cost producer!

A Leamington medicinal pot producer explains how Ontario pot could be priced
http://www.cbc.ca/beta/news/canada/windsor/a-leamington-medi…

[sunny3999]

Aphria Price Points (neues Video dazu)

Neufeld said the real advantage his company has is their low cost production.

"We'll be able to stick handle and navigate any troubled waters that may come up as we get closer and closer to July of 2018," he told CBC News.
http://www.cbc.ca/player/play/2661905247/

[sunny3999]

Aphria Special AGM

[sunny3999]

Interessanter Analyse auf BNN durch Bruce Campbell

http://www.bnn.ca/video/bruce-campbell-discusses-aphria~1209…

[sunny3999]

NEWS: Aphria USA - Liberty Health Science eröffnet 2 Dispensaries im Dezember 2017

mit Aphria Produkten:

LHS- Aphria US CEO says: "Aphria products will be available for purchase at our dispensary locations.”

[techinvestor69]

Aphria May Be the Best Value for Marijuana Investors’ Money

https://smallcappower.com/analyst-articles/aphria-tsx/

[sunny3999]

Aphria geht mit Tetra BioPharma in Phase 3 n USA/Kanada

http://caps.fool.com/Blogs/aphria39s-cannabis-going/1094447

Die patentierten Produkte mit news dazu: http://www.newswire.ca/news-releases/resolve-digital-health-…

Inhaler von Breeze (Resolve Digital Health):


Pods von Aphria:

[sunny3999]

News: Das dürfte für Aphria und TBP ein Volltreffer sein!

Tetra Bio-Pharma to engage in co-development and distribution partnership with major healthcare specialty distributor

http://tetrabiopharma.com/investors/press-releases/press-rel…

20 September, 2017
OTTAWA, ONTARIO--(Marketwired - Sept. 20, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

This privately-owned partner, which asked to remain unnamed for the time being, has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to over 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners, including the USA.

Tetra and its partner are working together to develop a new line of products, leveraging Tetra's clinical and product development expertise. The first product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018. Tetra and its partner will be tapping into the overall Over-The-Counter (OTC) topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis. Both companies are expecting to grab a share if the specialized OTC topical analgesics market in a short period of time and could see sales generated from this distribution channel reaching $3 million for Canada in the 1st year. Since the initial launch phase will be focused on the Canadian market, further guidance will be provided as Tetra's partner gets ready to launch in the US.

"We're excited to enter this specialized market as there is a significant need for our clinical expertise in product development. This partnership opens a new distribution channel for our pharmaceutical retail division not only in Canada, but also worldwide through their active partners in the US and Europe. Tetra remains committed and is actively developing partnerships to generate a significant revenue stream. This partnership demonstrates our team's focus and dedication in accelerating our commercialization strategy towards selling a specialized line of products in our pharmaceutical retail business," comments Bernard Fortier, CEO of Tetra Bio-Pharma.

[sunny3999]

Namaste Announces Product Acquisition Agreement With Aphria Inc.

http://www.globenewswire.com/news-release/2017/09/20/1125304…

[sunny3999]

Die Phase 4 Stutzen sind fertig, jetzt kann das Glas kommen!

Dann sollten ab nächstem Jahr im July weitere 70.000 kg zur Ernte möglich sein insgesamt 100.000 kg.

The columns are up on our 700,000 sq. ft., Part 4 expansion! Construction is progressing at a great pace and Part 4 expects to yield 70,000 kgs resulting in a total annual production of 100,000 kgs.

[sunny3999]

Hap Sneddon discusses Aphria

Hap Sneddon, chief portfolio manager, founder at Castlemoore Inc., discusses his outlook for shares of Aphria Inc.

http://www.bnn.ca/video/hap-sneddon-discusses-aphria~1214665…

[sunny3999]

Eine Schätzung der Q1 2018 Zahlen für Anfang Oktober

[sunny3999]

Cannabis Companies Make 'Hay' While The Sun Shines

http://www.prnewswire.com/news-releases/cannabis-companies-m…

[currahee]

Antwort auf Beitrag Nr.: 55.809.387 von sunny3999 am 23.09.17 22:08:06

ich gehe von 1000kg sold mit 7,70 rev. pro g

[sunny3999]

Aphria's 11,5 Mio invest in Scientus Pharma erhält ACMPR Lizenz

Scientus Pharma Granted ACMPR License From Health Canada

http://www.marketwired.com/press-release/-2234793.htm

[sunny3999]

Aphria mal hochgerechnet mit Vorschau und Gewinn (brutto) bis 2020

[sunny3999]

Should You Buy Aphria Inc. Ahead of Earnings?

https://www.fool.ca/2017/09/27/should-you-buy-aphria-inc-ahe…

[sunny3999]

Aphria-US = Liberty Health Science Lizenz für Florida wurde übertragen

http://markets.businessinsider.com/news/stocks/Liberty-Healt…
https://www.newcannabisventures.com/liberty-health-sciences-…

[MVAL]

Antwort auf Beitrag Nr.: 55.838.106 von sunny3999 am 27.09.17 22:04:00

Danke für die Aufstellung, Sunny!

Sieht vielversprechend aus. Ist diese Schätzung Deiner Meinung nach eher als konservativ oder ambitioniert einzustufen?

[sunny3999]

Ich sage mal leb wohl zu der $6,XX

[sunny3999]

Antwort auf Beitrag Nr.: 55.851.327 von MVAL am 29.09.17 14:38:51

Zitat von MVAL: Sieht vielversprechend aus. Ist diese Schätzung Deiner Meinung nach eher als konservativ oder ambitioniert einzustufen?

Schon ambitioniert, aber in 3-4 Jahren kann das sogar niedrig geschätzt sein, da Aphria's Management kein Luftschloß aus heißer Luft baut sondern eine Festung mit Chateau!

[MVAL]

Canadian Cannabis Hedge Fund Raises $25 Million

..."The GAC team is led by Managing Directors, Matt Shalhoub and Tyler Stuart, and a board of advisors that includes Shawn Dym, W. Brett Wilson, Vic Neufeld of Aphria, and Lorne Gertner."...

https://www.dailymarijuanaobserver.com/single-post/2017/09/2…

[wouserxx]

Antwort auf Beitrag Nr.: 55.853.259 von MVAL am 29.09.17 18:20:19

Träfe es so ein, wie du es voraussagst, wäre das natürlich ein Traum, aber ich habe noch leichte Zweifel. Vor allem wegen des Preiskampfes, der kommen wird, was selbst Vic schon des Öfteren betont hat. Die Margen und Gewinne müssten dann sinken, das ist nicht förderlich für den Aktienkurs. Wie siehst du das?

[MVAL]

Antwort auf Beitrag Nr.: 55.854.330 von wouserxx am 29.09.17 20:48:32

Sunny hat die Aufstellung gemacht ... Ich gebe die Frage daher mal weiter

[wouserxx]

Ich meine auch sunny. Hatte mich bloß auf den falschen Beitrag bezogen. Entschuldige!

[sunny3999]

Antwort auf Beitrag Nr.: 55.854.330 von wouserxx am 29.09.17 20:48:32

Aphria ist für den Preiskampf bestens vorbereitet!

Kosten unter $1/gramm bei Fertigstellung von Phase 4.

Dann kommt auf der Mersea Road eine weitere 1 Mio für Nuuvera, davon erhalten sie $0,10/gramm und 8% von den Baukosten gut geschrieben (haben also auch Anteile in Nuuvera).

Damit wird die Spiegelung von der 1 Mio sf für Nuuvera möglich also insgesamt 3 Mio sf in Leamington, somit bis zu 300.000 kg an Cannabis erntbar.

In Florida sind für 2018 geplant 300.000 sf = 30000 kg!

In Arizona haben eine 22,5% Beteiligung an 1,7 Mio. sf Greenhouse.....

Die sind somit für jeden Preiskampf gerüstet, dazu kommt das Aphria stärker ins medizinische Cannabis investiert mit:

- Nuuevera (Partnerschaft in 10 Länder unter anderem Deutschland also Europa)
- Scientus Pharma
- Tetra Biopharma
- Scythian Bioscience
- Kalytera Therapeutics

Hier sind die Margen mit Pharmaindustrie weit höher als der Recreational Markt.

Die werden und können den Wettbewerb an die Wand spielen ausser - irgendwann würde der Freilandanbau genehmigt - was ich stark bezweifle.

Also ich denke

[wouserxx]

Antwort auf Beitrag Nr.: 55.854.450 von sunny3999 am 29.09.17 21:13:52

Aber es ist nun nicht so, dass alle anderen schlafen werden. CGC ergänzt seine Produktion mittlerweile durch Gewächshäuser, ACB hat SKY kurz vor der Fertigstellung, ebenfalls im Gewächshausstil. Mir fehlt jetzt natürlich der Einblick, wie stark der Wettbewerbsvorteil für Aphria durch die ausgewiesene Expertise von Cervini und Cacciavillani ist und inwieweit die anderen in dieser Hinsicht mithalten können.
Vielleicht belässt es APH auch nicht nur beim Anbau, sondern geht noch ein Schritt weiter und schlägt einen weitern Weg in Richtung Pharmazie ein.

[wouserxx]

Mich erstaunt auch die Performance der letzten 4 Wochen. Die Erwartungen an die Quartalszahlen scheinen hoch zu sein, wobei ich es gar nicht so recht einschätzen kann, denn das Phase II Gewächshaus wird die Kosten zu Beginn nicht gerade nach unten drücken. Das müsste doch erst der Fall sein, wenn einmal komplett geerntet wurde?!

[MVAL]

Antwort auf Beitrag Nr.: 55.854.570 von wouserxx am 29.09.17 21:35:47

Wann werden denn die Zahlen veröffentlicht? Ist ein genaues Datum bekannt?

[wouserxx]

Antwort auf Beitrag Nr.: 55.857.294 von MVAL am 30.09.17 16:46:15

Angeblich am 13.10. Ist ein Freitag!

[sunny3999]

Antworten zusammengefasst an wouserxx und MVAL....

Zahlen sollen am 5. Okt bekannt gegeben werden (Donnerstag), es gibt auch Gerüchte das Zahlen erst am 13 Okt. kommen (Freitag). Ich schätze das erste Datum stimmt.

Zu dem Wettbewerb von Aphria:

Alle 3 sind führend......jedoch:

Canopy Growth (T:Weed) ist an so vielen Standorten mit Indoor/Greenhouse vertreten, das ein Managen für mich schwierig erscheint. Sie produzieren mehr als sie verkaufen können, was vermuten läßt, das sie eine suboptimale bedarfsgerechte Steuerung haben. Mit 16 Mio $ Umsatz nicht in der Gewinnzone, Riesenlager für ca. 1 Jahr und den Lagerbestand schon als Buchgewinn gemeldet. Wenn sie nur wie gemeldet an die staatliche CCBO verkaufen können, haben sie eventuell nur noch $5/gramm, die sie melden können. Ich sehe das kritisch, auch wenn das Lager sehr schnell wegen dem hohen Bedarf anzieht.

Aurora Cannabis (ACB) hat bereits heute eine sehr hohe Aktienanzahl (371 Mio+) und eine denkbar schlechte Finanzierung im Rücken, die Ihnen die Gewinne weg fressen, dazu kommt in 1-2 Jahren eine Ablösung einer Finanzierung, die das Unternehmen in einen Schräglage bringen kann. Lest euch mal die MDA durch. Die 800.000 sf (Hybrid-Greenhouse) am Flughafen sind durchaus beeindruckend, aber haben sie das Klima wie in Leamington (der wärmste Ort in Kanada im Vergleich) oder ein Management wie Aphria, das ihr Know-How von Cannabis Züchtung/Anbau an bereits 3 Firmen weiter verkaufen und sogar Anteile im Gegenzug sichern konnte ?

Die Strategie bei Aphria:
- bedarfsorientiert anzubauen
- höchste Qualitätstandards einhalten
- Know-How mit Ertragsmaximierung
- dieses Know-How als IP (Intelectuell Property) als geistiges Eigentum weiter verkaufen
- dabei Anteile sichern
- alles konzentriert auf wichtige Standorte fixiert diversifizieren (3 Mio sf in Leamington-Kanada)
- Arizona, Florida und Ohio in M&A Partnerschaften mit IP Verkauf
- sowie mit Nuveera die internationale Ausrichtung mit Anteilen und IP Verkauf an starke Investoren
- die wiederum international bereits aktiv sind
- Die Pharmaindustrie im Visier mit guten Margen,
- auch den Rec-Markt mit Tokio Smoke

und vieles mehr, was da alles im Hintergrund läuft würde ich gern wissen, da wird es einem sicher schwindlig.....

...den Vic Neufeld hat die Jamieson Vitamin in 17 Jahren zu eine Weltunternehmen mit 25% Marktanteil aufgebaut, das setzt er gerade bei Aphria in Zeitrafer als Highspeed um.

Die finanzstarken Leute, die dieses Management kennt zeigt sich schon im Namen von Schottenstein-Aphria die in Ohio die Lizenz beantragt haben. Delavaco Group mit dem Eigentümer Andrew DeFrancesco googelt mal was dem alles gehört oder schaut mal nach den Eigentümern von Jogenfrüz die Serruya Familie....und viele mehr die hier nicht genannt sind......weil noch im Hintergrund.

Also ich schätze immer noch das Aphria das sicherste von allen Anlagen in der Cannabisbranche ist.

[wouserxx]

Antwort auf Beitrag Nr.: 55.857.648 von sunny3999 am 30.09.17 19:14:10

Zu CGC: Ich habe mich auch schon gefragt, wie die das ganze Inventar wieder ausbuchen wollen, wenn es verkauft wird. Damals wurde es seitens CGCs mit einem Preis X eingebucht und wenn es dann nächstes Jahr zu einem Preis Y verkauft werden sollte , der unter Preis X liegt, wird doch deren Gewinn- und Verlustrechnung nicht sonderlich positiv ausfallen. Im letzten Quartal hatten sie einen Lagerbestand im Wert von 70 Million. Im Vergleich dazu lag der Wert bei APH und ACB bei ca 5 Millionen.

Insegesamt bin ich auch überzeugt von dieser Firma, nur deine Kalkulationen zum Aktienpreis sind für mich schon ziemlich hoch, weil die Prognosen auf dem aktuellen Preis pro Gramm basieren, aber wie der sich genau entwickeln wird, kann keiner so genau sagen, würde ich jetzt mal behaupten wollen.

[wouserxx]

Zu den von dir genannten Personen hatte ich mich auch schon informiert. Der Serruya hatte mich aufhorchen lassen.

[sunny3999]

Ich habe mir die Mühe gemacht alle Investierten-Partner-Firmen-Privatpersonen mal zusammen zu fassen:

Who is leading and who backup the company in collaboration (all with links):

Aphria's Top Management - Vic, Carl, Cole, John, Gary and Di…

Green Acre Capital including Brett Wilson, Vic, Lorne....

Delavaco Group - Andrea DeFrancesco and Group - LHS-Florida
Copperstate Farms Arizona 1,7 Mio sf with Fife Symington (So…

Serruya Private Equity - Yogen Früz

Hill and Gertner Capital Corp. - Tokio Smoke

Schottenstein Capital Group - American Eagle

Nuuvera Investors with "Ceo" Lorne Abony and lot more behind…

Nuuvera Germany (Europe)

Nuuvera North America + other 10 countries

Scientus Pharma with CEO Trevor Folk as Investor from Avro C…

Investments: Tetra Biopharm

Scythian Bioscience including Gary Leong (Aphria)

Cannaroyalty with lot of brands and Canada exclusive contrac…

Tokio Smoke with Alan and Lorne Gertner

Kalytera Therapeutics with Gary Leon as Director of Aphria

Medlab Australia

Massroots

and last but not least the Loblaw with Galen Weston Shoppers Drugmart - Pharmacy which are awaiting their green light licence from Health Canada to sell MMJ....

...and i am sure that there is more to come....

[sunny3999]

Antwort auf Beitrag Nr.: 55.858.014 von sunny3999 am 30.09.17 20:57:48

Ich habe das mal auch auf Stockhouse und bei Reddit unter Weedstocks gestellt:

http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

Bei Weedstocks unter:
Aphria looking at the big picture with Partner-Investors-Collaboration-Investments

https://www.reddit.com/r/weedstocks/

[sunny3999]

Gerade eben noch davon geschrieben!

APHRIA INC COM NPV (OTCMKTS:APHQF) FINDS A NEW OUTLET FOR EXCESS CASH

http://financeregistrar.com/aphria-inc-com-npv-otcmktsaphqf-…

[sunny3999]

update von Aphria's Partner-Invest-Investoren-Märkten....

Denke das nicht alles drin ist, da mir langsam der Platz ausgeht, dennoch eindrucksvoll oder?

[sunny3999]

Hier mal ein paar News verbunden und eine Schlußfolgerung gezogen!

Da Aphria ca. 10 Mio Aktien von Tetra Bio-Pharma besitzt die ca. 9% aller Aktien bedeuten, mit der folgenden News ein Partnerschaft verbunden ist "the commercial venture between Tetra and Aphria will enhanc…

Wenn man die News mit dieser verbindet das Shoppers Drugmart ca. 1 Mio für Entwicklung & Forschung in einen Lehrstuhl iin New Brunswick investiert: with a 1 Mio contribution from Shoppers Drugmart for a Healt… and adding that Tetra Bio-Pharma to Benefit from Intellectual Properties Cre…,

Schließe ich daraus, das es eine weit angelegte Zusammenarbeit von

Aphria - Shopper Drugmart - Tetra Bio-Pharma mit New Brunswick als Bindeglied in der Forschung vorliegt bei dem alle Parteien einen Gewinn erzielen, oder liege ich etwa falsch?

Schlußendliche Folgerung - das ist das erste Anzeichen, das Aphria und Shoppers eine Verbindung durch TBP haben.....es wird spannend!

[sunny3999]

Funds und Institutionen die in Aohria einkaufen:

http://quote.morningstar.ca/Quicktakes/owners/OwnersOverview…


Manulife Cdn Focused F 3,370,207 418,440 2.45 2.43 31/08/2017

TD Canadian Small Cap Equity - F 219,400 0 0.16 0.18 30/06/2017

Aurion II Equity Class F 121,500 121,500 0.09 2.99 31/07/2017

Manulife Cdn Focused Class F 131,478 17,060 0.10 2.52 31/08/2017

Front Street Tactical Equity Class A 50,000 50,000 0.04 2.16 31/07/2017

Marquest Small/Mid Cap 15,000 0 0.01 2.76 31/08/2017

Marquest Small Companies Class F 8,076 0 0.01 2.85 31/08/2017

Total: Top 7 funds 3,915,661 607,000 2.86

Manulife Asset Management Limited 3,501,685 435,500 2.54 2.43 31/08/2017

TD Asset Management Inc 219,400 0 0.16 0.18 30/06/2017

Aurion Capital Management Inc 121,500 121,500 0.09 2.99 31/07/2017

Front Street Capital 50,000 50,000 0.04 2.16 31/07/2017

BBVA Asset Management SGIIC 40,000 0 0.03 0.49 30/06/2017

Marquest Asset Management Inc 15,000 0 0.01 2.76 31/08/2017

IndexIQ Advisors LLC 9,785 0 0.01 0.49 28/09/2017

Seamark Asset Management Ltd 8,076 0 0.01 2.85 31/08/2017

Woodpecker Capital S.A. 8,416 -8,416 0.01 0.05 30/04/2017

Horrell Capital Management, Inc. 1,000 1,000 0 0 30/06/2017

Total: Top 10 institutions 3,974,862 599,584 2.90


Read more at http://www.stockhouse.com/companies/bullboard/t.aph/aphria-i…

[sunny3999]

David Butler ein Schreiberling bei SeekingAlpha frägt: Aphria Inc.: Hold Or Take Profits?

Ich halte ausser der Kurs geht in sehr kurzer Zeit durch die Decke.....wie beim letzten Mal...

https://seekingalpha.com/article/4111014-aphria-inc-hold-tak…

[Complexity]

Antwort auf Beitrag Nr.: 55.865.251 von sunny3999 am 02.10.17 15:43:32

Was verstehst du denn unter einem signifikanten Anstieg?

[sunny3999]

Antwort auf Beitrag Nr.: 55.865.800 von Complexity am 02.10.17 16:54:17

Das kommt auf die News und den Zahlen zusammen....

Zitat von Complexity: Was verstehst du denn unter einem signifikanten Anstieg?

Wenn Aphria eine Steigerung von 30% in Umsatz also über 7 Mio C$ und Gewinn mit weiteren News meldet, könnte der Kurs bis kurz vor die 10 C$ gehen.

Allgemein sind Anstiege von 50-100% innerhalb von 1-3 Monat mit einem "Korrekturbedarf", letztes Mal ging der Kurs an einem Tag von 7,80 auf 8,67 C$, da habe ich bei 8,50 versilbert und bin beim Gapup um die 6 wieder eingestiegen.

Nur es gibt leider keine Garantie, da im Moment die Fonds/Instis anfangen zu akkumulieren.

Entscheidung liegt bei jedem selbst und eben seiner Risikobereitschaft, Gewinne zu realisieren oder laufen zu lassen.

[wouserxx]

Antwort auf Beitrag Nr.: 55.866.748 von sunny3999 am 02.10.17 18:47:38

Aber den Wiedereinstieg zu finden, fällt doch dann schon schwer, oder?
Ich habe das Problem umgangen, indem ich noch eine weitere Position Anfang September eröffnet habe, die eigentlich bis zu den Zahlen laufen soll. Sollten die jetzt ungewöhnlich gut ausfallen, lasse ich ich sie noch weiterlaufen. Allerding rechne ich mit einem sell on news.

[sunny3999]

Vergleich der 3 großen mit dem Kauf von Fonds/Institutionen:

Aphria (Aph) Aktien dazu gekauft in %
Total: Top 7 funds 3,915,661 607,000 2.86%
Total: Top 10 institutions 3,974,862 599,584 2.90%

Canopy (T:Weed)
Total: Top 10 funds 4,208,168 -15,925 2.61%
Total: Top 10 institutions 4,594,067 -2,100 2.83%

Aurora Cannabis (ACB)
Total: Top 6 funds 2,935,299 0 0.82%
Total: Top 8 institutions 3,014,200 2,000 0.84%


Zu lesen auch unter: http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Beitrag vom Hotstock-Investor zu Aphria-USA = LHS

https://hotstock-investor.com/die-zweite-aphria/

Ich warte noch bis die USA eine klarere Richtung vorgibt. LHS braucht noch einiges an Geld bis sie die 430.000 sf gebaut haben...Finanzierung steht sicher an bei LHS.

Warum in LHS investieren, wenn Aphria als Mutter schon 38% von LHS gehört und eventuell nach Rückstufung von Schedule 1 auf 2/3, die LHS in Aphria einverleiben kann.

Auf jedenfall ist Florida medical MJ ein sehr interessanter Markt.....

[wouserxx]

Antwort auf Beitrag Nr.: 55.876.270 von sunny3999 am 04.10.17 10:55:40

Bei solchen Beiträgen bekomme ich einen faden Beigeschmack. Ein Pusherbeitrag, wie er im Buche steht.

[Geheimnisvoller]

Wann wird es nun die Zahlen genau geben: morgen oder am 13.10.?

Wer weiß das genau - vielen Dank für Antwort

Aphria ist eine klare Investition - bin auch dabei

[sunny3999]

Antwort auf Beitrag Nr.: 55.877.359 von Geheimnisvoller am 04.10.17 12:59:16

Leider weiß das keiner so genau...

Carl Merton (CFO) schrieb oder sagte einem auf Stockhouse, es werde der 13te Okt. sein, auf Internetplattformen steht der 5te Okt. oder eben irgend etwas dazwischen drin.

Aphria läßt da gern immer eine Hintertür offen, um den Shortern und Daytradern ein schnippchen zu schlagen - sagen wir mal der Überraschungsmoment ist umso größer.....

Dafür hat lt. Marc Davis aber schon die nächste Welle in Cannabisboom begonnen:
https://www.wallstreet-online.de/nachricht/9945250-chancen-r…

Marc Davis gehört die Internetplattform:
http://www.cannabiscapitalist.ca/home

[sunny3999]

Hier steht wieder der 5te Okt.....

https://weekherald.com/2017/10/04/aphria-inc-aph-scheduled-t…

[sunny3999]

Überprüfung von Aphria's Tokyo Smoke Marken Cannabis

Review of Aphria's Tokyo Smoke branded cannabis
https://news.lift.co/review-aphrias-tokyo-smoke-branded-cann…

[wouserxx]

Antwort auf Beitrag Nr.: 55.880.320 von sunny3999 am 04.10.17 19:16:47

14 Uhr werden wir alle schlauer sein!

[sunny3999]

News: Vic "Aphria is supportive of proposed taxation plan"

http://www.newswire.ca/news-releases/new-proposed-federal-ta…

[wouserxx]

Dann gibt es wohl heute keine Zahlen.

[sunny3999]

News: Aphria ist im kanadischen MMJ Co-Op:

http://www.newswire.ca/news-releases/canadas-licenced-produc…

[Geheimnisvoller]

Aphria's cash cost per gram is $0.791, one of the lowest among Canadian licensed producers.

Das macht Aphria jetzt im Vergleich zu den anderen Anbietern noch attraktiver - das ist einmalig.

https://mobile.tmxmoney.com/quote/readnews/?id=8388827529968…

[sunny3999]

Antwort auf Beitrag Nr.: 55.887.523 von Geheimnisvoller am 05.10.17 16:39:07

Zitat von Geheimnisvoller: Das macht Aphria jetzt im Vergleich zu den anderen Anbietern noch attraktiver - das ist einmalig.

Bis andere LP's in die Gewinnzone kommen macht Aphria bei knapp 0,8 $ Herstellungskosten - Gewinne im 2stelligen Millionenbereich.

Die Banken spielen in Kanada jetzt auch mit!

https://www.bloomberg.com/news/articles/2017-10-05/bank-of-m…

Bank of Montreal provides accounts to at least a dozen companies, including Aphria Inc., CannTrust Holdings Inc., and Invictus MD Strategies Corp., as well as investment firms Cannabis Wheaton Income Corp. and CannaRoyalty Corp.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[Geheimnisvoller]

Was denkt ihr - jetzt noch nachkaufen oder warten bis die Zahlen da sind, um evtl. in einen kleinen Gewinn-Mitnahme-Dipp zu kaufen?

[sunny3999]

Aphria Is Trying to Stake a Claim in the US Through Liberty Health Sciences

https://www.gurufocus.com/news/575393/aphria-is-trying-to-st…

[sunny3999]

Antwort auf Beitrag Nr.: 55.889.167 von Geheimnisvoller am 05.10.17 19:16:21

Zitat von Geheimnisvoller: Was denkt ihr - jetzt noch nachkaufen oder warten bis die Zahlen da sind, um evtl. in einen kleinen Gewinn-Mitnahme-Dipp zu kaufen?

Wenn gute Zahlen mit 20-30% Wachstum in Umsatz und Gewinn vermeldet werden......sollte der Kurs an Fahrt gewinnen.

Mit absoluter Sicherheit kann das leider keiner sagen, nur eines ist sicher die Anleger in Amerika werden aufgrund von Florida/Arizona und bald Ohio stärker von Aphria Notiz nehmen....

Ich bleibe mindestens bis das All-Time-High erreicht ist bei 8,77 C$. Dann entscheide ich neu ob ich die 2-Stelligkeit mitnehme oder auf einen Rücksetzer abwarte.

[sunny3999]

Introducing Aphria’s Improved Cannabis Oil Lineup

https://aphria.ca/blog/introducing-aphrias-improved-cannabis…

[sunny3999]

Antwort auf Beitrag Nr.: 55.889.248 von sunny3999 am 05.10.17 19:26:40

Der Link passt nicht mehr, deswegen der Beitrag in Vollversion....

Zitat von sunny3999: https://www.gurufocus.com/news/575393/aphria-is-trying-to-st…

Aphria Is Trying to Stake a Claim in the US Through Liberty Health Sciences
A look at how the company is trying to penetrate the US market through publicly traded subsidiary Liberty Health Sciences
October 05, 2017 | About: LHSIF +0% APH.TO +0%

A handful of billion-dollar medical marijuana companies control the space in Canada. One of the most well-known is Aphria Inc (TSE:APH), the Ontario-based producer, grow and retailer, headed up by former Ernst & Young partner Victor Neufeld. In Canada, medical marijuana is big business, with the countrywide market expected to be worth a little over $1.1 billion by 2020. In the US, however, the market is far bigger and growing faster than that of its above-the-border counterpart.

During 2016, the total medical marijuana industry was estimated to be worth $5.6 billion in the US.

Unsurprisingly, those companies at the forefront of the space in Canada are looking for ways to break into the US market and the above-mentioned Aphria has taken steps over the last six months to do exactly that. Back in April, the company made a strategic investment in an entity called DFMMJ Investment Ltd and then immediately announced that the latter would be acquiring all or substantially all of the assets of an entity called Chestnut Hill Tree Farm LLC, a Florida nursery authorized by the Florida Department of Health, Office of Compassionate Use, as a dispensing organization of medical cannabis to patients in need in the State of Florida.

DFMMJ then reverse merged into a publicly traded entity called SecureCom Mobile Inc, which resulted in a new company, what might be considered a sister company of Aphria, called Liberty Health Sciences.

As of last week, this entity now trades over the counter in the US under the ticker Liberty Health Sciences Inc. (LHSIF).

Essentially what we've got here, therefore, is a subsidiary of Aphria that trades publicly in the US and that allows Aphria to conduct operations in the US market (and thereby allows it direct access to the opportunity for growth in said market) without having to run things through the parent company. Liberty Health Sciences also has access to Aphria's technology and name in return for a 3% royalty on sales, and the above-mentioned Neufeld holds a board seat on the former.

So that's where things stand, where is the opportunity here?

Well, the first foray into the US market for Aphria, by way of Liberty Health Sciences, is the Chestnut Hill Tree Farm property mentioned above. It's one of just 11 license holders for growing and distributing medical marijuana in Florida and, with the backing of a Canadian medical marijuana behemoth like Aphria, it has a significant competitive advantage over of the license holders in the state.

So how big is the Florida medical marijuana market?

Right now, the leaders in medical marijuana in the US are Colorado and California. Over the coming five years, however, market analysts expect this to change dramatically. By 2020, Florida is projected to have a larger medical marijuana market than Colorado, with the former boasting a market size of $1.6 billion versus $1.5 billion for the latter, and there are more than 6 million qualifying patients within a total population of a little over 20.6 million individuals in the state.

By far and away the largest population of patients within this 6 million qualifying patient count suffer from arthritis, with this latter indication accounting for two-thirds of the target patient base. With that said, outside of arthritis, there are also a number of other indications including PTSD, glaucoma and HIV, all of which could benefit from medical marijuana administration.

To add a direct comparison to the Canadian market, as things stand, Canada has approximately 800,000 individuals qualifying as patients per license. Florida, by comparison, has more than 1.9 million patients per license. Consider the fact that, as mentioned above, Chestnut Hill Tree Farm, and by proxy, Liberty Health Sciences and Aphria, hold one of just 11 licenses issued in the state and it's easy to see why Aphria is pushing its way into the US market ahead of its competitors.

So where is the growth coming from near term?

The property currently held by Liberty Health Sciences covers 13,000 ft.² and has the capability to serve just shy of 10,000 customers annually with a maximum output capacity of around 700 kg. By December 2019, Liberty Health Sciences expects to have increased facility size to more than 400,000 ft.² allowing for 25,000 kg in annual production to serve more than 40,000 patients in the state.

The company also expects to expand its distribution network (made up primarily of dispensaries) to include Fort Lauderdale, Miami, Jacksonville, Orlando, Tallahassee, Tampa and Pensacola by early 2018, with each additional region allowing increased penetration towards the above mentioned 1.9 million individuals served per license in Florida.

Outside of Florida, Liberty Health Sciences has also applied for a license in Ohio (which is expected to be granted this month or next) with the goal being to build a production facility from scratch once issuance takes place.

Again, licenses are limited in Ohio (12 in total) and if Liberty Health Sciences can pick one up it offers Aphria further penetration into the US market, with a potential 2.8 million qualifying patients residing in the state.

At last count, as of August 25 this year, Aphria had $10 million cash on hand and no debt, with 8.75% insider ownership and a little over 38% of the company owned by notable shareholders. This removes a large portion of the dilution risk normally associated with these growth-type companies from the equation.

Both management and board for Liberty Health Sciences is strong, primarily consisting of individuals that command various roles in Aphria, something that really sets this company aside from many of the younger, less experienced companies trying to secure a portion of this fast-growing space right now.

In conclusion, Liberty Health Sciences is a unique play in this space given that it has a strong position in the domestic US medical marijuana market but also has the backing, both financial and operationally, of one of the strongest players in the industry in Canada.

Disclosure: the author has no positions in any of the stocks mentioned in this piece.


Read more at http://www.stockhouse.com/companies/bullboard/t.aph/aphria-i…" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.com/companies/bullboard/t.aph/aphria-i…

[sunny3999]

Cannabis Sektor Begeisterung sollte bis in den November weiter gehen: Bruce Campbell

https://smallcappower.com/videos/videos-top-stories/marijuan…

Marijuana Sector Excitement Should Continue into November: Bruce Campbell
OCTOBER 5, 2017

[sunny3999]

Für interessierte - es gibt ein neues Facebook-Profilbild im

Cannabis Aktien Forum und News !

[sunny3999]

Arbeitgeber müssen den Versicherten Arbeitnehmern die medizinische Cannabis Verschreibung vergüten!?

CBC News: Employee insurance plan must pay for medical marijuana, human rights board rules

http://www.cbc.ca/news/canada/nova-scotia/medical-marijuana-…

[sunny3999]

Canada Post startet Lieferung bis an die Haustür....

https://www.mtlblog.com/whats-happening/canada-post-to-start…

[sunny3999]

Das Momentum erhöht sich im Cannabis Sektor

https://technical420.com/cannabis-article/momentum-heating-c…

[wouserxx]

Antwort auf Beitrag Nr.: 55.896.358 von sunny3999 am 06.10.17 15:23:01

Für heute ist das Moemntum wohl erst einmal verpufft.

[sunny3999]

Antwort auf Beitrag Nr.: 55.896.841 von wouserxx am 06.10.17 16:20:08

Abwarten und Tee trinken....die haben höchstens noch 9 Monate um zu akkumulieren, das ist nicht viel Zeit

Zitat von wouserxx: Für heute ist das Moemntum wohl erst einmal verpufft.

[wouserxx]

Dass es nicht ewig so weitergehen kann, ist doch wohl auch klar. Wer sollen denn die Akkumulatoren sein?

[sunny3999]

Antwort auf Beitrag Nr.: 55.897.051 von wouserxx am 06.10.17 16:44:36

Schau dir auf Morningstar die Fonds/Institutionen an die sammeln gerade ein....

Zitat von wouserxx: Dass es nicht ewig so weitergehen kann, ist doch wohl auch klar. Wer sollen denn die Akkumulatoren sein?

http://quote.morningstar.ca/Quicktakes/owners/MajorSharehold…

[sunny3999]

Ist dein Portfolio für legalen Cannabis gerüstet?

Is Your Portfolio Prepared for Legal Pot?

https://www.energyandcapital.com/articles/is-your-portfolio-…

[sunny3999]

APHRIA - The Makings of a Cannabis Titan

Für die erst neu in Aphria-Investierten, ein lesenswerter Artikel....und bitte das Video anschauen!

http://www.cannabisbusinesstimes.com/article/the-makings-of-…




http://www.cannabisbusinesstimes.com/fileuploads/publication…

[sunny3999]

17000kg MMJ von Aphria in 2018/19!

Es gab gestern noch eine Meldung Nuuvera macht M&A mit Mira IX und kauft 17000kg MMJ von Aphria in 2018/19!

https://globenewswire.com/news-release/2017/10/06/1142453/0/…

[wouserxx]

Nuuvera übernimmt dann die Belieferung des Auslands, wenn ich das jetzt richtig durchdacht habe?

[sunny3999]

Antwort auf Beitrag Nr.: 55.901.245 von wouserxx am 07.10.17 11:23:08

Ich lese das so....ausser Amerika, da Aphria den Markt mit LHS beackert!

Zitat von wouserxx: Nuuvera übernimmt dann die Belieferung des Auslands, wenn ich das jetzt richtig durchdacht habe?

Nuuvera is engaged in the testing, formulation, production, extraction and sale of medicinal cannabis products in Canada and other legal International jurisdictions (excluding the United States, where no Nuuvera business is conducted).

Das heißt Aphria hat nun schon bereits 3 große Kunden mit:

1. Scientus Pharma (1 Million $ Abnahme im Quartal)
2. Tetra Biopharm (Vertriebspartner USA/Kanada nach erfolgreicher Phase 3 für PPP001 in US-Kan.)
3. Nuuvera (weltweit, Abnahme von 17,000 kg & Bau eines 1,0 Mio sf Gewächshauses,daß Aphria leitet)

Da ist noch nich die Rede von Rec-Markt....der 5-6x größer ist als der medizinische Cannabis Markt!

[sunny3999]

Aphria Partner Nuuvera und Tokio Smoke sind auf der Cannatech Global in London am 25-26 Okt. 2017

https://www.canna-tech.co/

[wouserxx]

Antwort auf Beitrag Nr.: 55.901.512 von sunny3999 am 07.10.17 12:21:59

Vielleicht hat man den US-Markt in der Pressmitteilung auch explizit ausgeklammert, um mehr Investoren in das Boot holen zu können. Schließlich gibt es immer noch keine klare Regelung zu den Investments von kanadischen Unternehmen in den US-Cannabismarkt. Aber deine Begründung ist die Offensichtlichere.

Wieso nimmt Aphria den Auslandsmarkt überhaupt über Nuuvera und LHS in Angriff? Um das Risiko erst einmal auszulagern, falls es doch zu Schwierigkeiten kommen könnte?

[sunny3999]

Antwort auf Beitrag Nr.: 55.902.085 von wouserxx am 07.10.17 14:54:27

Zitat von wouserxx: Wieso nimmt Aphria den Auslandsmarkt überhaupt über Nuuvera und LHS in Angriff? Um das Risiko erst einmal auszulagern, falls es doch zu Schwierigkeiten kommen könnte?

Bei LHS = Aphria USA gehören bereits 38% zu Aphria und Vic Neufeld (CEO Aphria), John Cervini (Gründer Aphria) und Aaron Serruya (CEO Jogen Früz) sitzen im Board von LHS.

Bei Nuuvera bekommen sie 8% von den Baukosten der 1 Mio sf Gewächshauses und 0,10 $/gramm des hergestellten Cannabis (Cash), dazu haben sie das Grundstück in der Mersea Road für 6 Mio $ gekauft, davon 50% jedoch an Nuuvera für 4 Mio $ verkauft => bleibt ein Gewinn von 1 Mio für das Grundstück!

So, damit aber Nuuvera schön geführt werden kann, haben sie sich dazu noch mit 2 Mio $ in Nuuvera eingekauft.

Somit sind sie im Falle von rechtlichen oder gesetzlichen Themen in den vielen verschiedenen US-Bundestaaten oder Länder in Europa etwas außen vor - kontrollieren dennoch und ziehen die Fäden.

Wenn Aphria und sein Management, diesen riesigen Weltmarkt alleine führen wollte, würden sie sich verzetteln und am Schluß Schwachstellen erzeugen, die das Unternehmen in Gefahr bringen können.

Man könnte Aphria auch als "Hedgefond" bezeichnen, die überall die Finger drin haben sich jedoch durch Anteile, Gewinnausschüttungen, Lizenzbeteiligung-/zahlungen nicht dem ganzen Risiko aussetzen.

Das wiederum sollte zu einer geringere Verwässerung der Aphria-Aktien führen, da alle Töchterfirmen sich selbst am Markt finanzieren müssen und Aphria nur bedingt zuschießt wenn sie die %Anteile stabil halten wollen.

Somit konzentriert sich Aphria-Gründer (John & Cole) auf die Kernkompetenz der IP (geistiges Eigentum) also Know-How der gesamten Cannabisherstellung mit dem speziellen Wissen der Gewächshausbewirtschaftung.

Vic Neufeld setzt sein Know-How und Kontakte ein um einen Weltmarktführer im Pharmazeutischen & Gesundheitswesen aufzubauen, wie er es bei Jamieson Vitamin (von 7% auf 27% Marktanteil) mit Vertriebsniederlassungen in 40 Ländern in 17 Jahren umgesetzt hatte.

Hier unten die links zu Jamieson Vitamin:
http://www.marketwired.com/press-release/former-jamieson-lab…
https://www.jamiesonvitamins.com/collections/all-products

Auszug aus der Aphria Meldung von 2014:
Vic previously served as CEO at Jamieson Laboratories, Canada's largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines. Vic brings 15 years experience as a chartered accountant and partner with Ernst & Young and 21 years leading Jamieson. When Vic began his career with Jamieson in 1993, the top five leading nutrition brands each had 7% market share respectively. Under Vic's leadership, Jamieson outpaced the competition and increased its market share to 27%. During his tenure with Jamieson, Vic led the company from $20 million in annual sales to over $250 million and expanded the company's distribution network to over 40 countries, building Jamieson to a globally recognized brand name.

[wouserxx]

Danke!!!!!!

[wouserxx]

Danke!!!!!!!

[sunny3999]

Vorbereitung auf die Aktionärsversammlung am 25 Okt. 2017

Hier die gesamte Dokumentation für das Meeting:

https://aphria.ca/wp-content/uploads/2017/09/Aphria-AGM-Circ…

2 Änderungen im Board: 1. Mr. Shawn Dym
is a managing director at York Plains Investment Corp. a private
Age: 37 investment vehicle focused on maximizing absolute returns by investing in a wide
Toronto, ON array of asset classes, including successful cannabis related investments. He currently
Director since: N/A serves on the board of advisors for Green Acre Capital, Canada’s first private
Independent Director: investment fund focused on the cannabis industry.

He has extensive experience managing companies with high growth both at York
Plains and as an entrepreneur. Since 2014 he has been president of Eddy Smart
Home Solutions Inc. a leading smart home water monitoring venture based out of Toronto.

Mr. Dym has more than a decade of experience in the energy industry, most recently co-founding National Home Services (NHS) and serving as its chief operating officer from 2008 to 2011. He
currently serves on the board of directors at Wellpoint Health and Totally Green. He
graduated from York University and holds an MBA from Harvard Business School.

Strategic qualifications:
• Extensive capital market expertise
• Early cannabis investor with strong overview of the industry

2. Ms. Renah Persofsky
is a widely-respected entrepreneur, strategist, innovator and Age: 58 change agent with a distinguished track record of success in creating Toronto, ON 27 start-up companies.
She has a rich history of investing in Director since: N/A early stage companies where she helps
mentor CEOs in the art of bringing Independent Director: YES MVP products to market, and growing
their business exponentially. She serves as Board Chair for mobile on-demand
senior care and child care start-up BookJane, advises award winning
payment card and platform technology firm Dynamics Inc., and is a board
member for retail/QSR automation software specialty firm MeazureUp Inc.
She is presently an executive consultant in the Innovation Group at CIBC.

Strategic qualifications:
• Strategic vision and entrepreneur expertise
• Capital markets and Schedule I banking experience

Arlene Dickinson und Robert Kozlov verlassen das Board der Direktoren.

[Sevcik]

Antwort auf Beitrag Nr.: 55.904.911 von sunny3999 am 08.10.17 11:30:46

durchaus sehr interessantes Investment.
Unschön nur die ständige Verwässerung, ist bekannt wie lang das noch anhält?

August15 52Mio
August16 73Mio
November16 101Mio
Februar17 111Mio
Juli17 138Mio

[sunny3999]

Antwort auf Beitrag Nr.: 55.905.902 von Sevcik am 08.10.17 15:29:38

Zitat von Sevcik: durchaus sehr interessantes Investment.
Unschön nur die ständige Verwässerung, ist bekannt wie lang das noch anhält?

Aphria sollte keine Finanzierung mehr benötigen, nach meiner Berechnung ausser

1. sie wollen einen Wettbewerber kaufen (eher unwahrscheinlich),
2. einen Partner übernehmen (durchaus denkbar z.B.: Tetra Bio-Pharma; Scientus Pharma....)
3. oder noch Cash für solche Maßnahmen auf der Bank bevorraten.

Hauptgrund für die Verwässerung unter anderem:
Um auf die 1 Mio square feet bauen zu können benötigen sie 171,5 Mio $ lt. Investor Deck Seite 10:
https://aphria.ca/wp-content/uploads/2017/01/Q4_2017_Aphria_…

weitere Gründe waren Partnerschaften und Anteile bei Partner wie;
- Copperstate/Arizona,
- Liberty Health Science
- CannaRoyalty
- Tetra Bio-Pharm
- Scientus Pharma
- Nuuvera
- Green Acre Capital
- Tokio Smoke
- Scythian Bioscience
- Kalythera
- u.v.m. siehe Bild unten....

Gewächshauskosten für 1 Mio sf im Bild!

[wouserxx]

Ich bin auch mal gespannt, wie sich die eigentständige Energieerzeugung auf die Kostenstruktur auswirken wird. Wird dieses Projekt zusammen mit Phase IV abgeschlossen sein?

[sunny3999]

Antwort auf Beitrag Nr.: 55.907.132 von wouserxx am 08.10.17 19:44:17

Zitat von wouserxx: Ich bin auch mal gespannt, wie sich die eigentständige Energieerzeugung auf die Kostenstruktur auswirken wird. Wird dieses Projekt zusammen mit Phase IV abgeschlossen sein?

Sinn würde es machen, es bereits vor dem Winter zu installieren um durch zusätzliche Beleuchtung und konstante Temperatur in der sonnenschwachen Jahreszeit den Cogenerator anzuschmeißen und somit die Ausbringung zu steigern, als auch die Energiekosten zu senken.

Ich habe "gehört", das einer der Gründer sich bereits im September darum gekümmert hätte, ob es jedoch früher installiert sein wird als die Fertigstellung mit Phase IV kann ich nicht sagen; GEPLANT war Ende Phase IV.

Wir werden es eventuell bald hören. Die Kosten werden in jedem Fall extrem nach unten und die Ausbringung nach oben gehen.

[sunny3999]

Sessions weict auf und gibt zu er kann den Cannabis-Zug nicht mehr aufhalten!

Damit könnte Aphria zum großen Gewinner im Wettbewerb werden!

https://moneymorning.com/2017/10/05/jeff-sessions-just-said-…

[sunny3999]

Antwort auf Beitrag Nr.: 55.907.132 von wouserxx am 08.10.17 19:44:17

Also nun doch lt. der Stadt Leamington Gasleitung bis Juni 2018 (lt. The Star)

https://www.thestar.com/news/canada/migrants/2017/10/09/leam…

[sunny3999]

Nun denkt auch der republikanische Senator aus Kentucky das Cannabis zu legalisieren!

[antwerp-lady]

Hallo, ich bin neu hier im Forum weil ich gerade erst gekauft habe,weiss jemand ob die Börse in Toronto heute geschlossen ist????

[sunny3999]

Antwort auf Beitrag Nr.: 55.912.586 von antwerp-lady am 09.10.17 16:14:02

Zitat von antwerp-lady: Hallo, ich bin neu hier im Forum weil ich gerade erst gekauft habe,weiss jemand ob die Börse in Toronto heute geschlossen ist????

Turkey-Day in Kanada - also Thanksgiving zu deutsch Erntedankfest, kein Handel ausser in USA unter OTC und da ist Aphria gerade mit 1,85% im Plus.....

Viel Glück uns Allen mit dem Aphria Invest.

6.060.11 (1.85%)
Real-Time Best Bid & Ask
6.05 / 6.08 (825 x 1100)

http://www.otcmarkets.com/stock/APHQF/quote

[sunny3999]

Cannabis Aktien starten eine mehrjährige Rallye

Experten Meinung: Cannabis Stocks Begin a Multi-Year Rally

http://www.cannabiscapitalist.ca/single-post/2017/10/04/Cann…

[antwerp-lady]

Antwort auf Beitrag Nr.: 55.912.733 von sunny3999 am 09.10.17 16:31:38

DANKE,DANKE

[sunny3999]

Fonds und Institutionen haben seit Mai insgesamt 3.879 Mio. Aktien eingesammelt

http://www.stockhouse.com/companies/bullboard?symbol=t.aph&p…

[sunny3999]

BBC News: Die Welle der Cannabis-Legalisierung hat England und ihre Politiker erreicht!

Cannabis: Tide of world opinion is moving to legalisation, Flynn says
Newport West MP Paul Flynn has urged MPs to back the legalisation of cannabis for medicinal use as he introduced a bill in the House of Commons.

The Labour backbencher said a majority of US states - 29 of the 50 - had passed such a measure along with about half a dozen European nations.
Mr Flynn said it was the "oldest medicine in the world", used as long as 5,000 years ago.

http://www.bbc.com/news/av/uk-wales-politics-41574658/cannab…

[sunny3999]

Aphria-US: Liberty Health Science wird innovatives Cannabis Dosierung mit Tabs in Florida liefern

https://www.newcannabisventures.com/liberty-health-to-offer-…

[sunny3999]

Beitrag aus SeekingAlpha über Liberty Health Science

Liberty Health Sciences: Unique Medical Marijuana Opportunity
Oct. 11, 2017 2:07 PM•LHSIF
Summary
Liberty Health Sciences controls a key license for medical marijuana in the state of Florida.
The company is in the process of opening dispensaries and expanding medical marijuana expansion.
Key backing of Canadian based Aphria provides the support for quick market share gains in a rapidly developing market.

https://seekingalpha.com/amp/article/4112990-liberty-health-…

[sunny3999]

Glückwunsch an Aphria zur Nominierung des Weltklasse Mitarbeiterpreises!

Congratulations Aphria ! Recipients of the 2017 Invest in a World Class Workforce Award

https://twitter.com/AphriaInc/status/918481175294902272

[sunny3999]

Video zu Aphria's Qualität auf höchstem Standard lt. Gründer Cole Cacciavillani

https://www.facebook.com/AphriaMMJ/videos/1281650555279980/

Aphria has always held itself to the highest standards when it comes to the cultivation and production of medical cannabis. Our co-founder and VP of Growing Operations, Cole Cacciavillani, tells us why it is important to control every aspect of the growing environment. From temperature controls and soil mixing to water and nutrient management, we’ve adopted quality processes that go above and beyond industry standards. This is solidified through our uncompromising #SeedtoSaleCertified quality promise that ensures that we only sell clean, safe and pure medical cannabis 100% of the time. No exceptions.

[sunny3999]

Vergleich Aphria versus Aurora bei SmallCapPower

https://smallcappower.com/analyst-articles/aurora-cannabis-v…

Conclusion

Overall, both companies have the potential to provide healthy returns for investors heading into recreational legalization in Canada.Aurora Cannabishas a slight edge given its aggressive plans with the recent investments in Germany and Australia. On the other hand, Aphria’s competitive advantage lies in its low-cost production profile leading to strong operating margins. Thus, Aphriacould be considered attractive from an investment perspective since the sign of a healthy business is converting the top-line into profits, and making profits at the operating level at this nascent stage of marijuana industry.

[sunny3999]

Aphria reports strong performance in Q1 2018, including record revenue and grams sold

http://www.newswire.ca/news-releases/aphria-reports-strong-p…

[sunny3999]

Aphria Posts 40% Sales Growth and 47% EBITDA Growth in Q1

https://www.newcannabisventures.com/aphria-posts-40-sales-gr…

[sunny3999]

Aphria MD&A und Interimszahlen stehen schon auf Sedar

http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

Alle Sedar fillings von Aphria:
http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issu…

[sunny3999]

Interview mit George Scorsis Aphria US=LHS und entwickelt eine IP-Tech im Pharmabereich!

TechRepublic: Video: The tech and science of medical cannabis

http://www.techrepublic.com/videos/video-the-tech-and-scienc…

[sunny3999]

Warum es wichtig ist alle Aspekte der Prozesse zu kontrollieren - Cole Cacciavillani (COO-Aphria)

Why is it important to control every aspect of the growing environment?

[sunny3999]

Ein selbstständiger Finanzcontroller hat alle Aphria Zahlen bewertet (leider in englisch)

Wer sich aber die Mühen macht wird reich belohnt, was bei Aphria alles aus den Zahlen zu lessen ist und was in Zukunft ansteht - Respekt!

http://www.stockhouse.com/companies/bullboard?symbol=aphqf&p…

[sunny3999]

Cannabis Gipfel in Oakland Kalifornien vom 13-15 Oktober!

George Scorsis von Aphria-US (Liberty Health Science-Florida) war dabei!
https://www.newwestsummit.com/

[sunny3999]

[cancoon]

Hi Sunny

Wir kennen uns von Poet Technologies. Du bist ja vielseitig. Wünsche dir mit den Pflanzen viel Erfolg.
Ich werde mich nach erfolgreicher Loslösung von Poet wohl mehr mit deutschen autoaktien Vergnügen.

Hier allen viel Erfolg.

[sunny3999]

Antwort auf Beitrag Nr.: 55.955.132 von cancoon am 15.10.17 04:28:38

Zitat von cancoon: Hi Sunny
Wir kennen uns von Poet Technologies. Du bist ja vielseitig. Wünsche dir mit den Pflanzen viel Erfolg.

Vielen Dank cancoon, du weißt das ich Poet's Sunnyforum 2014 gegründet hatte, die Gruppe in den besten Zeiten ca. 200 Mitglieder stark war und ich nach wie dort lese und schreibe.Hiermit Grüße ich alle POET'ler.

Das Motto war:

Ich war bis 2016 überzeugt von Poet, das sie einen Chip entwickeln, der die Welt mit Licht revolutioniert.

Ich habe nach meinem Poet-Ausstieg 3 Monate lang viele Werte analysiert um die Verluste aus Poet zu egalisieren - was mir bereits gelungen ist.

Jetzt kann und wird Cannabis nach 80 Jahren Prohibition im July 2018 in einem der führenden Industrienationen also Kanada legalisiert - nach höchsten Qualitätsstandards ohne Pestizide/Verunreinigungen oder fremde Beimischungen von Drogen wie es auf dem Schwarzmarkt üblich ist.

Dies sollte eine ganz neue Industrie und Branche im Pharma-/Gesundheits-/Privatkonsumbereich aufstreben lassen, die den Schwarzmarkt mit der Zeit eliminiert, wie es nach der Alkohlprohibition von 1920-1933 in Nordamerika geschah!

Da Aphria auch auf Basis von Sonnenlicht ihre Pflanzen als kostengünstigster Hersteller gedeihen und wachsen läßt und somit einen entstehenden Weltmarkt erobern kann, bin ich gar nicht soweit weg von Poet.

Ich hoffe & wünsche Allen, die noch bei Poet dabei sind oder hier eingestiegen sind ein ertragreichen Abschluss.

[sunny3999]

TIME Marijuana Goes Mainstreet: A Booming Business - Your Brain on Pot - Legalization Marches On

http://wesa.fm/post/auditor-general-marijuana-could-solve-pa…

http://www.dailymotion.com/video/x5xgeg7

[sunny3999]

This Canadian Marijuana Stock Is a Bet on the U.S. Cannabis Market, Too

http://host.madison.com/business/investment/markets-and-stoc…

[sunny3999]

Aphria's Copperstate Farm-Arizina Sprecher auf der Southwest Cannabis Konferenz vom 12-14 Okt.

auf dem PHOENIX CONVENTION CENTER...

https://swccexpo.com/phoenix2017/

Copperstate Farms Sprecher auf der Southwest Cannabis Conference und Expo 2017 PHOENIX CONVENTION CENTER: Ryan Hurley (CopperState Farm) and Jane Fix (CopperState Farm)

https://swccexpo.com/phoenix2017/speakers/

[sunny3999]

Kanada's Steuer für Freizeit Cannabis könnte ein Hauptgewinn für lizensierte Cannabis Produzenten werden!

Canada's Proposed Tax on Recreational Marijuana Looks to Be a Major Win for Pot Producers
[e-mail] (Sean Williams) Oct 15, 2017

http://host.madison.com/business/investment/markets-and-stoc…

[sunny3999]

Aphria US war mit Liberty Health Science Sponsor in Kalifornien vor der West Summit Cannabis Messe

https://www.themaven.net/theweedblog/events/new-west-summit-…

[sunny3999]

Chartguys ab 10:25" Aphria sollte die 7,92-8,00$ knacken unter 7,70$ könnte eine konso kommen!